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EPIGRAPH 
 
“A man may do an immense deal of good, if he does not care who gets the credit for it.” 
-Father Strickland, 1863 
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ABSTRACT 
 
 X-ray crystallography remains the most robust method to determine protein 
structure at the atomic level.  We demonstrate how these structural studies can directly 
contribute to unsolved problems in biology, with a focus on the growing problem of 
antibiotic resistance in bacterial infections.  Multi-drug efflux transporters are common and 
powerful resistance mechanisms that are capable of extruding a number of structurally 
unrelated antimicrobials, including antibiotics and toxic heavy metal ions, from the bacterial 
cell.  We begin by presenting the crystal structures of the individual pump components of the 
Escherichia coli Cus system, a paradigm for efflux machinery, and speculate on how these 
pumps assemble to fight diverse antimicrobials.  In Mycobacterium tuberculosis, the cell wall 
is critical to the virulence and antimicrobial resistance of these pathogens. Recent work 
shows that the MmpL transporter family contributes to cell wall biosynthesis by exporting 
fatty acids and lipidic elements of the cell wall. The expression of the M. tuberculosis MmpL 
proteins is controlled by a complex regulatory network, including the TetR family 
transcriptional regulators Rv3249c and Rv1816.  We demonstrate how the structures of these 
two proteins enhance understanding of the MmpL family of proteins and to develop new 
antibacterial tools to fight tuberculosis.  Neisseria gonorrhoeae is a Gram-negative human 
pathogen and the cause of the STD gonorrhea.  In N. gonorrhoeae, the MtrCDE multidrug 
efflux system mediates resistance to diverse antibiotics, nonionic detergents, antibacterial 
peptides, bile salts, and steroidal hormones. We have developed several techniques to 
assemble the complete MtrCDE tripartite efflux complex, which we present here.  These 
efforts have culminated in a low-resolution structure of the bipartite MtrCD complex.  
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Finally, we apply our crystallography techniques to the problem of chloroplast cell division.  
In plants and algae, chloroplast division proceeds by binary fission, involving the coordinated 
assembly of four rings, both inside and outside the cell.  We have determined the first high-
resolution crystal structure of the Arabidopsis thaliana cell division protein PARC6.  In 
addition, we obtained the co-crystal structure of PARC6 and PDV1, another protein within 
this network, revealing the molecular details of the intermembrane space interaction during 
chloroplast cell division. 
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SUMMARY 
 
Chapter I 
X-ray crystallography remains the most robust method to determine protein structure 
at the atomic level.  However, the bottlenecks of protein expression and purification often 
discourage further study.  Based on our experiences in expressing and purifying 
antimicrobial efflux proteins, we explain how a pure and homogenous protein sample can be 
successfully crystallized by the vapor diffusion method.  Further, we demonstrate how these 
structural studies can directly contribute to unsolved problems in biology; specifically, the 
growing problem of antibiotic resistance in bacterial infections, a leading cause of death 
worldwide. 
 
Chapter II 
A common and powerful resistance mechanism, bacterial multi-drug efflux 
transporters are capable of extruding and detoxifying a number of structurally unrelated 
antimicrobials, including antibiotics and toxic heavy metal ions, facilitating bacterial survival 
in noxious environments. Those transporters belonging to the resistance-nodulation-cell 
division (RND) superfamily typically assemble as tripartite efflux complexes, spanning the 
inner and outer membranes of the cell envelope. In Escherichia coli, the CusCFBA complex, 
which mediates resistance to copper(I) and silver(I) ions, is the only known RND transporter 
with a specificity for heavy metals.  Here, we present the crystal structures of the individual 
pump components of the Cus system, a paradigm for efflux machinery, and speculate on how 
RND pumps assemble to fight diverse antimicrobials. 
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Chapter III 
The Mycobacterium tuberculosis cell wall is critical to the virulence and 
antimicrobial resistance of these pathogens. Recent work shows that the MmpL transporter 
family, which belongs to the RND superfamily, contributes to cell wall biosynthesis by 
exporting fatty acids and lipidic elements of the cell wall. The expression of the M. 
tuberculosis MmpL proteins is controlled by a complex regulatory network, including the 
TetR family transcriptional regulators Rv3249c and Rv1816. We have determined the high-
resolution crystal structures of these two regulators. Combined with functional studies, the 
structures of these regulators give us clues on how they function, which is essential to 
understanding the mechanisms of the MmpL family of proteins and to develop new 
antibacterial tools to fight tuberculosis. 
 
Chapter IV 
Neisseria gonorrhoeae is a Gram-negative human pathogen and the cause of the STD 
gonorrhea.  Recently, treatment of gonorrhea has been severely compromised by the 
development of antibiotic-resistance strains.  The best characterized RND multidrug efflux 
system in N. gonorrhoeae is the MtrCDE multidrug efflux system.  This tripartite complex 
mediates the export of hydrophobic antimicrobial agents, such as antibiotics, nonionic 
detergents, certain antibacterial peptides, bile salts, and gonadal steroidal hormones. The 
availability of the three-dimensional structures of these efflux transporters and their 
accessory proteins should allow us to block their function.  However, this approach 
necessitates the high-resolution structure of a completely assembled RND tripartite efflux 
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complex.  Our efforts to elucidate the crystal structure of the MtrCDE pump has culminated 
in a low-resolution structure of the bipartite MtrCD complex.  
 
Chapter V 
Finally, we apply our crystallography techniques to the problem of chloroplast cell 
division.  In plants and algae, as in their cyanobacterial ancestors, chloroplast division 
proceeds by binary fission.  The fission process involves the coordinated assembly of four 
rings both inside and outside the cell at the midplastid: the inner PD ring, the inner Z-ring, 
the outer PD ring, and the outer DRP5B ring.  Within this network, a pair of paralogous inner 
envelope membrane proteins, PARC6 and ARC6, and a pair of paralogous outer envelope 
membrane proteins, PDV1 and PDV2, are likely responsible for bridging both the inner and 
outer membranes to connect the Z-ring and DRP5B ring.  We have determined the first high-
resolution crystal structure of the PARC6 protein.  In addition, we obtained the crystal 
structure of this PARC6 domain in complex with the intermembrane space domain of 
Arabiposis thaliana PDV1, revealing the molecular details of the intermembrane space 
interaction during chloroplast cell division. 
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CHAPTER I 
 CRYSTALLIZATION OF MEMBRANE PROTEINS BY VAPOR DIFFUSION 
 
 
Delmar, JA, Bolla, JR, Su, CC, and Yu, EW. (2015) Methods Enyzmol. 557: 363-92 
 
Introduction 
 
As of this writing, nearly 100,000 protein structures have been deposited to the PDB.  
Approximately 90% were solved by X-ray crystallography—by far the most successful 
technique used to study protein structure.  However, of more than 30,000 unique X-ray 
structures, only approximately 1% represent membrane proteins 
(http://blanco.biomol.uci.edu/mpstruc/).  In contrast to their share of the known structures, 
membrane proteins are estimated to comprise approximately 30% of all genes.1,2 They play 
the critical roles of gatekeepers, mediating messages and materials moving into and out of 
the cell.  For example, G-protein coupled receptors, which are responsible for vision, taste, 
smell and immune response in eukaryotes;3,4 multidrug efflux transporters, which confer 
antibiotic resistance to pathogenic bacteria;5 voltage-gated ion channels, such as those 
responsible for neuron firing and muscle contraction;6,7 and porins, through which bacteria, 
mitochondria, and chloroplasts exchange material, such as nutrients, with the extracellular 
environment.8,9  These proteins comprise at least 60% of all drug targets.10,11 
Unfortunately, understanding the structures and action mechanisms of important 
integral membrane proteins is often hampered by the difficulties associated with expression, 
purification, and crystallization.  There are at least two non-trivial tasks in the way of 
straightforward application of X-ray crystallography to membrane proteins: i) obtaining a 
sufficient quantity of purified protein and ii) producing high quality crystals.12  The latter will 
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be the focus of this chapter.  However, as any practicing membrane protein crystallographer 
can attest to, obtaining diffraction-quality crystals can be a formidable task, which requires a 
pure and homogeneous protein sample.  In this respect, sample preparation and 
crystallization are inseparable.  Thus, a significant portion of this review will be devoted to 
the topics of membrane protein expression and purification.  In addition, extensive examples 
and detailed discussions, based on our experiences in expressing, purifying, and crystallizing 
antimicrobial efflux proteins, will be provided.  Hopefully, by introducing the available 
methodologies and protocols, a rational approach can be made to the often anecdotal process 
of membrane protein crystallization. 
 
Membrane Protein Expression 
With few exceptions, membrane proteins are not abundant in their native 
environment.  For example, Escherichia coli cells were found to contain only eight 
transcripts per cell corresponding to the inner membrane copper transporter CusA, even after 
induction.13  Those few exceptions include the rhodopsins, porins, ATPases, photosynthetic 
reaction centers, and other light-harvesting complexes.14  Coincidentally, the first membrane 
protein structure determined by X-ray crystallography was the photosynthetic reaction center 
of Rhodopseudomonas viridis.15  It wasn’t until 1998, more than a decade later, that a 
membrane protein structure was obtained from a non-native, i.e. recombinant, source.16,17  To 
date, recombinant overexpression is the most common approach to obtain proteins of interest.  
Often, this step is the first bottleneck that must be overcome in order to produce the 
milligram quantities of pure protein necessary for a single crystallization experiment.12,14 
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Host 
Thus far, E. coli remains the favorite host for heterologous protein expression.  It 
grows quickly, tolerates a high cell density, and does so on a relatively lean diet.18  The 
protein yield from E. coli cells is also particularly high, compared to other organisms.  In one 
experiment, the expression of 20 membrane proteins in six host organisms (three prokaryotic, 
including E. coli, and three eukaryotic) was measured.12  Overall, the highest yields were 
achieved with E. coli cells.  Further, only two membrane proteins tested were not 
successfully overexpressed in E. coli. 
Bacterial proteins do tend to express better in E. coli, in general, but it is not a cure-all 
for heterologous membrane protein expression.  Especially for eukaryotic membrane 
proteins, other host organisms must be considered.12,19,20  Often, eukaryotic proteins contain 
post-translational modifications, such as phosphorylation, glycosylation, methylation, or 
acetylation, which a non-native host may be incapable of reproducing.21  E. coli and other 
bacterial hosts, in particular, tend to lack these post-translational capabilities.18 
Translational machinery will also vary between the host and native organism.  E. coli 
cells exhibit a clear codon bias, with the population of tRNA approximately proportional to 
the chromosomal frequency.22  Occurrence of rare codons or many minor codons in the target 
protein sequence has a marked effect on expression levels.  The reason for this is apparent 
when considering that an overexpressed membrane protein may represent a significant 
fraction of the total cellular protein.  In some cases, even a single rare codon can be 
responsible for reduced expression levels.22  Accordingly, optimal expression of a protein 
might be achieved by optimizing the codons for the particular host.  This can be a time 
consuming process.  For example, the Neisseria gonorrhoeae gene norM, encoding the 
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multidrug efflux pump NorM, contains nine rare codons for E. coli.  To overexpress the N. 
gonorrhoeae NorM membrane protein in E. coli TOP10 cells, our lab had to spend a few 
months fixing each of these codons.23  Even the E. coli gene acrD, which produces the 
aminoglycoside efflux pump AcrD, has 15 rare codons.  Thus, it is incompatible with E. coli 
host cells.  We had to correct each of these 15 codons in order to overexpress this membrane 
protein in E. coli BL21(DE3) cells.  Fortunately, several companies, such as Integrated DNA 
Technologies (IDT), offer protein codon optimization tools to correct for the codon bias 
encountered in many host cells. 
Upon translation, membrane proteins must then be chaperoned from the cytoplasm 
and properly inserted into the corresponding membrane.  This is of particular importance to 
outer membrane proteins of Gram-negative bacteria.  A proper signaling peptide is essential 
to guide the expressed protein across the inner membrane and anchor to the outer membrane.  
Differences in the lipid bilayer structure and composition, as well as differences in insertion 
machinery, of the native organism compared to the host determine whether this process 
results in an active membrane protein or an intractable aggregate.24,25 
Finally, properly overexpressed, folded, and active membrane proteins tend to be 
toxic to their host.12  The reason for this is obvious in the case of membrane channels or 
transporters, which directly control the permeability and delicate intracellular chemistry of 
their host, and can have direct roles in metabolism.  In an experiment conducted with 
Rhodopseudomonas blastica, the overexpression of porins resulted directly in lysis of the 
host cell.26,27  Thus, the amount of inducer, such as isopropyl β-D-1-thiogalactopyranoside or 
arabinose, as well as the expression time and temperature, are often found to be critical 
variables for optimal protein expression. 
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Various strains of E. coli have been commercially developed to address the 
challenges encountered in membrane protein overexpression.  Among those used in our lab, 
the BL21(DE3) strain (Novagen) is deficient in OmpT and lon proteases, which allows for 
increased protein stability;18 mutations in the lac promoter render C41(DE3) and C43(DE3) 
strains far less sensitive to the toxicity of membrane protein overexpression;28,29 and the 
BL21-CodonPlus strain (Stratagen) contains additional copies of rare E. coli tRNAs. 
In addition to using these specialized strains of E. coli, our lab also generates ∆acrB 
knockout strains by removing the acrB gene, which encodes the multidrug efflux pump 
AcrB.  Deletions of abundant native membrane proteins have been shown to facilitate the 
purification process and produce a more homogenous protein.27  In many cases, without this 
specific deletion, our attempts at crystallizing membrane proteins would result in crystals of 
AcrB, instead. 
 
Vector 
In general, it is not easy to predict whether an expression vector is suitable for the 
protein of interest.  Choosing a vector that is compatible with both the membrane protein 
target and host organism, and one that is tailored to the desired expression and purification 
systems, is typically a trial-and-error process.  Luckily, many powerful expression vectors 
are commercially available.  In particular, our lab likes the pET-type vectors (Novagen) for 
the expression of α-helical transmembrane proteins.  For β-barrel transmembrane proteins, 
we have inordinate success with the pBAD-type vectors (Life Technologies). 
If a particular protein cannot be expressed with any combination of vectors and host 
cells, one may want to think about expressing the protein fused with green fluorescent 
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protein (GFP) or maltose-binding protein (MBP).  In many cases, the expression levels of 
these fusion proteins are much higher than the parental ones.20  It has also been reported that 
protein expression can be improved simply by single-point mutagenesis.  To this end, Molina 
et al. subjected eight bacterial and one human membrane proteins to cycles of random 
mutagenesis.29  In five of these proteins, expression levels could be increased, as much as 40-
fold, by one round of mutagenesis corresponding to approximately 6 mutations per 1000 
residues.  Further, the structure of the first β1-adrenergic receptor was solved with one 
mutation, cysteine-to-lysine, which reportedly improved expression.30 
 
Membrane Protein Purification 
Successfully overexpressed membrane proteins must be extracted and purified from 
the host’s lipid membrane before crystallization, with the intention of providing as similar an 
environment as possible to the native bilayer (Fig. 1).  At the same time, we wish to leave out 
all the properties that make the bilayer unsuitable for crystallization, such as heterogeneity, 
polarity, charge, etc.24  Ideally, these should be replaced by the most important indicators of 
crystallizability: monodispersity, and stability.31  This is a difficult task, indeed.  As stated by 
Bowie, membrane proteins are “delicate weaklings, unable to withstand the rigors of life 
outside the safety of the bilayer.”32  While detergent-based solubilization is the most popular 
and effective technique to replace the bilayer, most membrane proteins are only marginally 
stable even in the best available detergent.33 
The reason for their weakness is twofold: i) detergent, often smaller than the lipid 
environment it is replacing, may not completely cover the largely hydrophobic surface of the 
membrane protein and ii) membrane proteins, of diverse function, tend to exhibit much 
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conformational flexibility, with some conformations more stable than others.  Without the 
ordering imposed by the bilayer, they are free to adopt those conformations that may favor 
aggregation.33 
 
Detergent 
Beginning with 
the first membrane 
protein crystal structure 
in 1980, detergents have 
been rationally designed 
especially for the 
purpose of facilitating 
protein purification and 
crystallization.  The 
number of these 
detergents is now 
estimated in the 100s.17  Nonetheless, only a small subset have been successful.  The search 
for a suitable detergent benefits greatly from internet-based databases, which compile the 
crystallization conditions of all membrane proteins to date.  For example, “Membrane 
Proteins of Known Structure” (http://blanco.biomol.uci.edu/mpstruc/) is particularly helpful. 
At least structurally, all detergents are similar—a hydrophilic headgroup joined to a 
hydrophobic tail.  This amphipathic character allows the detergent monomers to interact with 
both the hydrophobic surfaces of membrane proteins and solvent, as well as each other.34  All 
 
Figure 1. Cartoon representation cross-section of a membrane 
protein solubilized in (a) lipid bilayer of the host cell and (b) 
detergent introduced during the purification process.  Upon 
removal of the protein from the native lipid (blue) environment, 
the protein-detergent complex consists of a uniform disordered 
ring of detergent monomers (red) making hydrophobic contacts 
with the surface of the protein (green). 
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detergents used for membrane protein crystallization are alkyl-chain, between 7 and 14 
carbons in length, with varying headgroups.17  A detergent falls into one of three categories 
based on the properties of the headgroup: ionic, nonionic, or zwitterionic (Fig. 2).  
Importantly, the most 
effective families of mild 
detergents for purification 
and crystallization have 
non-ionic or, less 
commonly, zwitterionic 
headgroups.  Besides 
solubilization, other 
detergent effects on 
membrane proteins can 
include inactivation, 
denaturation, or 
aggregation.35  In these 
cases, harsh ionic 
detergents are often responsible.  For example, the ionic detergent sodium dodecyl sulfate 
(SDS) is used in gel electrophoresis for exactly the purpose of protein denaturation.  As of 
the publication of their paper in 2008, Newstead et al. reported that no outer membrane 
proteins to date had been crystallized with ionic detergent.36 
To determine the effect of non-ionic and zwitterionic detergents on stability, Sonoda 
et al. used six common detergents to solubilize 24 prokaryotic and eukaryotic membrane 
 
Figure 2. Representative structures of commonly used 
detergents of three classes: (a) n-Dodecyl β-D-maltoside 
(DDM); non-ionic (b) Lauryldimethylamine-oxide (LDAO); 
zwitterionic. (c) Sodium dodecyl sulfate (SDS); anionic.  Atoms 
are colored C, green; O, red; N, blue; and S, yellow. 
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transporters.37  The average stability measured was greatest for the two longest chain lengths 
of detergent, n-dodecyl-β-D-maltoside (DDM) and dodecyl nonaethylene glycol ether 
(C12E9), both non-ionic.  In a similar study, Mancusso et al. examined 20 homologous lipid 
phosphatases.31  All 20 purified membrane proteins tended to be unstable in DDM solution, 
and all precipitated when concentrated over 1 mg/mL.  When DDM was exchanged for other 
detergents, both the stability and monodispersity of the sample varied.  In one of the tested 
samples, LP-1, both these traits improved when solubilized with 6-cyclohexyl-1-hexyl-β-D-
maltoside (CYMAL-6).  The size-exclusion chromatography peaks were sharper and the 
protein could be concentrated to 4 mg/mL.  Taken together, these results indicate the 
preference of membrane proteins for long-chain, non-ionic detergents.  For instance, DDM, 
with its 12 alkyl-carbons, is well known to stabilize membrane proteins and is often used for 
both solubilization and crystallization.38 
 
Protein-detergent complex 
After purification in the best available detergent, the membrane protein carries 
between 40 and 200% of its own weight in detergent.34,39  Save one or two molecules, all of 
these detergent coats are believed to be unstructured.40  Their shapes are also known, based 
on the low-resolution neutron structures of two reaction centers, from Rhodopseudomonas 
viridis and Rhodobacter sphaeroides.41,42  Remarkably, the shape of detergent surrounding 
each protein molecule is somewhat similar and is independent of the detergent molecules (n-
dodecyl-N,N-dimethylamine-N-oxide (LDAO) and n-octyl-β-D-glucopyranoside (β-OG), 
respectively).  In each case, the hydrophobic surface of the protein was covered in detergent 
molecules, wrapping the protein in a toroidal ring.  Approximately 200 molecules cover 40% 
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of the surface area of each reaction center.  The shear amount of detergent in each protein-
detergent complex, the building blocks of the crystal lattice, demonstrates that the detergent 
is at least as important as the protein itself in crystallization. 
Within the solvent surrounding the protein-detergent complex, detergent monomers 
exist which self-associate and bind to the membrane protein surface in a concentration-
dependent manner, with a minimum concentration equal to the critical micelle concentration 
(CMC).  For example, at 0.3% (w/v) β-OG, each monomer of human prostaglandin synthase 
was found to bind at least 40 molecules of detergent.  At 0.7% (w/v) β-OG, the number of 
bound detergent molecules roughly doubled.34  Crystallization is mostly done at detergent 
concentrations greater than the CMC, where equilibrium exists between detergent monomers, 
micelles, and detergent involved with the protein-detergent complex, with the concentration 
of monomers approximately equal to the CMC.17  As a higher CMC detergent will have more 
monomers in solution, it is expected that those monomers will exchange more readily 
between detergent micelles and the protein molecule surface.34 
 
Membrane Protein Crystallization via Vapor Diffusion 
Many techniques exist to crystallize membrane proteins, including the recently 
developed lipidic cubic phase,43,44 bicelle,45 and vesicle fusion46 methods.  This chapter will 
focus on the vapor diffusion approach.  The most common and successful method of 
membrane protein crystallization, to date, this approach has allowed researchers in our lab to 
determine the crystal structures of a number of membrane proteins.  These include the inner 
membrane efflux pumps CusA,47 AcrB,48 and MtrD,49 the outer membrane channels CusC,50 
MtrE,51 and CmeC,52 as well as the CusBA adaptor-transporter efflux complex.53 
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If not for the necessary presence of detergent, the crystallization of membrane 
proteins via vapor diffusion would be exactly similar to that of soluble proteins.  While 
protein-protein interactions dominate the crystallization of soluble proteins, both detergent-
detergent and protein-detergent interactions are additional considerations for the membrane 
protein crystallographer.  Unlike crystallization of water-soluble proteins, choosing the right 
detergent has been the key success for our membrane protein crystallization efforts.  In our 
opinion, this is the most important factor for obtaining high quality membrane protein 
crystals suitable for X-ray diffraction.  Thus, the rule of thumb is that more efforts should be 
made to screen a variety of mild detergents than to optimize other parameters when 
crystallizing a new membrane protein.  
In a simple crystallization experiment, a precipitant solution, containing at least 
buffer, precipitant, and salt components, is mixed with a protein solution, containing the 
purified protein-detergent complexes.  This forces the protein solution into a state of 
supersaturation.  To escape, the protein-detergent complex has two routes: i) aggregation and 
ii) crystallization.  If the crystallization solution is not too harsh and the protein-detergent 
complex has enough time to make specific interactions with its neighbors, the latter results.  
In general, a slow introduction of the crystallization solution to the protein-detergent 
complex facilitates this, resulting in larger crystals with fewer imperfections.54   
Compared to other techniques, the conditions for crystallizing membrane protein via 
vapor diffusion tend to be very mild, involving a mixture of relatively low concentrations of 
precipitant, salt, and buffer.  In short, a small quantity of the purified protein solution is 
mixed, usually in equal ratio, with the crystallization solution contained in the well 
(precipitant solution).  This drop, now half precipitant solution and half protein solution, is 
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either mounted in the well itself (sitting-drop) (Fig. 3a) or inverted above the well (hanging-
drop) (Fig. 3b), and the chamber is made airtight.  Vapor diffusion describes the evaporation 
of volatile species in the drop into the chamber, followed by diffusion across the chamber 
into the well.  The end 
result of this process is 
chemical equilibrium 
between the drop and 
well.  Because the well is 
much bigger, the 
equilibrium 
concentrations of drop 
components are 
approximated by the 
concentrations in the 
well.  
For simplicity, it 
is generally assumed that 
only water is exchanged 
between the drop and 
well.55  However, any 
volatile species can evaporate into the chamber and exchange between the drop and well.  
When it reaches equilibrium, or close to it, the hanging or sitting drop will manifest different 
types and degrees of phase behavior.  In addition to the protein, the detergent and the 
 
 
Figure 3. A 24-well plate in which either (a) sitting-drop or (b) 
hanging-drop vapor diffusion is done.  The well solution (colored 
red) is mixed in equal proportion with protein solution (colored 
blue).  In the sitting-drop technique, the resulting mixture sits on 
a pedestal above the well solution and the top of the chamber is 
sealed with grease and glass.  In the hanging-drop technique, the 
mixed drop is included on the glass slide itself, inverted and 
sealed with grease atop the chamber. 
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interactions between the two must be considered.  The phase transition of detergent is 
relatively complex.  It can crystallize, aggregate into micelles, or separate into detergent-rich, 
and detergent-poor phases.25,56  Thus, searching for the right crystallization condition 
involves exploring point-by-point a complicated many-dimensional phase diagram for both 
protein and detergent. 
The dimensions of this phase space include, at least, both protein and detergent 
concentrations, detergent type, precipitant concentration and type, buffer pH and type, salt 
concentration and type, and additive concentration and type.  Further, the optimal 
crystallization conditions occupy only a very small volume of this phase space.  Finally, the 
contribution of these factors to crystallization is non-linear.  In general, the effect of one 
component on the solubility of the protein is coupled to the effect of another.57  Even with the 
advent of robotic screening technology, capable of testing up to 40,000 conditions per day,58 
crystallization cannot be approached naively. 
There are two general approaches to navigating the phase space of a protein: i) a ‘grid 
search,’ by systematic screening of what are believed to be the important variables,59 or ii) 
using a ‘coarse matrix screen,’ heavily biased on known crystallization conditions of other 
proteins.60  To date, many coarse matrix screens designed specifically for membrane 
proteins, including MemGold (Molecular Dimensions) and MembFac (Hampton Research), 
have been made commercially available.  In many cases, these screening kits are 
instrumental in the search for initial crystallization conditions.  The individual components of 
these conditions and their roles in the crystallization process will be discussed in the 
following sections, with an emphasis on the most common and successful ones. 
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Detergent 
Some say that the biggest hurdle in membrane protein crystallization is not obtaining 
the crystals, but optimizing them for high-resolution X-ray diffraction.37  In this respect, no 
other variable is more influential in the success of membrane protein crystallization than 
detergent.   
Although no single detergent category can be generally applied to membrane protein 
crystallization, statistical evidence suggests that some are more useful than others.   Almost 
all successfully used detergents are nonionic alkyl sugars with C7-C14 alkyl chains.  By far, 
the most crystal structures have been solved using the alkylmaltoside family of detergents—
nearly one half of all α-helical proteins.61  This family includes the single most popular 
detergent, DDM, which contains 12 carbons in the main alkyl chain. By contrast, the 
alkylglucoside family of detergents are most commonly used to crystallize outer membrane 
proteins.37  They include the second most popular detergent, β-OG, which is an 8 carbon 
alkyl-chained detergent. 
Recently, the development of new detergents has emerged as a tool for handling 
difficult membrane proteins.62  Non-conventional approaches, such as amphipols,63 
nanodiscs,63 hemifluorinated surfactants,63,64 cholate acid-based amphiphiles,65 and the new 
family of maltose-neopentyl glycol amphiphiles66 have been proven to aid in the 
solubilization of membrane proteins, while retaining their structure and function.  This new 
generation of amphiphiles is particularly promising, and may eventually have a large role in 
the solubilization, stabilization, and crystallization of membrane proteins for high resolution 
structural analysis.  
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Precipitant 
Based on their mechanism of action, precipitants can be divided into three categories: 
i) salts, ii) organic solvents, and iii) long-chain polymers.  As will be discussed in the 
following section, salt acts as a precipitant by either dehydrating the protein molecules or 
altering the ionic strength. 
Organic solvents, such as ethanol or isopropanol, generally act to reduce the dielectric 
constant of the crystallization solution.  This makes electrostatic interactions weaker and 
reduces the solubility of ionic compounds slightly.  Interestingly, one of the first membrane 
proteins to be crystallized, the hydrophobic seed protein crambin, was initially solubilized in 
ethanol and crystallized by slowly adding water.34,67  At high concentrations, most of these 
compounds are denaturing.  However, 2-Methyl-2,4-pentanediol (MPD) has been remarkably 
successful for outer membrane protein crystallization.36 
The third and most successful category of precipitants comprises the long-chain 
polymers, including polyethylene glycols (PEGs).  More than 80% of all membrane proteins 
have been successfully crystallized with various molecular weights of PEGs36,61 and 100% of 
all membrane proteins in our lab.  The mechanism of action of these polymers is attributed to 
volume exclusion effects.57  Unlike other components of the crystallization solution, PEGs 
have no consistent conformation, resembling a flail.  PEGs with molecular weights between 
400 and 20000 Da have been effective for membrane protein crystallization, with the larger 
ones obviously being more forceful.    
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Salt 
Salt ions, both cationic and anionic, can alter the solubility of proteins.  This effect 
was first discovered by Franz Hofmeister.68  The action mechanism is not entirely clear.  
However, it is thought to be due to specific interactions between ions, protein 
macromolecules, and water molecules in the solvent layer surrounding the protein.  The 
effect of anions are usually ordered: 
 
The order of cations is usually given as: 
 
Early members of the series tend to increase solvent surface tension and decrease the 
solubility of nonpolar molecules.  They strengthen the hydrophobic interaction and this effect 
is often referred to “salting out”.  In this way, ammonium sulfate precipitation is commonly 
used in protein purification.  Additionally, more than 10% of membrane protein crystals 
reported in the PDB are crystallized with the help of this salt.61  By contrast, later ions in the 
series tend to increase the solubility of nonpolar molecules and decrease the order of water 
molecules.  They weaken the hydrophobic interaction and this effect is called “salting in”.  
Typically, ions that have a strong “salting in” effect are strong denaturants, because they 
interact much more strongly with the unfolded protein than with its native folded form. 
 
Buffer 
The actual net charge of the protein is determined not only by its composite amino 
acids, but by the pH of the solvent.69  For each amino acid, its charge is determined by its 
pKa; at a pH below the pKa, an amino acid is positively charged and vice versa.  Therefore, 
SO42− > HPO42− >CH3CO2− >Cl− > NO3− > Br− >ClO3− > I − >ClO4− > SCN −
NH4+ > K + > Na+ > Li+ >Mg2+ >Ca2+
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altering the pH of the crystallization solution will alter the degree of electrostatic interaction, 
mainly, between the protein-detergent complexes. 
At a pH equal to the pI, which is an average of the pKa of the surface residues of the 
protein, the net charge is neutralized and solubility drops dramatically.  While this is usually 
too strong a condition for crystallization, it is common to find the optimal crystallization pH 
nearby.69  The pH determines the charge of the zwitterionic detergents in a similar way. 
Although no direct correlation appears to exist between predicted pI and the pH at 
which crystallization was reported, there is a good correlation between their difference, pH-
pI, and pI.  Specifically, acidic proteins tend to crystallize between 0 and 2.5 pH units above 
their pI, while basic proteins crystallize between 0.5 and 3 pH units below their pI.70 
 
Case Studies 
Crystallization of the E. coli CusA heavy-metal efflux pump 
Initially, we cloned the E. coli cusA gene into pET15b to form the expression vector 
pET15bΩcusA.  This expression vector was then used to transform E. coli BL21(DE3) cells 
and overexpress the full-length CusA membrane protein, containing a 6xHis tag at the N-
terminus.  The expressed protein was purified using a Ni2+-affinity column to >95% purity.  
The final purified protein was then dialyzed and concentrated to 20 mg/mL in buffer 
containing 20 mM Na-HEPES (pH 7.5) and 0.05% DDM for crystallization trials.  The 
original protein crystals crystallized fairly quickly, and these crystals diffracted X-rays to 4 Å 
resolution.  However, mass spectrometry identified these as crystals of the E. coli AcrB 
protein, which was probably co-purified with the CusA protein as a contaminant. 
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 To avoid further contamination with the AcrB protein, we made an E. coli knockout 
strain BL21(DE3)ΔacrB, which harbors a deletion in the chromosomal acrB gene. The CusA 
transporter was then overexpressed using the transformed cells 
BL21(DE3)ΔacrB/pET15bΩcusA and purified using a Ni2+-affinity column.  The purified 
protein was then dialyzed, concentrated to 20 mg/mL in buffer containing 20 mM Na-HEPES 
(pH 7.5) and 0.05% DDM, and subjected to crystallization trials using sitting-drop vapor 
diffusion.  This time, mass spectrometry confirmed that the crystals were composed of CusA 
molecules.  However, these crystals diffracted X-rays poorly, to ~9 Å resolution.  After 
extensive screening, with as many salts, PEGs, pHs, temperatures, additives, and detergents 
available to us, we finally obtained plate-shaped crystals by adding 0.05% CYMAL-6 to the 
initial crystallization condition.  Although these plate-shaped crystals were much better in 
quality, they diffracted X-rays anisotropically to a resolution of ~5 Å in one dimension and 
~8 Å in the other.     
 As the addition of CYMAL-6 significantly improved the crystal quality, we decided 
to use CYMAL-6 to purify and crystallize the CusA protein.  During this process, we also 
found that the additives Jeffamine M-600 (JM-600) and glycerol further improved their 
quality.  Thus, the final crystallization condition was 2 µL protein solution (containing 20 
mg/ml CusA protein in 20 mM Na-HEPES (pH 7.5) and 0.05% (w/v) CYMAL-6) mixed 
with 2 µL of reservoir solution containing 10% PEG 3350, 0.1 M Na-MES (pH 6.5), 0.4 M 
(NH4)2SO4, 1% JM-600, and 10% glycerol.  The resulting mixture was equilibrated against 
500 µl of the reservoir solution.  Typically, the dimensions of the crystals were 0.2 mm x 0.2 
mm x 0.2 mm (Fig. 4a).  Crystals of CusA were found to be trigonal with space group R32 (a 
= b = 178.4 Å, c = 285.8 Å) (Fig. 4b).47  Based on the molecular weight of CusA (115.72 
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kDa), it was found that a single molecule occupied the asymmetric unit with a solvent 
content of 67.5%.  The final crystal structure of the CusA transporter was determined to a 
resolution of 3.5 Å. 
 
Crystallization of the E. coli CusBA adaptor-transporter complex 
 As of this article’s publication, CusBA remains the only adaptor-transporter complex 
for which a high resolution X-ray structure is available.  For purification of this important 
complex, the individual proteins of the CusA transporter and CusB71 adaptor were 
individually overexpressed in E. coli cells BL21(DE3)ΔacrB/pET15bΩcusA and 
 
 
Figure 4. Crystal structure of the E. coli inner membrane heavy metal efflux pump CusA.  
(a) A single crystal of CusA. (b) Packing diagram of the CusA crystal viewed orthogonal to 
the long axis of the unit cell. 
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BL21(DE3)ΔacrB/pET15bΩcusB, respectively.  The CusA protein was solubilized with 2% 
CYMAL-6 and purified using Ni2+-affinity chromatography, as mentioned previously.  The 
CusB protein was also purified using a Ni2+-affinity column, without the addition of any 
detergent.  Co-crystals of the CusBA complex were obtained using sitting-drop vapor 
diffusion.  After extensive optimization, the CusBA crystals were grown at room temperature 
in 24-well plates with a final crystallization condition of 2 µL protein solution (containing 
0.1 mM CusA and 0.1 mM CusB in 20 mM Na-HEPES (pH 7.5) and 0.05% (w/v) CYMAL-
6) mixed with 2 µL of reservoir solution containing 10% PEG 6000, 0.1 M Na-HEPES (pH 
7.5), 0.1 M ammonium acetate, and 20% glycerol.  The resulting mixture was equilibrated 
against 500 µL of the reservoir solution.  Co-crystals of CusBA grew to a full size in the 
drops within two months.  Typically, the dimensions of the crystals were 0.1 mm x 0.1 mm x 
0.1 mm (Fig. 5a). 
The co-crystals of the CusBA adaptor-transporter complex took a trigonal space 
group R32 with unit cell parameters a = b = 160.2 Å, c = 682.7 Å (Fig. 5b).53  Based on the 
molecular weights of CusA (115.7 kDa) and CusB (42.3 kDa), the asymmetric unit contained 
one CusA and two CusB molecules with a solvent content of 70.8%.  As it turns out, the 
presence of CusB drastically improved crystal quality in comparison with the crystals of 
CusA alone.  The reason for this may be that CusB enlarges that hydrophilic surface of the 
membrane protein, thereby providing additional surface for crystal contacts.  The final 
structure of the CusBA adaptor-transporter complex was determined to a resolution of 2.9 Å. 
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Crystallization of the N. gonorrhoeae MtrD multidrug efflux pump 
It took us a few years of effort to crystallize the MtrD membrane protein.  First, two 
different constructs, based on the protein sequence of MtrD in N. gonorrhoeae strain FA19, 
were used to express the MtrD protein, containing a 6xHis tag at the N- or C-terminus, 
respectively.  The open reading frame (ORF) of mtrD from N. gonorrhoeae FA19 was cloned 
into pET15b to form each expression vectors. After screening of expression conditions, only 
the C-terminal 6xHis tagged MtrD protein could be expressed in E. coli C43(DE3)ΔacrB 
 
 
Figure 5. Crystal structure of the E. coli inner membrane heavy metal efflux pump CusA in 
complex with the periplasmic membrane fusion protein CusB.  (a) A single crystal of the 
CusBA complex. (b) Packing diagram of the CusBA cocrystal viewed orthogonal to the long 
axis of the unit cell. 
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cells, which harbor a deletion in the chromosomal acrB gene.  Using these conditions, we 
then purified the MtrD protein using a Ni2+-column.  Optimization of the initial crystals with 
respect to primary and secondary detergent, salt, precipitant, pH and temperature, yielded 
only showers of microcrystals.  Unfortunately, these microcrystals did not even diffract X-
rays to low resolution.  
Based on protein sequence alignments of different N. gonorrhoeae strains, we 
decided to focus on the homologous MtrD efflux pump from N. gonorrhoeae strain PID332.  
The alignment indicated that MtrD of strain PID332 is 11 amino acids shorter at the C-
terminus in comparison with FA19 MtrD.  We then cloned the N. gonorrhoeae PID332 mtrD 
gene into pET15b to generate the pET15bΩmtrD expression vector.  This recombinant 
plasmid encoding the N. gonorrhoeae PID332 MtrD protein, with a 6xHis at the C-terminus, 
was then transformed into C43(DE3)ΔacrB cells to overexpress this protein.  Upon 
expression, MtrD was solubilized in 2% CYMAL-6 and subjected to purification using Ni2+-
affinity chromatography.  Initial crystallization trials, using 0.05% CYMAL-6 as a primary 
detergent, did not yield any crystals.  However, small cubic shaped crystals appeared in the 
drops after adding sucrose monododecanoate (SM) as a secondary detergent.  Subsequent 
crystallization trials were carried out using both CYMAL-6 and SM detergents.  After 
extensive optimization, the final MtrD crystals were grown at room temperature using 
sitting-drop vapor diffusion with the following procedures.  A 2 µL protein solution 
containing 0.2 mM MtrD in buffer solution (20 mM Na-HEPES (pH 7.5), 0.05% (w/v) 
CYMAL-6, and 0.5% (w/v) SM) was mixed with 2 µL of reservoir solution, containing 30% 
PEG 400, 0.1 M Na-Bicene (pH 8.5), 0.1 M NH4SO4, 0.05 M BaCl2, and 9% glycerol.  The 
resulting mixture was equilibrated against 500 µL of the reservoir solution.  Typically, the 
  
23 
dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm (Fig. 6a).  Crystals of MtrD 
belonged to space group R32 (a = b = 153.0 Å, c = 360.7 Å) (Fig. 6b).49  Analysis of the 
Matthews coefficient indicated the presence of one MtrD molecule (113.69 kDa) per 
asymmetric unit, with a solvent content of 66.7%.  The final crystal structure of the MtrD 
transporter was determined to a resolution of 3.5 Å. 
 
 
 
Figure 6. Crystal structure of the N. gonorrhoeae inner membrane multidrug efflux pump 
MtrD.  (a) A single crystal of MtrD. (b) Packing diagram of the MtrD crystal viewed 
orthogonal to the long axis of the unit cell. 
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Crystallization of the E. coli CusC heavy-metal efflux channel 
The CusC outer membrane channel is one of the most well-studied proteins in our 
laboratory.  Its structures have allowed us to unmask the sequential transition of 
conformations leading to the folding and membrane insertion of this channel.  To express 
CusC, the ORF of cusC from E. coli K12 genomic DNA was cloned into pBAD22 to produce 
the expression vector pBAD22ΩcusC.  This expression system included a CusC signaling 
peptide at the N-terminus as well as a 6xHis tag at the C-terminal end.  The N-terminal 
signaling peptide was needed to guide the channel protein to express at the outer membrane.  
It should be noted that this signaling peptide would be removed automatically when the CusC 
protein was matured in the cell.  This recombinant plasmid was then used to transform the 
C43(DE3)ΔacrB cells to overexpress the channel protein.  To ensure that the harvested CusC 
protein was attached to or anchored the E. coli outer membrane, and not the inner membrane, 
we performed a pre-extraction procedure using 0.5% sodium lauroyl sarcosinate to 
selectively dissolve and remove proteins of the inner membrane.  The CusC outer membrane 
protein was then solubilized in 2 % (w/v) DDM.  The extracted protein was purified with a 
Ni2+-affinity column to >95% purity.  The purified protein was then dialyzed and 
concentrated to 15 mg/mL in buffer containing 20 mM Na-HEPES (pH 7.5), 200 mM NaCl, 
and 0.05% (w/v) DDM for crystallization trials. 
 Sitting-drop vapor diffusion was employed for initial crystal screening.  During this 
screening, we found that the full-length CusC channel could be crystallized only in the 
presence of 2% (w/v) β-OG, which served as a secondary detergent to DDM.  It was also 
found that the addition of a small amount of JM 600 could improve the quality of the 
crystals.  The best crystals of CusC were grown at room temperature with a reservoir solution 
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containing 8% PEG 3350, 0.05 M sodium acetate (pH 4.0), 0.2 M (NH4)2SO4, 1% JM 600, 
and 2% β-OG. Typically, the dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm 
(Fig. 7a). 
 Crystals of the full-length CusC channel took the space group R32 with the unit-cell 
parameters a = b = 88.5 Å, c = 474.42 Å (Fig. 7b).50  Based on the molecular weight of CusC 
(49.30 kDa), only one CusC molecule occupied the asymmetric unit with a solvent content of 
67.8%.  The final model was refined to a resolution of 2.1 Å. 
 
 
Figure 7. Crystal structure of the E. coli outer membrane channel CusC.  (a) A single 
crystal of CusC. (b) Packing diagram of the CusC crystal viewed orthogonal to the long 
axis of the unit cell. 
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It is interesting to note that a single point mutation in the first cysteine residue of 
CusC resulted in a dramatically different conformation.  Instead of the four-stranded beta-
sheet present in the wild-type CusC monomer, the corresponding residues in this mutant form 
two independent random loops.  By mutating or deleting this key residue, we obtained a 
different structure entirely, which corresponds to the state immediately before membrane 
insertion.50  In this membrane protein, even the modification of one residue can prevent 
anchoring and insertion into the bilayer.  Therefore, one should be cautious when 
crystallizing membrane proteins with any mutations or truncated sequences. 
 
Crystallization of the N. gonorrhoeae MtrE multidrug efflux channel 
The construct used to express the N. gonorrhoeae MtrE outer membrane channel was 
similar to that of E. coli CusC.  However, after several trials, we found that the signaling 
peptide sequence of Pseudomonas aeruginosa OprM was the best peptide for expressing the 
N. gonorrhoeae MtrE heterogeneously in E. coli.  In short, the ORF of mtrE from N. 
gonorrhoeae FA19 was cloned into pBAD22 to form the expression vector pBAD22ΩmtrE, 
which included the P. aeruginosa OprM signaling peptide at the N-terminus and a 6xHis tag 
at the C-terminus.  The full-length MtrE protein was then expressed in E. coli C43(DE3) 
cells possessing this vector.  The procedures for protein extraction and purification were the 
same as those for the CusC membrane protein.  The purified protein was dialyzed and 
concentrated to 15 mg/mL in buffer containing 20 mM Na-HEPES (pH 7.5), 200 mM NaCl, 
and 0.05% (w/v) DDM for crystallization trials. 
Crystals of MtrE were obtained using sitting-drop vapor diffusion.  Based on crystal 
screening, the following procedure was adopted.  A 2 µL protein solution containing 15 
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mg/ml MtrE protein in 20 mM Na-HEPES (pH 7.5), 200 mM NaCl, and 0.05% (w/v) DDM 
was mixed with a 2 µL of reservoir solution containing 20% PEG 400, 0.2 M sodium acetate 
(pH 4.6), 0.25 M MgSO4, and 2% (w/v) β-OG.  The resultant mixture was equilibrated 
against 500 µl of the reservoir solution at room temperature.  Crystals of MtrE grew to a full 
size in the drops within two weeks.  Typically, the dimensions of the crystals were 0.1 mm x 
0.1 mm x 0.2 mm (Fig. 8a). 
Crystals of the MtrE channel protein belonged to the space group P6322 (a = b = 93.9 
Å, c = 391.5 Å) (Fig. 8b).51  Analysis of the Matthews coefficient indicated the presence of 
 
 
Figure 8. Crystal structure of the N. gonorrhoeae outer membrane channel MtrE.  (a) A 
single crystal of MtrE. (b) Packing diagram of the MtrE crystal viewed orthogonal to the 
long axis of the unit cell. 
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one MtrE protomer (49.29 kDa) per asymmetric unit, with a solvent content of 75.8%.  The 
final structural model was resolved to a resolution of 3.3 Å.  
 
Crystallization of the C. jejuni CmeC multidrug efflux channel 
The construct used to express the C. jejuni CmeC outer membrane channel was 
similar to that of N. gonorrhoeae MtrE.  Briefly, the full-length CmeC membrane protein 
containing a 6xHis tag at the C-terminus was overproduced in E. coli 
C43(DE3)/pBAD22bΩcmeC cells.  This expression system included an OprM signaling 
peptide at the N-terminus and a 6xHis tag at the C-terminus.  The purified protein was 
dialyzed and concentrated to 15 mg/mL in buffer containing 20 mM Na-HEPES (pH 7.5), 
200 mM NaCl and 0.05% DDM. 
Initial crystallization trials were not successful and did not yield even poor quality 
crystals.  These trials were followed by extensive screening of secondary detergents.  
Fortunately, hexagonal shaped CmeC crystals were obtained, but only in drops containing the 
detergent C8E4.  Further optimization of the crystallization conditions eventually produced 
well diffracting crystals.   
Crystals of CmeC were obtained using sitting-drop vapor diffusion at room 
temperature in 24-well plates with the following procedures.  A 2 µL protein solution 
containing 15 mg/mL CmeC protein in 20 mM Na-HEPES (pH 7.5), 200 mM NaCl, and 
0.05% (w/v) DDM was mixed with 2 µl of reservoir solution containing 18% PEG 400, 0.1 
M sodium acetate (pH 4.0), 0.3 M (NH4)2SO4, and 2% C8E4.  The resulting mixture was 
equilibrated against 500 µl of the reservoir solution.  Crystals of CmeC grew to a full size in 
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the drops within two weeks.  Typically, the dimensions of the crystals were 0.1 mm x 0.2 
mm x 0.2 mm (Fig. 9a). 
Crystals of the CmeC outer membrane channel belonged to the space group C2221 
with unit-cell parameters: a = 92.38 Å, b = 147.35 Å, c = 420.43 Å (Fig. 9b).52  Based on the 
molecular weight of CmeC (54.26 kDa), three molecules were found in the asymmetric unit 
with a solvent content of 80.6%.  These three molecules assembled to form a trimeric 
channel within the unit cell.  The final crystal structure was determined to a resolution of 2.4 
Å. 
 
 
 
Figure 9. Crystal structure of the C. jejuni outer membrane channel CmeC.  (a) A single 
crystal of CmeC. (b) Packing diagram of the CmeC crystal viewed orthogonal to the long 
axis of the unit cell. 
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Concluding Remarks 
      For the routine availability of three-dimensional membrane protein structures to 
become possible, there is still a mountain to climb.  Like the state of soluble protein 
crystallization 20 years ago, initial data is still being acquired to facilitate the large-scale 
investigations demanded today.  Only then can loftier goals of crystallization be achieved.  
For example, no atomic-resolution model of a drug efflux complex, spanning both the inner 
and outer bilayer, has been reported to date.  In Gram-negative bacteria, such complexes are 
responsible for conferring resistance to commonly used antibiotics, a problem that is 
exacerbated by the increased use of these drugs.  While bacterial infections remain a leading 
cause of death worldwide, invaluable structural information leading to antibiotic resistance 
mechanisms would provide a platform to produce new drugs and inhibitors that increase the 
efficacy of our weakened therapies. 
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CHAPTER II 
 BACTERIAL MULTIDRUG EFFLUX TRANSPORTERS 
 
 
Delmar, JA, Su, CC, and Yu, EW. (2014) Annu. Rev. Biophys. 43: 97-117 
 
Multi-Drug Resistance in Bacteria 
Antibiotics and other antimicrobial therapies have been used to treat infections for 
over a century. It is widely accepted that the increased use of these drugs has resulted in 
bacteria that are adapted and more resistant to the typical treatments. Until recently, the 
major means of antimicrobial resistance in bacteria was believed to be similar to the 
breakdown of penicillin by β-lactamase, i.e., modification of the offending compound by a 
drug-specific enzyme.54,97 However, as antibiotic engineering advances, so too do the 
methods of resistance. Currently, there are three major mechanisms bacteria use to avoid the 
toxic effects of biocides.80,97,102 
The first, enzymatic alteration, can be divided into two classes: 1) those enzymes that 
degrade the drug, like β-lactamase, and 2) those that chemically modify it. An example of the 
second class is the periplasmic copper oxidase CueO in Escherichia coli, which relieves the 
copper sensitivity of the cell by oxidizing toxic Cu(I) to less toxic Cu(II).113,114 As metals 
cannot be chemically degraded, bacteria must employ alternative methods of detoxification 
in the case of copper or silver poisoning.64,77 Accordingly, the second method of bacterial 
drug resistance involves enzymatic alteration of the target of the drug, rather than the drug 
itself. Fluoroquinolone resistance in bacteria is most commonly attributed to this mechanism; 
specifically, modification of the enzyme DNA gyrase.41,97 While the first two methods are 
limited due to their specificity for a single drug or drug-binding site, the third mechanism is 
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more general. By expelling a toxin before it can act, or by preventing it from entering the cell 
altogether, a bacterium utilizes its most potent form of resistance. 
The first line of cellular defense is either its surrounding peptidoglycan web (Gram-
positive) or the outer lipid membrane (Gram-negative).79 However, the peptidoglycan shell is 
too coarse to limit the diffusion of very small molecules. Thus, Gram-negative bacteria are 
inherently less susceptible to toxins.81 Pseudomonas aeruginosa is one example of a 
pathogen with exceptionally high resistance to a wide range of antibiotics. It also possesses 
exceptionally narrow porins—outer-membrane proteins that allow passive diffusion of small 
molecules like sugars and amino acids. Thus, P. aeruginosa possesses an exceptionally-
impermeable outer membrane.4,80,81 Despite this fact, neither simple nor porin-facilitated 
diffusion across the cell membrane is enough to explain the intrinsic antimicrobial resistance 
of certain bacteria. In two related studies, the minimum inhibitory concentration (MIC) of 
antibiotics tetracycline and cephalothin in E. coli increased by only factors of 1.5 and 2, 
respectively, when porin expression was interrupted.42,55,91 Furthermore, it is common for the 
most effective antibiotics to exhibit some hydrophobicity, which increases the permeability 
of the lipid bilayer to these drugs.80 
Not diffusion, but active transport is now recognized as the major player in 
antimicrobial resistance.37,97 To remove toxic molecules that enter via porins or porin-like 
transport systems, the cell utilizes a powerful pumping mechanism. Composed of one or 
more protein components, these multi-drug efflux pumps traverse the cell membrane, bind 
and actively pump out a broad range of noxious agents; in some cases, from the cytoplasm all 
the way to the outside of the cell. Metal-ion and antibiotic resistance systems of this type 
have been found encoded on plasmids of every eubacterial group tested, from E. coli to 
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Streptomyces sp.109 For example, E. coli’s pco (for plasmid-borne copper resistance 
determinant) and P. syringae’s cop operon.14 Many important resistance systems, including 
the subject of this review, are chromosomally represented, as well. 
 
Heavy-Metal Resistance in Bacteria 
In addition to preventing the action of drugs, bacteria utilize efflux pumps to regulate 
the delicate cellular levels of metal ions, which are among the most common enzymatic 
cofactors. Around 40% of all enzymes contain transition metals such as Mg, Zn, Fe, Mn, Ca, 
Co and Cu, and even Cd has been found in the carbonic anhydrase of a certain algae.52,77,126 
Cytochrome c oxidase, the last step in the mitochondrial and bacterial electron transport 
chain; prokaryotic superoxide dismutase, which detoxifies dangerous superoxide radicals; 
lysyl oxidase, a collagen-elastin cross-linker; and tyrosinase, a melanin producer, are all 
enzymes that require bound copper ion to function.108 However, while transition metals such 
as copper are important and necessary components of the cellular environment, in excess 
they are extremely toxic. In recent experiments, E. coli cultures showed diminished to no 
growth at CuCl2 concentrations as low as 1 mM.8,76 and in another study growth defects were 
observed at concentrations exceeding 8 µM.64 Non-essential metals can be toxic at even 
lower concentrations. Silver, for example, is such an efficient biocide that its effects can be 
observed on the nM scale.98 
The primary cause of this toxicity is the high reactivity of transition metals; e.g., 
cations in particular have a high affinity for thiol and thioether residues, imidazoles, sulfides 
and nucleic acids.24,77 Furthermore, most transition metals have similar binding affinities for 
these groups. Copper, however, is exceptional for its ability to push nearly any other metal 
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out of complex,76 and a mismatch of enzyme and metal ion cofactor will typically result in 
inactivation of the enzyme. Cytoplasmic copper interferes with the formation of iron-sulfur 
clusters, necessary for the activity of, for example, the citric acid cycle enzyme aconitase or 
the heme group of cytochrome c.76,77 Finally, due to their high redox potential, copper and 
iron are able to participate in the following Fenton-type reaction:  
Cu+ + H2O2 → Cu2+ + OH− + OH 
which generates dangerous hydroxyl radicals from hydrogen peroxide and Cu+ or 
Fe2+.34,64,77 These radicals are capable of reacting with basically anything and can cause 
damage to DNA, lipids and proteins. 
While the mechanisms of heavy-metal toxicity have only been elucidated over the last 
century, the biocidal properties of copper and silver have been exploited for millennia.18,29,111  
The use of silver is increasingly common, and both copper and silver are popular and 
effective sterilizers, viz., brass doorknobs, silverware, copper and silver water filters, silver-
coated catheters, silver-containing bandages, mineral sanitizers in pools and silver nitrate and 
silver sulfadiazine, which are common antiseptics used to treat burns.29,89,110,112  Many 
transition metal ions are essential cellular ingredients, however the efficacy of these metal-
based antimicrobial treatments has forced bacteria to handle copper and silver with the same 
machinery as they do to antibiotics. 
 
Classes of Multi-Drug Efflux Pumps 
Based on sequence similarity, transport function, substrate specificity and energy 
coupling, ten families of efflux proteins have been classified as members of five 
superfamilies:100,101 1) the adenosine triphosphate (ATP)-binding cassette (ABC) 
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superfamily; 2) the major facilitator superfamily (MFS); 3) the small multi-drug resistance 
(SMR) superfamily; 4) the resistance-nodulation-cell division (RND) superfamily and 5) the 
multi-drug and toxic compound extrusion (MATE) superfamily (Fig. 1).13,86,99,124  As an 
energy source, ABC transporters utilize ATP to drive toxins from the cell, while the other 
four superfamilies rely on an electrochemical gradient. Specifically, MFS, RND and SMR 
proteins employ the proton-motive force and the MATE superfamily is characterized by 
either Na+- or H+-substrate antiport.102  
Gram-negative bacteria have been found to contain members of all five 
superfamilies,82 which contribute to their intrinsic resistance to diverse antimicrobials. RND 
transporters are capable of forming powerful cooperative multi-protein structures that bridge 
 
 
Figure 1. Functional diversity among efflux proteins. Based on mode of transport, energy 
coupling mechanism, and phylogeny, these proteins are divided into five superfamilies. ABC 
superfamily proteins use ATP to transport diverse antimicrobials across the cellular inner 
membrane. MFS, SMR, and RND proteins function via an H+-substrate antiport mechanism. 
MATE proteins use both H+ and Na+ as energy sources. RND transporters in particular can 
form multiprotein structures that bridge the inner and outer membranes. 
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both the inner and outer membranes.132 They are essential to the multi-drug resistance 
observed in many pathogens.97 
Unfortunately, structural information is available for few members of the RND 
superfamily. Whereas only two have resolved crystal structures, including AcrB71 and 
CusA,62 there are a total of seven known RND proteins in E. coli. These seven transporters 
can be categorized into two distinct sub-families. AcrB,21,70,71,83,84,90,103,105,116,123,130,131 
AcrD,1,84,96 AcrF,53,63,84 MdtB,10,47,72,84 MdtC10,47,72,84 and YhiV12,49,84 are multi-drug efflux 
pumps of the hydrophobic and amphiphilic efflux RND (HAE-RND) protein family75,123 and 
CusA62,84,117 belongs to the heavy-metal efflux RND (HME-RND) family.75,123 
CusA, which specifically recognizes and confers resistance to Ag(I) and Cu(I) ions, is 
one of few known members of the HME-RND family, which includes CusA homolog SilA in 
Salmonella typhimurium32 and CzcA of Ralstonia sp. CH34.27,78 CusA is unique not only as 
the only known E. coli HME-RND transporter, but also as the only HME-RND protein, 
among all organisms, with available crystal structures. Among all RND efflux systems, 
CusCFBA is one of just three, including MexAB-OprM2,3,38,106 and AcrAB-TolC,50,67,104,123 
with structures for each component. It is also the first efflux complex for which the adaptor 
and transporter were co-crystallized.119 
Four proteins are found to operate in conjunction with CusA, making it only one of 
two known tetrapartite efflux systems. The fully-assembled complex consists of the inner-
membrane, substrate-binding transporter, or pump, CusA; the periplasmic membrane fusion 
protein (MFP), or adaptor, CusB; the outer membrane factor (OMF), or channel, CusC; as 
well as the small, periplasmic, metal-binding protein, or chaperone, CusF, a component that 
has no analog in HAE-RND complexes (Fig. 2). While HAE-RND proteins are typically of 
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broad specificity, HME-RND proteins have been shown to be very specific, with the ability 
to distinguish between monovalent and divalent ions.8,123 
Despite their differences, metal and antibiotic resistance systems are thought to have 
much in common.9 In fact, the line that distinguishes one from another is sometimes blurred. 
In addition to copper and silver, the cus determinant has been implicated in E. coli resistance 
to drugs dinitrobenzene, 
dinitrophenol and 
fosmomycin.19,84 Thus, 
both HAE- and HME-
RND proteins are 
believed to be key 
components of the 
acquired and intrinsic 
resistance of Gram-
negative pathogens to 
antimicrobials. The 
acquisition of even one 
RND system by a 
bacterium can increase 
its tolerance to a broad 
spectrum of drugs. For example, the Acr system in E. coli has been linked with resistance to 
tetracycline, chloramphenicol, fluoroquinolones, novobiocin, erythromycin, fusidic acid, 
rifampin, ethidium bromide, acriflavin, crystal violet, sodium dodecyl sulfate (SDS) and 
 
 
Figure 2. Model of the fully assembled CusCFBA tetrapartite 
efflux system. In E. coli, this HME-RND complex is 
responsible for extruding Cu+ and Ag+ ions directly from the 
cell using the proton-motive force.  The complex consists of 
the inner membrane transporter CusA (yellow), the membrane 
fusion adaptor CusB (blue), the outer membrane channel 
CusC (green), and the periplasmic metallochaperone CusF 
(purple). Cu+ and Ag+ ions have been found in complex with 
CusA, CusB, and CusF. 
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deoxycholate—an unprecedented number of antibiotics, chemotherapeutics, detergents and 
dyes.81 Perhaps as a direct consequence of the use of these compounds, including metal-
based antimicrobial therapies, RND resistance systems are being discovered with increasing 
frequency.48,93,110 Thus, these resistance systems pose a formidable clinical threat. As their 
prevalence in pathogens increases, so too does the need to understand them. 
Although this review will focus on the details of the CusCFBA tetrapartite 
Cu(I)/Ag(I) transporter, many similarities are expected to be found between heavy-metal 
extrusion and antibiotic extrusion in general. Where appropriate throughout the article and as 
much as possible, parallels will be drawn between Cus and other known RND systems, with 
emphasis on the well-characterized MexAB-OprM and AcrAB-TolC efflux pumps, model 
systems for bacterial drug resistance. 
 
Copper and Silver Resistance in E. coli 
By the time the E. coli genome was completely sequenced,11 already two HME-RND 
pumps and their corresponding complexes had been found in other organisms: CzcCBA in 
Ralstonia sp. CH3427,73,78 and SilCBA in S. typhimurium.32,110,112 The earliest example SilA, 
with nearly 87% sequence identity to CusA, was purified from a hospital strain of S. 
typhimurium at Massachusetts General in 1975. S. typhimurium expressing this plasmid-
encoded transporter were found to be resistant to a “disturbing” number of antibiotics and 
metal ions, including the popular silver nitrate.65 Ultimately, infection led to the deaths of 
three patients and the closing of the burn ward.110 Based in part on their sequence similarity 
to the deadly sil, czc and other known antimicrobial efflux pumps, 37 open reading frames in 
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the E. coli genome were identified as putative drug transporters. In addition to CusA, this list 
includes six other RND proteins.84,87 
The architecture of the cus locus consists of two back-to-back operons, cusCFBA and 
cusRS (formerly ylcBCD-ybdE and ylcA-ybcZ, respectively). The cusA gene is preceded by 
cusB, encoding the MFP, and cusC, encoding the OMF. Between cusB and cusC is the short 
ORF cusF, homologous to the corresponding gene in sil, for a small periplasmic chaperone 
protein.25 Transcribed in the opposite direction are cusR and cusS, encoding a response 
regulator and histidine kinase, respectively. Upstream of cusA and cusB is a promoter region 
with high sequence similarity to those of pcoAp, pcoEp, silCp, silEp, copAp and copHp—all 
copper and silver resistance genes of Gram-negative bacteria.25,32,78 Although the function of 
each cus gene was unknown at the time of discovery, all previously determined cusA 
homologs were found to be preceded by a cusB homolog and organized as an operon, 
including the acr and mex loci. In the closely-related heavy-metal resistance domains czc and 
cnr of R. metallidurans and the sil determinant of Salmonella, the OMF gene is also part of 
the operon. However, in the case of acr and mex, the outer membrane channel genes (tolC 
and oprM, respectively) were found elsewhere. 
Several early experiments sought to characterize the new genes and their results led to 
the discovery that the cus locus encodes, primarily, a copper- and silver-transporting 
machine. This makes cus special in E. coli as one of only two chromosomally-encoded 
copper resistance systems and the only one implicated in silver resistance. The other copper 
locus, cue, encodes the membrane protein CopA and soluble protein CueO. Both would be 
found to share the substrate Cu(I), however CopA is a P-type ATPase, resting in the inner 
membrane, while CueO is a periplasmic multi-copper oxidase. CopA and CueO are both 
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regulated by CueR, which is a transcriptional activator induced by copper.17 The role of cue 
and the proteins it encodes provide key insights to the cooperative nature of copper resistance 
in E. coli.28,64,74,76,85,88,92,93,95,113,114,129 
At first, the CusCFBA efflux system was not believed to be related to copper-
resistance at all. Franke et al. were not able to distinguish the sensitivity of ΔcusA to CuCl2 
from that of the wild-type, under aerobic conditions.25 Grass and Rensing also showed that 
the MICs of CuCl2 in ΔcusA and wild-type strains were indistinguishable (3.5 mM) and, 
additionally, that there was no observed difference between the growth of ΔcusA::cm and the 
double mutant ΔcusA::cmcopA::km in the copper medium.28 However, their susceptibility 
assays indicated a slight MIC difference of CuCl2 in copA::kmΔcueO::cm and copA::km (2.5 
mM compared to 2.25 mM, respectively), a large difference in ΔcueO::cm and 
ΔcusA::cmΔcueO::cm (2.75 mM compared to 1.3 mM, respectively) and no difference at all 
between ΔcueOΔcusA::cm, copA::kmΔcueOcusA::cm and copA::kmΔcueOcusCFBA::cm. 
It is clear from these results that CueO and particularly CopA each have a major role 
in conferring aerobic copper resistance in E. coli, whereas CusA alone had little to no role. 
Either the expression of CueO and CopA should be much higher at the copper concentrations 
tested or they should be much more efficient transporters. Indeed, in P. syringae, CopA was 
shown to bind as many as 11 copper atoms.15 In addition, E. coli CueO was found to have at 
least five copper binding sites per molecule, with Km nearly 4-fold higher and kcat 8- and 30-
fold higher, respectively, than for yeast Fet3 and human ceruloplasmin.113 Expression levels 
seem to fit this scheme, as well. Thieme et al. found that after addition of 1mM CuCl2 
expression reached a maximum of 334, 180 and 8 transcripts per cell, of CopA, CueO and 
CusA, respectively.122 
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Although CusA expression had no noticeable effect on aerobic copper resistance 
compared to the wild-type cell, a striking difference was observed between the aerobic and 
anaerobic growth of E. coli knockout strain ΔcusR.85 In the absence of oxygen, the ΔcusR 
strain was remarkably sensitive to Cu(I); more than the wild-type and ΔcueO, and nearly 
identical to ΔcopA. Under aerobic conditions, the half-maximal inductions of both cueO and 
copA were found to occur at 3 µM CuSO4 and cusC at 200 µM.85 In stark contrast to the 
aerobic case, the half-maximal anaerobic inductions of each protein were found to be 60, 70 
and 3 µM for cueO, cusC and copA, respectively. While the expression level of CopA was 
unchanged, CueO expression fell and CusC expression increased dramatically in the absence 
of oxygen. 
In an oxidizing environment, the dominant copper species should be Cu(II) and in the 
reducing environment it should be Cu(I). However, because Ag(I) is the dominant silver ion 
species with or without oxygen, there should be no difference in the aerobic or anaerobic 
silver-resistance conferred by CusA. The susceptibility experiments of Franke et al. were 
among the first to confirm the importance of CusA in Ag(I) resistance. They observed that 
while the wild-type E. coli strain grew in the presence of up to 25 µM Ag(I), the ΔcusA 
knockout strain did not.26 Additionally, ΔcusA, ΔcusAΔcopA and ΔcusCFBA knockout strains 
were very sensitive to AgNO3, compared to ΔcopA knockouts and the wild-type strain, 
agreeing with the experiments of Gupta et al.25,33 
Surprisingly, neither CopA nor CueO were implicated in silver resistance. While 
copper resistance in E. coli can be understood in terms of three synergistic components, 
regarding silver tolerance CusCFBA has no peers. In fact, the cus domain was even 
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prematurely named agr before its role in copper-resistance was known.110 The presence of 
periplasmic Ag(I) actually inhibits the activity of the copper transporter CueO.114 
To determine the importance of each component of the tetrapartite efflux system in 
conferring copper resistance, various knockout strains of E. coli were prepared and grown in 
a medium containing CuCl2. The MIC was determined for each strain and the results were as 
follows: ΔcueO grew uninhibited in up to 3.25 mM CuCl2, ΔcueOΔcusA in 1.5, ΔcueOΔcusB 
in 1.5, ΔcueOΔcusC in 1.75, ΔcueOΔcusCΔtolC in 1.75 and, finally, ΔcueOΔcusF in 2.25.26 
Thus, all of the proteins in the cus operon were found to be necessary in conferring the 
maximal copper resistance in vivo. The small effect of CusC deletion was initially proposed 
to be due to TolC replacement, as in the Acr tripartite efflux system, however the 
ΔcueOΔcusCΔtolC knockout strain was no less resistant to copper. Therefore, CusC should 
be specific to the CusCFBA pump and not replaceable—at least not by TolC. 
That copper resistance was strong no matter which subset of components were 
expressed, and that full copper resistance could not be conferred without expressing the 
entire pump, suggests that each piece has an active role in heavy-metal efflux. In the 
following sections, we will examine these roles, describing the structure and proposed 
function of each component, piece-by-piece. 
 
CusA—Inner-Membrane Transporter, “the Pump” 
Prior to the successful X-ray experiments of Long et al. in 2010, diffraction-quality 
crystals had been obtained for only two other RND pumps: E. coli AcrB61 and P. aeruginosa 
MexB.106 Based in part on this experiment, CusA was revealed to be the main substrate-
binding transporter of this efflux system.   
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The apo-crystal structure of CusA was first determined to a resolution of 3.52 Å with 
98% of the 1,047 residues (residues 5-504 and 516-1040) included in the final model (pdb: 
3K07), and it suggests that 
CusA exists as a 
homotrimer (Fig. 3).62 The 
tertiary structure contains 
12-transmembrane α-
helices (TMs), typical of 
membrane transport 
proteins.36 TMs 4, 5, 10 
and 11 are confined to the 
cytoplasm and 2 and 8 to 
the periplasm, while the 
rest are embedded within 
the inner-membrane. Like 
AcrB and MexB before it, CusA can be divided into six sub-domains: PN1, PN2, PC1 and 
PC2 which comprise the pore domain and DN and DC which are presumed to form the CusB 
docking domain. Perhaps the most striking feature of CusA is one α-helix that extends 
horizontally into the bottom of a cleft created by PC1 and PC2 of the periplasmic domain, 
roughly dividing the transmembrane and periplasmic domains. Sitting atop this helical 
divider are three adjacent methionine residues (M573, M623 and M672). These same 
methionines were identified earlier as three of nine total conserved methionines among 
similar putative drug transporters, including SilA.93 Although the exact role of these 
 
Figure 3. Crystal structure of the apo-CusA efflux pump. The 
ribbon diagram (orange) depicts the CusA protomer found in 
the asymmetric unit of the crystal lattice. The electron density 
map corresponds to the CusA homotrimer, which is formed by 
symmetry within the crystal. Subdomains PN1, PN2, PC1, and 
PC2 form the pore domain, whereas subdomains DN and DC 
comprise the docking domain, which presumably interacts 
with the CusC channel. 
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methionines was not yet clear, they were found to be indispensable with respect to copper 
resistance. When mutated to isoleucines, the M573I, M623I and M672I mutants were 
entirely unable to relieve the copper sensitivity of the ΔcueO knockout strain in vivo.93 In the 
E. coli ΔacrBΔcueO knockout strain, Long et al. found that the MICs for CuSO4 in mutants 
M573I, M623I and M672I were drastically lower than in the wild-type (0.50 mM and 2.25 
mM, respectively), while there was no noticeable difference in the MIC level of these 
mutants when compared to the complete knockout ΔcusA. For silver ions, the same effect 
was also observed. The MIC of AgNO3 in E. coli expressing CusA mutants M573I, M623I 
and M672I was 12.5 µM, compared to 30 µM in the wild-type and 10 µM in the ΔcusA 
knockout strain. In fact, the three-methionine motif is especially common among Cu(I)-
resistance proteins,45,95,127 which suggests the importance of M573, M623 and M672 to the 
specificity of the CusA pump. 
An open question for the almost eight years between experiments was answered when 
the ion-bound structures of CusA were obtained, by soaking the apo-crystals in Cu(I) and 
Ag(I) solutions, individually (pdbs: 3KSS and 3KSO, respectively).62 The root mean square 
deviation (RMSD) between the Cu(I)- and Ag(I)-bound structures was 1 Å, suggesting that 
these two structures are nearly identical. Accordingly, Cu(I) and Ag(I) were found to 
coordinate M573, M623 and M672 in each structure (Fig. 4). In addition to the Cu(I)- and 
Ag(I)-binding sites, they revealed that metal binding triggers a large conformational change 
in the pump. The RMSD between the ligand-bound and apo-CusA structures was 3.9 Å. This 
deviation is mainly attributed to a 30° opening between sub-domains PC1 and PC2, creating 
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a kind of doorway for metal ions to enter the periplasmic domain of the pump (Fig. 4). The 
cleft was found closed in the apo-crystal and open in the ligand-bound crystal, suggesting 
that the binding site is revealed in the presence of Ag(I) or Cu(I) and hidden in their absence. 
As well as exposing it to the periplasm, the shift more closely coordinates the three 
methionines involved 
in binding. In 
comparison with the 
apo and ion-bound 
CusA structures, it is 
found that 
transmembrane 
helices TM1, TM2, 
TM3, TM6 and TM8 
and pore domain PN1 
also move noticeably 
toward the direction 
of the outer 
membrane upon metal 
binding.   
 
 
Figure 4. Crystal structure of the metal ion-bound CusA efflux 
pump. (a) The ribbon diagram and electron density map 
correspond to the Cu+- or Ag+-CusA subunit (blue). The binding of 
Cu+ or Ag+ by CusA is correlated with a major conformational 
change in the pump. The separation between the PC1 and PC2 
subdomains of each Cu+- and Ag+-CusA subunit is exaggerated 
compared to that of apo-CusA. (b) In the metal ion binding site of 
CusA, the bound Ag+ and Cu+ ions (red) are closely coordinated by 
methionine residues M623, M672, and M573. 
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Besides the main three-methionine binding site, four distinct methionine pairs were 
identified from each protomer of CusA (Fig. 5). Prior to this experiment, two-methionine or 
two-cysteine binding sites for copper were identified in at least four other copper tolerance 
proteins: CusF,58 CueR,17 Atx15 and CopC.6,133 In CusA, three of these pairs, M410-M501, 
M403-M486 and M391-M1009, are found below the main binding site in the transmembrane 
domain and one, M271-M755, is positioned in the periplasm above the three-methionine site. 
All of these methionine 
coordination sites were 
found on the inside of the 
channel formed by each 
protomer of the CusA pump. 
Based on their locations, it 
was proposed that the 
methionine ladder created by 
these pairs could shuttle ions 
in a stepwise fashion for ion 
extrusion. Thus, the 
periplasmic methionines 
may serve as a transition of 
the transported metal ion 
from CusA to the putative 
outer-membrane channel 
CusC. 
 
Figure 5. Metal ion extrusion pathways of the CusA efflux 
pump.  Four methionine pairs depicted by space-filling models 
(Carbon, green; Oxygen, orange; Nitrogen, blue; Sulfur, 
yellow) in each protomer of CusA form the path for Cu+ or Ag+ 
transport. Metal ions may enter from the cytoplasmic side of the 
channel via M410-M501 or through the periplasmic cleft 
between the subdomains PC1 and PC2 via the three-methionine 
binding sites M573, M623, and M672 (dashed black arrows). 
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Susceptibility assays were carried out to determine the utility of these ladder 
methionines.62 When one methionine in each pair was mutated to an isoleucine, the MIC of 
CuSO4 dropped to 1.25 mM for M391I and 1.75 mM for M410I, M486I and M755I, 
compared to 2.25 mM in the wild-type CusA. Silver resistance was also stunted, as the ladder 
mutants brought the MIC for AgNO3 to 10 µM, 17.5 µM, 17.5 µM and 12.5 µM for M391I, 
M410I, M486I and M755I, respectively. 
In addition to the in vivo susceptibility assays, which demonstrated the importance of 
each residue in conferring copper and silver resistance, in vitro transport assays were 
employed to determine their roles in metal ion transport. CusA was reconstituted into 
liposomes containing Phen Green SK and the fluorescent signal was measured in the 
presence of extravesicular Ag+. In the wild-type CusA-loaded liposomes, quenching of the 
fluorescent signal was detected as soon as the silver ions were introduced into the medium. 
However, in the case of three-methionine binding site mutants M573I, M623I and M672I, 
and the methionine ladder mutants M391I, M486I and M755I, no quenching was detected, 
indicating that the extravesicular Ag+ could not traverse the membrane. Thus, these 
methionine residues were also implicated in CusA transport, and CusA was shown to have 
the ability to transport silver directly from the cytoplasm. It should be noted that a similar 
transport capability has also been found with CzcA27 and AcrD.1 
Based on the crystal structure, the dynamics of the trimeric CusA pump was 
calculated using the elastic network model.7,62 The result indeed suggests that CusA 
functions through three coupled motions in which the periplasmic cleft formed by 
subdomains PC1 and PC2 alternately open and close, similar to AcrB23,69,70,70,90,103-105 and 
MexB.106 
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CusB—Membrane Fusion Protein, “the Adaptor” 
The structure of apo-CusB, the first of any HME-RND family MFP, was solved two 
years prior to that of CusA.62,120 Before the experiments of Su et al. in 2009,117 both AcrA67 
and MexA3,39 had produced well-diffracting crystals. Although the CusCFBA complex has 
many similarities to AcrAB-TolC and MexAB-OprM, CusB itself shares only 13% identity 
and 52% similarity with MexA and 16% identity and 54% similarity with AcrA.120 
Therefore, we should expect 
significant differences 
between these membrane 
fusion proteins.  
The crystal structure 
of CusB was resolved to 3.4 
Å with 78.1% of the total 
residues (89-385) included 
(pdb: 3OOC) (Fig. 6).120 Like 
AcrA, multiple 
conformations (here denoted 
A and B) of CusB were 
observed inside a single 
crystal, highlighting the 
flexibility of this MFP.67,121 
The overall fold, like that of 
MexA,3,38,121 can be divided 
 
 
Figure 6. Crystal structures of the CusB adaptor. (a) 
Conformation A (blue) and conformation B (red) of each 
subunit are depicted by the ribbon diagram. The two distinct 
structures of the elongated CusB molecule suggest the 
flexible nature of this protein. (b) Each protomer of CusB 
can be divided into four domains. An effective hinge 
between domains 2 and 3 is responsible for the 
conformational change between conformation A and 
conformation B of CusB. 
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into four domains: three β-domains and one α-helical domain. The first β-domain was 
identical in both structures, consisting of the N- and C-terminal ends of the protein arranged 
in a six β-stranded fashion. This domain was believed to interact directly with the CusA 
pump. Domain 2 in conformations A and B are quite dissimilar, consisting of two β-strands, 
four β-sheets and one short α-helix in A and six β-strands and two α-helices in B. Domains 3 
and 4 were largely unchanged between each conformation, consisting of eight β-strands and 
an all α-helical three-helix bundle, respectively. When conformations A and B were 
superimposed, the overall RMSD calculated between alpha-carbons was 2.6 Å, indicating a 
significant structural difference between the two molecules. However, the superimposition of 
domains 1 and 2 of each conformation resulted in an RMSD of only 0.8 Å. Similarly, 
domains 3 and 4 of A and B could be superimposed to give an RMSD of only 0.8 Å. 
Therefore, the difference between conformations can be summarized as a shift of domains 1 
and 2 with respect to 3 and 4. Best described as a rotation of ~20° about a hinge between the 
two groups, the difference between conformations results in a shift from what was called the 
“open” conformation of molecule A to the “closed” conformation of molecule  
Several years earlier, in the absence of structural information, Bagai et al. attempted 
to characterize the binding of Ag(I) and Cu(I) by CusB using isothermal titration calorimetry 
(ITC), X-ray absorption spectroscopy and in vitro susceptibility assays.8 Titration of Ag(I) 
into apo-CusB noticeably affected the measured binding enthalpy in a way that was not seen 
in the control, indicating that CusB does indeed bind Ag(I) in vitro. The equilibrium 
dissociation constant Kd for CusB-Ag(I) binding was measured to be 24.7 nM with a 1:1 
Ag(I)-to-CusB molar ratio. Previously, this group had used x-ray absorption spectroscopy to 
characterize the binding environment of Cu(I) in the CusB-Cu(I) complex and found that the 
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data was consistent with a three-sulfur coordination. Since there are no cysteine residues in 
CusB, the bound Cu(I) ion should be coordinated by three proximal methionines, as in CusA. 
Of the nine total methionines in CusB, only four were found to be well-conserved and 
these residues are M21, M36, M38 and M283. Bagai et al. relied on ITC and site-directed 
mutagenesis to determine if these methionines are important for metal binding. Methionine 
mutants M21I, M36I, M38I and M283I were prepared, titrated with Ag(NH3)2+ and the 
binding enthalpy was measured. Compared to the wild-type, the mutation of M21 to 
isoleucine resulted in a 10-fold reduction in binding affinity of CusB for Ag(I). The M36I 
and M38I mutants resulted in no detectable affinity at all, while M283I had a similar affinity 
to the wild-type. 
This experiment was supplemented with an in vivo susceptibility assay using the same 
CusB mutants, indicating that M21, M36 and M38 probably form a specific binding site for 
metal ions.8 Tragically, this three-methionine metal binding site identified by Bagai et al. is 
located in a region too disordered to obtain meaningful x-ray diffraction data. In combination 
with their results, the structure of the CusBA adaptor-transporter complex,119 which we will 
discuss in the next section, strongly supports the N-terminal residues M21, M36 and M38 as 
the specific Cu(I)/Ag(I) binding site of CusB. 
 
CusBA—Adaptor-Transporter Complex, “the Co-crystal” 
When it was published in 2011, the CusBA co-crystal structure was the first of its 
kind. This experiment was critical in elucidating specific interactions between the pump and 
adaptor molecules as well as developing detailed mechanisms of metal ion extrusion by the 
CusCFBA tetrapartite efflux complex. Its structure was first resolved to 2.90 Å (pdb: 3NE5), 
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revealing that each CusA monomer interacts with each of two protomers of CusB (Fig. 7).119 
The structure included 1,686 amino acid residues of the total 1,861 (residues 4-1,043 of 
CusA, residues 79-400 of molecule 1 of CusB and residues 79-402 of molecule 2 of CusB). 
Based on the co-crystal structure, the trimeric CusA pump is found to contact six CusB 
 
Figure 7. Cocrystal structure of the CusBA adaptor-transporter complex. The ribbon 
diagram depicts the CusBA protomer found in the asymmetric unit of the crystal lattice, and 
the electron density map corresponds to the CusBA efflux complex. Each subunit of CusBA 
consists of one CusA molecule (green) and two CusB molecules (magenta and blue). The 
full structure includes the hexameric CusB adaptor and the trimeric CusA transporter. 
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adaptor molecules, which form a hexameric channel right above the periplasmic domain of 
CusA. The structure of the CusB hexamer mimics an inverted funnel. Domain 1 and the 
lower half of domain 2 of CusB create a cap-like structure, whereas domains 3, 4, and the 
upper half of domain 2 form the central channel of the funnel. The inner surface of the cap 
fits closely on top of the periplasmic domain of the CusA trimer. The funnel-like structure of 
hexameric CusB creates a channel extending contiguously from the top of the trimeric CusA 
pump. The narrowest section of the channel is at the hinge of CusB, between domains 2 and 
3. The hexameric CusB channel formed above the cap of the adaptor is ~62 Å in length with 
an average internal diameter of ~37 Å. Thus, the interior of the channel gives rise to a large 
elongated cavity with a volume of ~65,000 Å3. The lower half of the channel is primarily 
created by β-barrels, whereas the upper half is an entirely α-helical tunnel. The inner surface 
of the channel is predominantly negatively charged, as indicated by the electrostatic surface 
distribution, which suggests that the interior surface of the channel may have the capacity to 
bind to positively charged metal ions. One striking feature of this possible extrusion pathway 
is that the inner surface of the hexameric CusB channel is predominantly composed of 
negatively charged residues, suggesting that the interior surface of the channel may have the 
capacity to bind to positively charged metal ions. 
It is worth noting that the 1:2 relationship of CusA to CusB has led to the conclusion 
that that the entire assembled structure should be CusA3-CusB6-CusC3. This assembly is 
indeed in good agreement with the predicted 3:6:3 polypeptide ratios of these three-part 
complexes.43,94,115 
ITC was used to determine the binding affinity of CusB to the CusA pump, indicating 
a tight interaction with a Kd of 5.1 µM. Molecule 1 of CusB interacts predominantly with 
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CusA through charge–charge interactions, with residues K95, D386, E388 and R397 forming 
four salt bridges with D155, R771, R777 and E584 of CusA, respectively. Interestingly, the 
interaction between molecule 2 of CusB and CusA is mediated not by charge-charge but by 
charge–dipole and dipole–dipole interactions. Specifically, Q108, S109, S253 and N312 of 
molecule 2 of CusB form hydrogen bonds with Q785, Q194, D800 and Q198 of CusA, 
respectively.119 
Recently, artificial peptides, DARPins, have been introduced to bind and effectively 
inhibit the AcrB transporter.105 The inhibitor-binding site is found right above the cleft 
formed between PC1 and PC2 of AcrB. Interestingly, the location of this inhibitor-binding 
site corresponds to the binding site for molecule 2 of CusB in the CusBA complex. Thus, it is 
likely that the mechanism of action for these inhibitors may be the disruption of the adaptor-
transporter interaction by competition. 
By soaking the apo-crystals in Cu(I) solution, three distinct Cu(I)-bound structures 
were obtained, designated as the pre-extrusion 1, pre-extrusion 2 and extrusion states (pdbs: 
3T56, 3T51 and 3T53, respectively).117 The conformation of the pre-extrusion 1 structure 
was most similar to the binding state observed in CusA-Cu(I), where the periplasmic cleft 
formed by PC1 and PC2 was open. In the pre-extrusion 2 state, the conformation of the CusA 
molecule was more similar to the apo-CusA form (designated as the resting state), with a 
closed periplasmic cleft and disassembled three-methionine binding site. The extrusion form 
of CusBA-Cu(I) was nearly identical to the structure of apo-CusBA; similar to the pre-
extrusion 2 state, if not for a subtle motion of a short C-terminal helix of molecule 1 of CusB 
(residues 391-400), which appears to push against another helix of CusA (582-589) and in 
turn a loop (residues 609-626) directly below the PC1 helix. Based on these interactions, it 
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was proposed that CusB may be able to tune the width of the channel formed by the CusA 
pump, optimizing the process of metal ion extrusion. 
The conserved charged residues R83, E567, D617, E625, R664 and K678 in the 
periplasmic domain CusA can be seen in the CusBA structure to form a line along the inner 
wall of the methionine ladder (Fig. 8). These intriguingly positioned residues were mutated 
to alanines and expressed in the BL21(DE3) ΔcueOΔcusA knockout strain, to determine their 
importance in copper resistance. The MICs of CuSO4 in E. coli carrying these mutant CusA 
pumps were uniformly 0.5 mM; identical to the empty vector and much less than the 2.25 
 
 
Figure 8. Cu+ binding site and conserved charged residues in a schematic 
representation of the CusA channel. The conserved residues R83, E567, D617, E625, 
R669, and K678 lining the channel in the periplasmic domain are indicated. The 
dotted red circle marks the location of the Cu+ binding site formed by the methionine 
triad M573, M623, and M672. The paths for metal transport through the periplasmic 
cleft and transmembrane region are illustrated with curved black arrows. 
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mM of the wild-type. An in vitro fluorescence assay was also used to determine these 
residues’ importance in silver transport. When liposomes containing the mutant proteins and 
loaded with fluorescent indicator Phen Green SK were exposed to extravesicular Ag+ ions no 
quenching of the signal was observed, suggesting that these mutant transporters were unable 
to transport Ag+ across the membrane.  
In the earlier work, it was shown that the methionine residues M21, M36 and M38 of 
CusB represent the most likely Cu(I)- and Ag(I)-binding site. In both crystal structures of the 
CusB protein and CusBA adaptor-transporter complex, these methionines were located in the 
disordered N-terminus and their locations could not be resolved. The CusBA co-crystal 
structure revealed that the disordered N-terminal regions of both CusB molecules are located 
directly outside the periplasmic cleft of CusA, created by helices PC1 and PC2.119 
Previously, that same cleft was shown to house CusA’s single three-methionine binding 
site.62 Therefore, it was suggested that CusB may transfer bound Cu(I) and Ag(I) at this 
location from the periplasm to the CusA pump for extrusion. 
 
CusC—Outer Membrane Factor, “the Channel” 
Kulathila et al. published the complete structure (with the exception of disordered 
residues 21-31) in 2011, to a resolution of 2.3 Å (pdb: 3PIK).51 Based on the symmetry of the 
crystal and on gel-filtration measurements, CusC should assemble as a homotrimer, 
described as “cannon-shaped.” Each subunit of CusC in the trimer forms a ~130 Å long α/β 
barrel, containing four β-strands (contributing to the 12-stranded outer membrane β-barrel) 
and nine α-helices (forming the elongated periplasmic α-barrel) (Fig. 9). The trimeric CusC 
channel creates a large cylindrical internal cavity of ~28,000 Å3. Interestingly, the structure 
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of CusC suggests that the N-terminal cysteine residue of each protomer is covalently linked 
to the outer membrane via a thioester bond. This N-terminal cysteine residue may play an 
important role in protein-membrane interactions and could be critical for the insertion of this 
channel protein into the 
outer membrane.   
The cannon 
shape is remarkably 
similar to that of both 
TolC50 and OprM,2 
considering that TolC 
could not replace CusC 
in the mature pump.26 
Many outer-membrane 
channels exhibit the 
character of 
interchangeability. For 
example, AcrAB 
shares TolC with 
AcrEF and a hemolysin 
secretion system in E. coli,53 and in R. metallidurans cnrC deletion could be functionally 
restored by czcC or nccC expression.76 However, CusC is believed to only work within the 
Cus efflux system. This irreplaceability may be partly due to the unique secondary structure 
 
 
Figure 9. Crystal structure of the CusC outer membrane 
transporter. The CusC monomer (red) within the asymmetric unit 
of the crystal is depicted by the ribbon diagram. The electron 
density map corresponds to the biological CusC trimer, which is 
created by crystal symmetry. Each subunit of CusC consists of 
four β-strands atop nine α-helices, which are arranged as a 
barrel in the trimeric structure. 
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of CusB among members of the MFP family. Specifically, CusB forms a three α-helical 
domain, which is supposed to directly interact with the CusC channel. 
The RMSD calculated over alpha-carbons between CusC and TolC was measured at 
only 1.6 Å, and between CusC and OprM it was only 1.3 Å. Much of this difference is due to 
the exceptionally wide extracellular opening of CusC (~30 Å in diameter) compared to those 
of OprM or TolC (~12 Å). While the extracellular end of each channel is quite different in 
size, the periplasmic sides are all nearly closed in their respective crystal structures. 
Therefore, the CusC channel may require a substantial conformational change before 
allowing extrusion of substrates. Thus far, almost all available crystal structures of outer 
membrane channels are closed at one or both sides. It would be interesting to visualize the 
open conformational state of these channel proteins by crystallography. 
Although CusC was found to be highly specific to the CusCFBA pump as its outer 
membrane factor, there was no evidence of copper or silver specificity in the channel. The 
effects of soaking apo-CusC crystals in high concentrations of Cu(I) or Ag(I), even 
exceeding 10 mM, could not be observed by X-ray diffraction. Both CusA and CusB were 
found to coordinate their bound Cu(I) and Ag(I) with methionine residues, however the five 
methionines in CusC are far removed from one another as seen in the apo-structure. It is 
unlikely that CusC possesses any binding sites or specificity for Ag(I) and Cu(I) ions, 
however, as seen in the electrostatic charge distribution, the interior surface of the channel is 
“strikingly” electronegative.39 Although not an indication of specificity for metal ions, a 
similar but less electronegative feature was also observed in the hexameric CusB channel of 
the crystal structure of the CusBA complex. If the hexameric CusB and trimeric CusC 
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channels form the extrusion pathway of the pump, the electrostatic gradient created by the 
two interior surfaces may provide a possible pathway for ion extrusion. 
To understand how the CusBA complex interacts with CusC, a CusCBA fitting model 
was constructed based on the crystal structures of CusBA complex and CusC protein. The 
final CusC3-CusB6-CusA3 structural model represents an assembled tripartite efflux complex 
spanning both the inner and outer membranes of E. coli to extrude metal ions (Fig. 10). 
 
 
Figure 10. Docking of CusC to CusBA. The α-helical end of CusC interacts with the α-helices 
(domain 4) of CusB in the CusBA complex. The surface rendering of the CusC3-CusB6-CusA3 
complex is colored as follows: brown, CusC trimer; purple, CusB hexamer; green, CusA 
trimer. 
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CusF—Small Periplasmic Metal-Binding Protein, “the Chaperone” 
So far, each component (CusA, CusB and CusC) of our tetrapartite complex has a 
counterpart in the protypical multi-drug resistance systems AcrAB-TolC and MexAB-OprM. 
Then, there is CusF. When the cusF gene was first sequenced, nothing like it had been found 
in any known RND systems or any drug transporters.110 However, by the time its crystal 
structure was published, more than 35 CusF homologues had been identified among Gram-
negative bacteria, including two putative heavy-metal resistance determinants: czc of R. 
metallidurans and sil of S. typhimurium.59 The function of these proteins was largely 
unknown; nonetheless, three conserved residues M47, M49 and H36 were identified among 
their sequences, suggesting that these residues may represent a potential binding site. 
The crystal structure of apo-CusF was published by Loftin et al. in 2005 (pdb: 
1ZEQ),59 and two years later the CusF-Ag(I) complex structure was solved by the same 
group (pdb: 2QCP).58 The apo-structure was resolved to 1.5 Å, including ~93% of the total 
residues (residues 6-88). Based on the diffraction results, the structure of CusF can be simply 
described as a small five-stranded β-barrel, composed of two anti-parallel three-stranded β-
sheets which were packed orthogonally. The CusF-Ag(I) complex was resolved to 1.0 Å, 
including residues 10-88.58 An RMSD of only 0.5 Å was calculated between the apo and ion-
bound structures, indicating that these two structures are essentially the same. The bound 
Ag(I) in CusF was found to be indeed coordinated by H36, M47 and M49. 
The crystal structure of the CusF-Cu(I) complex (pdb: 2VB2) (Fig. 11) was published 
by Xue et al., one year later, with a resolution of 1.7 Å and including residues 13-87.128 Their 
structure was nearly identical to both the previous CusF-Ag(I) complex and apo-CusF 
structures. However, there was a slight conformational change observed upon Cu(I) binding, 
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which includes a twist of residues M47 and M49 to accommodate the bound metal ion. Upon 
ion-binding, these side chains swiveled to more closely coordinate the bound Cu(I), with a 
fourth residue, W44, implicated in binding. The proximity of this tryptophan residue to Cu(I) 
(~2.7 Å as determined by x-ray absorption spectroscopy) was “unprecedented” among 
previous metal-binding sites, and introduces a novel motif for Cu(I)-binding. 
Although it was found to bind both 
Cu(I) and Ag(I), it was yet unclear what role 
CusF might have in the efflux process. 
Recent experiments strongly suggest the 
possibility of a hand-off of bound Cu(I) or 
Ag(I) from CusF to CusB.9,16,66 Presumably, 
the specific interaction between CusF and 
CusB is critical for a direct transfer of Cu(I) 
and Ag(I) ions before extrusion via the 
CusCFBA efflux complex. Thus, the 
interaction between these two components 
may mark the initial step for metal ion 
extrusion by the CusCFBA tetrapartite 
efflux complex. 
 
 
 
 
 
 
Figure 11. Crystal structure of the metal ion-
-bound CusF metallochaperone. The binding 
of Cu+ and Ag+ (red) is coordinated by M47, 
M49, W44, and H36, which form a novel 
metal ion-binding site in CusF. 
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Concluding Remarks 
It has been well established that overexpression of RND multi-drug efflux pumps led 
to a resistant phenotype in pathogenic organisms. This problem is exacerbated by the ease 
with which many of these resistance genes can pass from one microorganism to another 
through plasmid transfer.20 Because of the fact that these multi-drug efflux pumps are able to 
respond to a wide spectrum of substrates, pathogenic bacteria that overexpress these pumps 
can be selected for by many different agents. For example, the organic compound 
nonoxynol-9, which is widely used as an active ingredient in most spermicide creams and 
jellies, can select Neisseria gonorrhoeae mutants that overexpress the MtrCDE RND-type 
multi-drug efflux pump.125 Thus, it is very important to understand the molecular mechanism 
as well as detailed structural information of these efflux pumps to combat infectious diseases. 
The availability of the three-dimensional structures of these efflux transporters 
potentially allows us to rationally design agents that block their function. However, there is 
still quite a mountain to climb in the development toward achieving this goal. For instance, a 
crystallographic model of these RND tripartite efflux complexes has not yet been reported. 
One direct approach to obtain the complete picture of these efflux complexes is to elucidate 
the structures of individual components as well as the assembled complexes of these efflux 
systems. This invaluable structural information should be able to provide a platform for 
producing new drugs and inhibitors to heighten bacterial sensitivity to these antimicrobials. 
In addition, the outer membrane channel proteins of these RND efflux complexes that span 
the outer membrane and expose to the surface of bacterial cells make them ideal targets for 
vaccines. Thus, the knowledge of these outer membrane channels is essential for the 
development of vaccines against bacterial diseases. 
  
68 
To date, no efflux pump inhibitor has been licensed for use in the clinical treatment of 
bacterial infections. Bacterial efflux pump inhibitors may probably simultaneously inhibit 
human detoxification systems and bacterial multi-drug efflux pumps. This will require a 
thorough research to ensure that these inhibitors are specific solely for the bacterial efflux 
pumps, minimizing their side effects to the host. As RND pumps assemble as tripartite 
complexes, one method to inhibit the drug-resistant phenotype is to prevent the assembly of 
complex formation by blocking the different components from forming a functional complex. 
The possibility of this approach has been demonstrated by the crystal structure of AcrB in 
complex with the designed ankyrin repeat protein inhibitor (DARPin).105 Based on the 
structural information of the CusBA adaptor-transporter complex,119 the inhibitor in principle 
is bound in such a way that the AcrB transporter is not able to form a functional complex 
with the AcrA adaptor. Therefore, the structural information of multi-drug efflux pumps, 
particularly with their assembled complex models, is of importance. In the case of the Cus 
efflux system, the availability of the co-crystal structures of the adaptor-transporter CusBA, 
channel-adaptor CusCB, and complete tetrapartite CusCFBA efflux complexes are essential 
in order to achieve this task although co-crystallization of different components of these 
RND efflux systems have been proven to be extremely difficult. 
Another potential approach is to target the transcriptional regulators that modulate the 
expression of these RND pumps. For example, the global regulator CmeR controls the 
expression of several genes, including cmeABC which produces the CmeABC RND efflux 
complex,30,55-57 and the transcriptional repressor MtrR which regulates the expression level of 
the MtrCDE tripartite multi-drug efflux pump.35,40,107,125 By inhibiting the interactions 
between the regulators and their corresponding substrates, expression of these transporter 
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genes could potentially be blocked. Recently, more examples of RND transporters regulated 
by two-component systems have been identified, including E. coli CusRS, which controls the 
expression of the CusCFBA efflux complex.31,68 The structures of different components of 
these regulatory systems may potentially allow us to rationally design inhibitors that reduce 
the level of efflux pump expression. 
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CHAPTER III 
 STRUCTURAL BASIS FOR THE REGULATION OF THE MMPL TRANSPORTERS OF 
MYCOBACTERIUM TUBERCULOSIS 
 
 
Delmar, JA, Chou, TH, Wright, CC, Licon, MH, Doh, JK, Radhakrishnan, A, Kumar, N, Lei, 
HT, Bolla, JR, Rajashankar, KR, Su, CC, Purdy, GE, and Yu, EW. (2015) J. Biol. Chem. 
290(47): 28559-28574 
 
Introduction 
Tuberculosis remains a significant global health problem. Its causative agent, 
Mycobacterium tuberculosis (Mtb), infects more than one third of the world’s population (1). 
The treatment of tuberculosis is notoriously difficult and is recently complicated by the 
emergence of multiple drug- resistant, extensively drug-resistant, or totally drug-resistant 
strains (2– 6). The mycobacterial cell wall is unique in composition, and cell wall lipids 
contribute to Mtb virulence (7–11). 
Understanding the molecular mechanisms underlying the biogenesis of the 
mycobacterial cell wall not only elucidates the basic biology of pathogenic mycobacteria but 
also identifies potential targets for antimicrobials. Mycolic acids are essential to 
mycobacterial viability and are incorporated as trehalose dimycolate and arabinogalactan 
mycolates. Biosynthesis of these respective mycobacterial cell wall lipids is targeted by the 
first line anti-tuberculosis drugs isoniazid and ethambutol (12-14). Mycobacterial cell wall 
biosynthesis is facilitated by the MmpL (mycobacterium membrane protein large) 
transporters (15), which belong to the RND (resistance-nodulation-cell division) superfamily 
(16). Based on the genomic sequence of M. tuberculosis H37Rv (15), this organism harbors 
14 different MmpL proteins. MmpL3 is essential, and MmpL4, MmpL5, MmpL7, MmpL8, 
MmpL10, and MmpL11 are required for full Mtb virulence. Similar to the RND efflux 
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pumps of Gram-negative bacteria, several of these MmpL transporters appear to work in 
conjunction with smaller accessory proteins called MmpS (mycobacterial membrane protein 
small) (7, 17, 18). However, unlike other RND family proteins, the MmpL proteins in M. 
tuberculosis are not believed to export antibiotics (7). Instead, there is strong evidence that 
these MmpL trans- porters and their MmpS accessory proteins are responsible for shuttling 
fatty acid and lipid components of the cell wall, such as trehalose monomycolate, sulfolipids, 
phthiocerol dimycocerosate, diacyltrehalose, monomeromycolyl diacylglycerol, and 
mycolate wax ester (7–9, 11, 19, 20, 22–25).  
Cell wall biogenesis and subsequent remodeling is crucial to the ability of Mtb to 
establish and maintain infection. It is therefore likely that Mtb carefully controls expression 
of cell wall lipid biosynthetic enzymes and MmpL lipid transporters. We capitalized on data 
made available by the Tuberculosis Systems Biology Consortium to begin an in-depth 
analysis of how mmpL and mmpS genes are regulated. Currently, ChIP-Seq data for 82 of the 
180 Mtb transcription factors are available on the Tuberculosis Database (26 –29). Utilizing 
these data, we recently showed that the MarR family regulator Rv0678 regulates the mmpS2-
mmpL2, mmpS4- mmpL4, and mmpS5-mmpL5 genes (30). In addition, we determined the 
crystal structure of Rv0678, which provided crucial insight into the induction mechanism of 
Rv0678 (30). Intriguingly, the Rv0678 crystal structure indicated the existence of a fortuitous 
bound ligand that was identified as 2-palmitoylglycerol (C21H42O4). The induced 
conformational change leading to substrate-mediated derepression is primarily caused by a 
rigid body rotational motion of the entire DNA-binding domain of the regulator toward the 
dimerization domain (30).  
In this paper, we report the crystal structures of the TetR family transcriptional 
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regulators Rv3249c and Rv1816, chosen based upon their predicted regulatory interactions 
with the mmpL3 or mmpL11 loci. Binding of these transcriptional regulators to the promoter 
and intragenic regions of mmpL
 
genes is summarized in Fig. 1. The crystal structures 
reported here highlight the unique properties of these regulators.  
Typically, the TetR family regulators are α-helical dimeric proteins, consisting of a 
smaller N-terminal DNA-binding domain and a larger C-terminal regulatory domain (31, 32). 
The N-terminal domains are quite conserved in protein sequences and form a helix-turn-helix 
motif for DNA binding. However, the C-terminal sequences are poorly conserved, forming 
ligand-specific binding domains for inducing molecules. Our data indicate that saturated fatty 
acids are able to bind at the C-terminal ligand-binding domains of Rv3249c and Rv1816. 
Interestingly, we have recently also found that the M. tuberculosis Rv0302 regulator can 
recognize fatty acid molecules (33).  
These findings suggest that fatty acids may be the natural ligands of these regulatory 
proteins. We used fluorescence polarization and EMSA to demonstrate that these proteins 
regulate multiple mmpL genes. These results emphasize the complexity of the mmpL 
regulatory system and a novel mechanism by which the bacterium can sense metabolic state 
to modulate cell wall lipid biosynthesis and transport to maintain homeostasis and promote 
virulence.  
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Figure 1. Schematic depiction of transcription factor binding sites in the mmpL genes of 
interest. ChIP-Seq data for each transcription factor was obtained from Tuberculosis 
Database. In these experiments, FLAG-tagged transcription factors were episomally expressed 
in Mtb under the control of an anhydrotetracycline-inducible promoter (29). The colored 
shapes corresponding to each transcription factor (red circle, Rv3249c; blue triangle, 
Rv1816) are placed at the putative binding sites. 
  
84 
Experimental Procedures 
Cloning of rv3249c and rv1816 
The rv3249c ORF from genomic DNA of M. tuberculosis strain H37Rv was 
amplified by PCR using the primers 5’-
CTTTAAGAAGGAGATATACCATGGTGAGCACTCCAAGCGCTAC-3’ and 5’-
GATCCTCAGTGATGATGGTGGTGATGGGGGACATTGATCACACCGTG-3’ to 
generate a product that encodes a Rv3249c recombinant protein with a His6 tag at the C 
terminus. The corresponding PCR product was digested with NcoI and BamHI, extracted 
from the agarose gel, and inserted into pET15b as described by the manufacturer (Merck). 
The recombinant plasmid (pET15bΩrv3249c) was transformed into DH10b cells, and the 
transformants were selected on LB agar plates containing 100 µg/mL ampicillin. The 
presence of the correct rv3249c sequence in the plasmid construct was verified by DNA 
sequencing.  
The procedures for producing the recombinant plasmid pET15bΩrv1816 were the 
same as those for pET15bΩrv3249c. The rv1816 ORF from genomic DNA of M. 
tuberculosis strain H37Rv was amplified by PCR using the primers 5’-
CTTTAAGAAGGAGATATACCATGTTGTGTCAGACTTGCCGCGTG-3’ and ‘5-
GATCCTCAGTGATGATGGTGGTGATGCTCGGCCAGCACGGCCAC-3’ to generate a 
product that encodes the Rv1816 recombinant protein with a His6 tag at the C terminus.  
 
Expression and purification of Rv3249c and Rv1816 
Briefly, the full-length Rv3249c protein containing a His6 tag at the C terminus was 
overproduced in E. coli BL21(DE3) cells possessing pET15bΩrv3249c. The cells were 
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grown in 6 L of LB medium with 100 µg/mL ampicillin at 37 °C. When the A600 reached 0.5, 
the culture was treated with 0.2 mM isopropyl-β-D-thiogalactopyranoside to induce Rv3249c 
expression, and cells were harvested within 3 h. The collected bacterial cells were suspended 
in 100 mL of ice-cold buffer containing 20 mM Na-HEPES (pH 7.2), 200 mM NaCl, 10 mM 
MgCl2, and 0.2 mg of DNase I (Sigma-Aldrich). The cells were then lysed with a French 
pressure cell. Cell debris was removed by centrifugation for 45 min at 4 °C and 20,000 
rev/min. The crude lysate was filtered through a 0.2 µm membrane and was loaded onto a 5-
mL Hi-Trap Ni2-chelating column (GE Healthcare Biosciences) pre-equilibrated with 20 mM 
Na-HEPES (pH 7.2) and 200 mM NaCl. To remove unbound proteins and impurities, the 
column was first washed with six column volumes of buffer containing 50 mM imidazole, 
250 mM NaCl, and 20 mM Na-HEPES (pH 7.2). The Rv3249c protein was then eluted with 
four column volumes of buffer containing 300 mM imidazole, 250 mM NaCl, and 20 mM 
Na-HEPES (pH 7.2). The purity of the Rv3249c protein (>95%) was judged using 12.5% 
SDS-PAGE stained with Coomassie Brilliant Blue. The purified protein was then 
concentrated to 10 mg/mL. 
For the His6 SeMet-Rv3249c protein expression, a 10 mL LB broth overnight culture 
containing E.coli BL21(DE3)/pET15bΩrv3249c cells was transferred into 60 mL of LB 
broth containing 100 µg/mL ampicillin and grown at 37 °C. When the A600 value reached 1.2, 
cells were harvested by centrifugation at 5,000 g for 10 min and then washed two times with 
10 mL of M9 minimal salt solution. The cells were resuspended in 60 mL of M9 medium and 
then transferred into a 6 L pre-warmed M9 solution containing 100 µg/mL ampicillin. The 
cell culture was incubated at 37 °C with shaking. When the A600 reached 0.4, 100 mg/L of 
lysine, phenylalanine, and threonine, 50 mg/L isoleucine, leucine, and valine, and 60 mg/L of 
  
86 
L-selenomethionine were added. The culture was induced with 0.2 mM isopropyl-β-D-
thiogalactopyranoside after 15 min. The cells were then harvested within 3 h after induction. 
The procedures for purifying SeMet-Rv3249c were identical to those of the native protein.  
The full-length Rv1816 protein containing a His6 tag at the C terminus was 
overproduced in E. coli BL21(DE3) cells possessing pET15bΩrv1816. The procedures for 
expressing and purifying the Rv1816 protein were the same as those for Rv3249c. The purity 
of the Rv1816 protein (>95%) was judged using 12.5% SDS-PAGE stained with Coomassie 
Brilliant Blue. The purified protein was then concentrated to 10 mg/mL.  
 
Crystallization of Rv3249c and Rv1816 
The His6 Rv3249c crystals were grown in microcentrifuge tubes (Fisher Scientific). 
Briefly, 10 µL aliquots of protein solution containing 20 mg/mL Rv3249c protein in 20 mM 
Na-HEPES (pH 7.5), 250 mM NaCl, and 300 mM imidazole were incubated at 4 °C. Crystals 
of Rv3249c grew to a full size within 2 weeks. Typically, the dimensions of the crystals were 
0.05 mm x 0.05 mm x 0.1 mm. Cryoprotection was achieved by raising the glycerol 
concentration stepwise to 40% with a 5% increment in each step. Crystals of SeMet-Rv3249c 
were obtained using the same procedures as for the native Rv3249c crystals. Typically, the 
dimensions of the crystals were 0.05 mm x 0.05 mm x 0.1 mm.  
The His6 Rv1816 crystals were grown at room temperature in 24-well plates 
(Hampton Research, Aliso Viejo, CA) using hanging drop vapor diffusion with the following 
procedures. A 1 µL protein solution containing 10 mg/mL Rv1816 protein in 20 mM Na-
HEPES (pH 7.5), 250 mM NaCl, and 300 mM imidazole was mixed with 1 µL of reservoir 
solution containing 0.05 M sodium cacodylate (pH 6.5), 2 M ammonium sulfate, and 10 mM 
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magnesium sulfate. The resultant mixture was equilibrated against 500 µL of the reservoir 
solution. Hexagonal crystals appeared within 2 days and grew to full size in the drop within 1 
week. Typically, the dimensions of the crystals were 0.05 mm x 0.05 mm x 0.1 mm. 
Cryoprotection was achieved by raising the ammonium sulfate concentration stepwise to 3.5 
M.  
 
Data collection, structural determination, and refinement 
All diffraction data were collected at 100 K at Beamline 24ID-C located at the 
Advanced Photon Source, using a Pilatus 6M detector (Dectris Ltd., Switzerland). 
Diffraction data were processed using DENZO and scaled using SCALEPACK (34).  
The Rv3249c crystals belong to the space group C2 (Table 1). Based on the molecular weight 
of Rv3249c (22.8 kDa), six Rv3249c molecules are expected in the asymmetric unit with a 
solvent content of 62.96%. Within the asymmetric unit of SeMet-Rv3249c, 12 selenium sites 
(two per monomer) were identified using SHELXC and SHELXD (35) as implemented in  
the HKL2MAP package (36). The full-length Rv3249c protein contains two methionine 
residues; both were identified as SeMet sites in each protomer. Single anomalous dispersion 
was employed to obtain experimental phases using the program MLPHARE (37, 38). The 
resulting phases were then subjected to density modification and NCS averaging using the 
program PARROT (39) using the native structure factor amplitudes. The SeMet sites were 
also used to trace the molecules by anomalous difference Fourier maps, where we could 
ascertain the proper registry of SeMet residues. The initial model, which consists of three 
dimeric molecules, was constructed manually using program Coot (40). Then the model was 
refined using PHENIX (41), leaving 5% of reflections in the Free-R set.  
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Table 1. Data collection, phasing and structural refinement statistics of Rv3249c and 
Rv1816. 
Data set  Rv3249c Native SeMet-Rv3249c Rv1816 
Data collection  
Wavelength (Å)  0.9792 0.9792 0.9792 
Space group  C2 C2 P212121 
Cell constants (Å)     
a  233.5 232.0 40.5 
b  75.3 75.4 86.5 
c  125.0 121.0 129.9 
α, β, γ (°)  90, 121.6, 90 90, 121.1, 90 90, 90, 90 
Resolution (Å)  3.59 (3.72-3.59) 3.40 (3.52-3.40) 2.00 (2.07-2.00) 
Completeness (%)  95.7 (97.6)   98.4 (96.1) 99.9 (100.0) 
Total reflections  491,698 2,356,230 1,011,787 
Unique reflections  22,121 24,714 31,661 
Redundancy  3.5 (3.6) 5.8 (5.1) 6.3 (6.5) 
Rmerge (%)  11.4 (39.1) 5.0 (41.6) 6.4 (41.3) 
〈I/σ(I)〉   11.0 (4.2) 27.9 (3.5) 24.1 (5.4) 
Phasing  
Number of sites   12  
Resolution used (Å)   4.0  
Phasing power     
(acentric/centric)   1.0/0.69  
RCullis     
(acentric/centric)   0.88/0.90  
Figure of merit     
(acentric/centric)   0.43/0.20  
Refinement  
Resolution (Å)  40-3.59  40-2.00 
Rwork (%)  17.70  17.75 
Rfree (%)  27.82  22.16 
Overall B-factor (Å2)  51.37  55.68 
Rms deviations     
Bond (Å)  1.676  1.392 
Angles (o)  0.013  0.013 
Ramachandran analysis  
Most favored (%)  97  94.7 
Allowed (%)  2.5  5.2 
Generously allowed (%)  0.5  0.1 
Disallowed (%)  0  0.0 
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Iterations of refinement using PHENIX (41) and CNS (42) and model building in Coot (40) 
lead to the current model, which consists of three dimeric structures with a total number of 
1,160 residues (Table 1). 
The Rv1816 crystal belongs to the space group P212121, resulting in a single Rv1816 
dimer (25.4 kDa) in the asymmetric unit with a solvent content of 51.78%. The structure of 
Rv1816 was determined using molecular replacement. The partial structure of the TetR 
family protein SCO4313 (residues 61–229) (Protein Data Bank code 2OI8) was utilized as a 
template. The resulting phases were then subjected to density modification using the program 
RESOLVE (43). The remaining part of the model was manually constructed using the 
program Coot (40). Model was then refined using PHENIX (41), leaving 5% of reflections in 
the Free-R set. Iterations of refinement using PHENIX (41) and CNS (42) and model 
building in Coot (40) lead to the current model of the Rv1816 dimer, consisting of a total 
number of 449 residues (Table 1).  
 
Identification of fortuitous ligands 
To identify the nature of the bound ligand in crystals of Rv3249c, we used GC-MS. 
The Rv3249c crystals were extensively washed with the crystallization buffer and transferred 
into deionized water. The mixture was then incubated at 100 °C for 5 min, and then 
chloroform was added into the mixture to a final concentration of 80% (v/v) to denature the 
protein and allow for the extraction of ligand. GC-MS analysis indicated that the mass of the 
bound ligand was n-hexadecanoic acid, also called palmitic acid.  
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We used the same method to identify the bound ligand in crystals of Rv1816. GC-MS 
analysis indicated that the mass of the bound ligand corresponded to isopropyl dodecanoate, 
also called isopropyl laurate.  
 
Isothermal titration calorimetry for ligand binding 
We used isothermal titration calorimetry (ITC) to determine the binding affinity of 
palmitic acid to the purified Rv3249c regulator. Measurements were performed on a VP-
Microcalorimeter (MicroCal, Northampton, MA) at 25 °C. Before titration, the protein was 
thoroughly dialyzed against buffer containing 10 mM sodium phosphate (pH 7.2), 100 mM 
NaCl, and 0.001% DDM. The protein concentration was determined using the Bradford 
assay. The dimeric Rv3249c sample was then adjusted to a final concentration of 10 µM. The 
ligand solution containing 500 µM palmitic acid, 10 mM sodium phosphate (pH 7.2), 100 
mM NaCl, and 0.001% DDM was used as the titrant. Binding experiments were carried out 
with the protein solution (1.4 mL) in the cell and the ligand solution as the injectant. Thirty 
injections of 10 µL each of the ligand solution were used for data collection.  
Injections occurred at intervals of 240 s, and the duration time of each injection was 
20 s. Heat transfer (µcal/s) was measured as a function of elapsed time (s). The mean 
enthalpies measured from injection of the ligand in the buffer were subtracted from raw 
titration data before data analysis with ORIGIN software (MicroCal). Titration curves were 
fitted by a non-linear least squares method to a function for the binding of a ligand to a 
macromolecule. Nonlinear regression fitting to the binding isotherm provided us with the 
equilibrium binding constant (KA = 1/KD) and enthalpy of binding (ΔH). Based on the values 
of KA, the change in free energy (ΔG) and entropy  
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(ΔS) were calculated with the equation: ΔG = -RT lnKA = ΔH - TΔS, where T is 273 K and R 
is 1.9872 cal/K per mol. Calorimetry trials were also carried out in the absence of Rv3249c in 
the same experimental conditions. No change in heat was observed in the injections 
throughout the experiment.  
ITC was also used to determine the binding affinities of palmitate and laurate to the 
purified Rv1816 regulator. The Rv1816 protein was thoroughly dialyzed against buffer 
containing 10 mM sodium phosphate (pH 7.2), 100 mM NaCl, and 0.001% DDM. The 
dimeric Rv1816 sample was then adjusted to a final concentration of 10 µM. The ligand 
solution contained 400 µM palmitic or lauric acid, 10 mM sodium phosphate (pH 7.2), 100 
mM NaCl, and 0.001% DDM. The procedures for these binding experiments were identical 
to those for the Rv3249c protein.  
 
Fluorescence polarization assay for DNA binding 
Fluorescence polarization assays were used to determine the affinities for DNA 
binding by Rv3249c and Rv1816, respectively. All oligodeoxynucleotides and their 
corresponding fluorescein-labeled oligodeoxynucleotides were purchased from Integrated  
DNA Technologies, Inc. (Coralville, IA). The sequences of these oligodeoxynucleotides are 
indicated in Table 2. In short, the fluoresceinated dsDNA was prepared by annealing the 
oligodeoxynucleotide and its corresponding fluorescein-labeled oligodeoxynucleotide 
together. Fluorescence polarization experiment was done using a DNA binding solution 
containing 10 mM sodium phosphate (pH 7.2), 100 mM NaCl, 2.5 nM fluoresceinated DNA, 
and 1 µg of poly(dI-dC) as nonspecific DNA. The protein solution containing 500 nM 
dimeric Rv3249c or Rv1816, and 2.5 nM of the respective fluoresceinated DNA was titrated 
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into the DNA binding solution until the millipolarization became unchanged. All 
measurements were performed at 25 °C using a PerkinElmer LS55 spectrofluorometer 
equipped with a Hamamatsu R928 photomultiplier. The excitation wavelength was 490 nm, 
and the fluorescence polarization signal (in ΔP) was measured at 525 nm. Each titration point 
recorded was an average of 15 measurements. The data were analyzed using the equation, p 
= {(Pbound - Pfree)[protein]/(KD + [protein])} + Pfree, where P is the polarization measured at a 
given total protein concentration, Pfree is the initial polarization of free fluorescein-labeled 
DNA, Pbound is the maximum polarization of specifically bound DNA, and [protein] is the 
protein concentration. The titration experiments were repeated for three times to obtained the 
average KD value. Curve fitting was accomplished using the program ORIGIN (OriginLab  
Corporation, Northampton, MA).  
 
Table 2. Affinity for DNA binding by Rv3249c or Rv1816. 
a F denotes the fluorescein that was covalently attached to the 5’ end of the oligonucleotide 
(reversed) by a hexamethylene linker.  
 
Transcription	
Factor	
DNA	sequence	 Location	 Kd	(nM)	
Rv3249c	 5’-TTTTGACCTCGCCGTAAACGATGTAAACG-3’	
5’-F-CGTTTACATCGTTTACGGCGAGGTCAAAA-3’a	
mmpS1-
mmpL1	
18.7	±	9.5	
	 	 	 	 	
	 5’-CGTGACATCGACCGTTTCGATGTTCGG-3’	 mmpL11	 5.6	±	1.0	
	 5’-F-CCGAACATCGAAACGGTCGATGTCACG-3’a	 	 	
	 	 	 	
	 5’-AATGAATGTCAACACATTTGACATTTCAG-3’	 rv1067c	 26.9	±	4.9	
	
	
Rv1816	
5’-F-CTGAAATGTCAAATGTGTTGACATTCATT-3’a	
	
5’-CTTCGCGCGGGTCGCGCGGCT-3’	
5’-F-AGCCGCGCGACCCGCGCGAAG-3’a	
	
5’-ACAGATTTCGTGAAATCGGG-3’	
5’-F-CCCGATTTCACGAAATCTGT-3’a	
	
	
mmpL13b	
	
	
rv1094	
	
	
4.3	±	0.4	
	
	
6.9	±	0.7	
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Electrophoretic mobility shift assay 
Probes were amplified from the H37Rv genome using the primers listed in Table 
3. All probes were labeled with digoxigenin using the Roche DIG gel shift kit. For EMSA 
analysis, 12 nM Dig-labeled probe and the indicated micromolar concentrations of protein 
were incubated for 45 min at room temperature in the Roche binding buffer modified by the 
addition of 0.25 mg/mL herring sperm DNA, and 0.75 mg/mL poly(d[I-C]). For ligand 
competition assays, stock solutions of fatty acids were made in DMSO and a solvent control 
reaction included at the highest concentration of DMSO. All reactions were resolved on a 6% 
native polyacrylamide gel in TBE buffer and transferred to nylon membrane and Dig-labeled 
DNA-protein complexes detected following the manufacturer’s recommendations.  
Chemiluminescent signals were acquired using an ImageQuant LAS 4000 (GE).  
 
Table 3. Primers for EMSA probes. 
 
These findings suggest that fatty acids may be the natural
ligands of these regulatory proteins. We used fluorescence
polarization and EMSA to demonstrate that these proteins reg-
ulate multiplemmpL genes. These results emphasize the com-
plexity of themmpL regulatory system and a novel mechanism
by which the bacterium can sense metabolic state to modulate
cell wall lipid biosynthesis and transport to maintain homeo-
stasis and promote virulence.
Experimental Procedures
Cloning of rv3249c and rv1816—The rv3249c ORF from
genomicDNAofM. tuberculosis strainH37Rvwas amplified by
PCR using the primers 5!-CTTTAAGAAGGAGATATACCA-
TGGTGAGCACTCCAAGCGCTAC-3! and 5!-GATCCTCA-
GTGATGATGGTGGTGATGGGGGACATTGATCACAC-
CGTG-3! to generate a product that encodes a Rv3249c
recombinant protein with a His6 tag at the C terminus. The
corresponding PCR product was digested with NcoI and
BamHI, extracted from the agarose gel, and inserted into pET-
15b as described by the manufacturer (Merck). The rec-
ombinant plasmid (pET15b"rv3249c) was transformed into
DH10b cells, and the transformants were selected on LB agar
plates containing 100 !g/ml ampicillin. The presence of the
correct rv3249c sequence in the plasmid construct was verified
by DNA sequencing.
The procedures for producing the recombinant plasmid
pET15b"rv1816 were the same as those for pET15b"rv3249c.
The rv1816 ORF from genomic DNA ofM. tuberculosis strain
H37Rv was amplified by PCR using the pri ers 5!-CTTTAA-
GAAGGAGATATACCATGTTGTGTCAGACTTGCCGCG-
TG-3! and 5!-GATCCTCAGTGATGATGGTGGTGATGCT-
CGGCCAGCACGGCCAC-3! to generate a product that
enco es t e Rv1816 re ombinant protein with His6 tag at the
C terminus.
Expression and Purification of Rv3249c and Rv1816—Briefly,
the full-length Rv3249c protein containing a His6 tag at the C
terminus was overproduced in Escherichia coli BL21(DE3) cells
possessing pET15b"rv3249c. The cells were grown in 6 liters of
TABLE 1
Data collection, phasing and structural refinement statistics of
Rv3249c and Rv1816
Data set Rv3249c SeMet-Rv3249c Rv1816
Data collection
Wavelength (Å) 0.9792 0.9792 0.9792
Space group C2 C2 P212121
Cell constants (Å)
a 233.5 232.0 40.5
b 75.3 75.4 86.5
c 125.0 121.0 129.9
", #, $ (°) 90, 121.6, 90 90, 121.1, 90 90, 90, 90
Resolution (Å) 3.59 (3.72–3.59) 3.40 (3.52–3.40) 2.00 (2.07–2.00)
Completeness (%) 95.7 (97.6) 98.4 (96.1) 99.9 (100.0)
Total reflections 491,698 2,356,230 1,011,787
Unique reflections 22,121 24,714 31,661
Redundancy 3.5 (3.6) 5.8 (5.1) 6.3 (6.5)
Rmerge (%) 11.4 (39.1) 5.0 (41.6) 6.4 (41.3)
#I/%(I)$ 11.0 (4.2) 27.9 (3.5) 24.1 (5.4)
Phasing
Number of sites 12
Resolution used (Å) 4.0
Phasing power
(acentric/centric)
1.0/0.69
RCullis (acentric/centric) 0.88/0.90
Figure of merit
(acentric/centric)
0.43/0.20
Refinement
Resolution (Å) 40–3.59 40–2.00
Rwork (%) 17.70 17.75
Rfree (%) 27.82 22.16
Overall B-factor (Å2) 51.37 55.68
Root mean square
deviations
Bond (Å) 1.676 1.392
Angles (o) 0.013 0.013
Ramachandran analysis
Most favored (%) 97 94.7
Allowed (%) 2.5 5.2
Generously allowed (%) 0.5 0.1
Disallowed (%) 0 0.0
TABLE 2
Affinity for DNA binding by Rv3249c or Rv1816
Regulator DNA Sequence Location KD
nM
Rv3249c 5!-CGTGACATCGACCGTTTCGATGTTCGG-3! mmpL11 5.6% 1.0
5!-F- CCGAACATCGAAACGGTCGATGTCACG-3!a
Rv3249c 5!-TTTTGACCTCGCCGTAAACGATGTAAACG-3! mmpS1/L1 18.7% 6.5
5!-F-CGTTTACATCGTTTACGGCGAGGTCAAAA-3!a
Rv3249c 5!-AATGAATGTCAACACATTTGACATTTCAG-3! rv1067c 26.9% 4.9
5!-F-CTGAAATGTCAAATGTGTTGACATTCATT-3!a
Rv1816 5!-CTTCGCGCGGGTCGCGCGGCT-3! mmpL13b 4.3% 0.4
5!-F-AGCCGCGCGACCCGCGCGAAG-3!a
Rv1816 5!-ACAGATTTCGTGAAATCGGG-3! rv1094 6.9% 0.7
5!-F-CCCGATTTCACGAAATCTGT-3!a
a F denotes the fluorescein that was covalently attached to the 5! end of the oligodeoxynucleotide (reversed) by a hexamethylene linker.
TABLE 3
Primers for EMSA probes
Primer Sequence
Rv1816–1F 5!-CTCGGTTGTGTCAGACTTGC-3!
Rv1816–1R 5!-CAACAGCTCATCACGACTGG-3!
Rv1816–2F 5!-TGGGCCTTGCTATACGGTAG-3!
Rv1816–2R 5!-GCAGAAAGCACTTTGTGACG-3!
mmpL3.1816F 5!-GGCAACACGGTGATAGACAG-3!
mmpL3.1816R 5!-GAAGGCTACGACACCGAGAC-3!
Rv0204.1816F 5!-GGATGACAAGTCGCAGGTTT-3!
Rv0204.1816R 5!-CATCTCGGCGATGTTGATCT-3!
mmpl11.1816F 5!-ATCTCGTGTGACGAGTCGAA-3!
mmpl11.1816R 5!-GTCAGCGTTAGTGCACTGGT-3!
mmpL7.1816F 5!-AGTACGTCGTCGCCTTTCTC-3!
mmpL7.1816R 5!-ATAATTGATGGCGGGGATTC-3!
kasA.1816F 5!-TCCAAGTGAGTCAGCCTTCC-3!
kasA.1816R 5!-ACCGGATCCTTGAGGTGAC-3!
mmpS3.1816F 5!-GTCCATCGTTGGAGTTCGAT-3!
mmpS3.1816R 5!-CGGTGACTTACGTCGATGC-3!
rv1094.1816F 5!-TCGAGGAGTGGAGTCTGGTC-3!
rv1094.1816R 5!-GACGTAGTCGTGGGCGAAC-3!
mmpL3.3249cF 5!-ATGACCCCGATTACGATGAA-3!
mmpL3.3249cR 5!-GAGGACATCGCTGGTGTTTT-3!
mmpL11.3249cF 5!-CGGTAGCGCATCAGGATGAA-3!
mmpL11.3249cR 5!-CGCTGGAACCTGCCTATCAT-3!
rv3249c.3249cF 5!-AGAGCACATTGGCGTCGTTA-3!
rv3249c.3249cR 5!-CGGCAACTTTTACGAAGCGT-3!
mmpS1.3249cF 5!-TGATGTGAGCCAAACACCGA-3!
mmpS1.3249cR 5!-TTTGACCTCGCCGTAAACGA-3!
rv1067.3249cF 5!-GAATTGCTCGTGCGATCCGG-3!
rv1067.3249cR 5!-GATCCGGTGTGACGACGTATC-3!
Structures of Transcriptional Regulators Rv3249c and Rv1816
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Results and Discussion 
Overall structure of Rv3249c 
The crystal structure of the 211-amino acid Rv3249c protein was determined to a 
resolution of 3.59 Å using single anomalous dispersion (Table 1 and Fig. 2). Six molecules of 
Rv3249c are found in the asymmetric unit, which assemble as three independent dimers. 
Superimposition of these six Rv3249c molecules gives root mean square deviations between 
0.8 and 1.0 Å over 190 Cα atoms, indicating that their conformations are nearly identical to 
each other.  
Like other members of the TetR family regulators (31, 32), the structure of Rv3249c 
suggests that this regulator is an all α-helical protein. Each subunit of Rv3249c dimer is 
composed of 10 α-helices (α1-α10 and α1’-α10’, respectively) (Fig. 3). These helices are 
designated as α1 (16–36), α2 (49–53), α3 (57–64), α4 (67–92), α5 (97–114), α6 (116–123), 
α7 (128– 134), α8 (138 –155), α9 (162–181), and α10 (190 –205). The overall architecture 
can be divided into two domains. Residues	16 –77, comprising α1, α2, and α3, and the N-
terminal end of	α4, form the DNA-binding domain. Helices α2 and α3 exhibit the classical 
helix-turn-helix motif, typical of these regulators. Residues 68 –205, comprising the C-
terminal end of α4 through α10, form the ligand-binding domain of Rv3249c. Helices α4, 
α5, α8, and α9 form an antiparallel four-helix bundle, which creates a large ligand-binding 
cavity to accommodate for the inducing ligands. Helices α6 and α7, and the loop connecting 
these two short helices create the floor of this ligand-binding site. It should be noted that a 
typical TetR regulator normally utilizes a single helix, which runs horizontally to form the 
bottom of the ligand-binding site. Rv3249c is distinct in that it employs two inclined helices 
to create a V-shaped bottom, allowing it to enlarge the volume of the binding site.  
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Figure 2. Stereo view of the experimental electron density maps of Rv3249c at a 
resolution of 3. 59 Å. A, the electron density maps are contoured at 1.0 σ. The Cα 
traces of the three Rv3249c dimers in the asymmetric unit are in slate, wheat, 
green, cyan, yellow, and magenta. B, anomalous signals of the 12 selenium sites 
(contoured at 5 σ) found in the asymmetric unit are colored red. The Cα traces of 
the three Rv3249c dimers in the asymmetric unit are in green, cyan, white, light 
pink, magenta, and yellow. C, representative section of electron density in the 
vicinity of helices α9 and α10. The solvent-flattened electron density (40–3.59 Å) is 
contoured at 1.0 σ and superimposed with the final refined model (green, carbon; 
red, oxygen; blue nitrogen; yellow, sulfur). 
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Indeed, each subunit of Rv3249c possesses a very large cavity, which was estimated to be 
450 Å3 within the C-terminal ligand binding domain. Based on this observation, we expect 
that this regulator can accommodate a large inducing ligand.  
The smaller N-terminal 
domain of Rv3249c shares 
considerable structural similarities 
with other TetR family members. 
However, this domain also 
presents some noticeable 
differences. Helix α1, consisting of 
21 amino acids, is relatively long 
compared with other members of 
the family. This helix tilts upward 
by 15° in relation to the horizontal 
surface, which is perpendicular to 
the vertical plane formed by the 
dimer interface. This orientation 
facilitates the two N-terminal 
domains within the dimer to shift 
away from each other, leaving a 
relatively large gap between the 
two DNA recognition helices α3 
 
 
Figure 3. Structure of the M. tuberculosis Rv3249c 
regulator. A, ribbon diagram of a protomer of 
Rv3249c. The molecule is colored using a rainbow 
gradient from the N terminus (blue) to the C terminus 
(red). B, ribbon diagram of the Rv3249c dimer. Each 
subunit of Rv3249c is labeled with a different color 
(orange and green). The figure was prepared using 
PyMOL. 
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and α3’. Helices α3 and α3’ play a key role in the binding of cognate DNA. Because the 
distance between two consecutive major grooves of a B-form DNA is ~34 Å, the center to 
center distance between helices α3 and α3’ of the regulator has to be about 34 Å to bind the 
DNA. In Rv3249c, this center to center distance, according to the separation between Cα 
atoms of Y61 and Y61’, was measured to be 47 Å, suggesting that, in this conformation, the 
regulator cannot bind B-DNA, and this conformation should correspond to the induced form.  
The relatively large center to center distance also indicated that the crystallized 
Rv3249c protein has an attached ligand. As expected, a large extra electron density was 
found within the C-terminal regulatory domain of the ligand-binding site of each subunit of 
Rv3249c, indicating the existence of a fortuitous bound ligand co-purified and co-crystallized 
with this regulator. To identify the unknown bound ligand, GC-MS was used to study these 
 
 
Figure 4. Identification of the fortuitous ligand of Rv3249c by GC-MS. A, electron 
ionization spectrum of the strongest GC peak at 10.45 min. B, GC-MS spectrum of n-
hexadecanoic acid from the internal GC-MS library. The ligand was identified as 
palmitic acid. 
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Rv3249c crystals (Fig. 4). The data suggest that the fortuitous ligand is palmitic acid, also 
called hexadecanoic acid, a saturated fatty acid containing 16 carbons with the molecular 
formula C16H32O2. Because this fatty acid was found to be co-purified and co-crystallized 
with the Rv3249c regulator, fatty acids may be the natural substrates of this protein.  
The bound palmitic acid is completely buried in the Rv3249c binding cavity (Fig. 5). 
Extensive hydrophobic interactions are found to anchor this acid. Within 5 Å of the bound 
ligand, there are at least 22 amino acids, including Ala-75, Leu-78, Ala-79, Leu-82, Leu-83, 
Val-86, Phe-101, Gly-104, Phe-105, Phe-108, Leu-117, Val-118, Leu-130, Leu-133, Ile-141, 
Ala-145, Leu-149, Ile-172, Val-173, Cys-176, Leu-177, and Val-180, involved to secure the 
binding (Fig. 5). Many of these residues are hydrophobic in nature.  
 
Overall structure of Rv1816 
The crystal structure of the 234-amino acid protein Rv1816 was determined to a 
resolution of 2.00 Å (Table 1 and Fig. 6). Because M. tuberculosis Rv1816 shares 31% 
protein sequence identity with Streptomyces coelicolor SCO4313 (Protein Data Bank code 
2OI8), we utilized the existing structure of SCO4313 from the Protein Data Bank as a search 
model for molecular replacement to obtain the crystal structure of Rv1816. Two molecules of 
Rv1816, which assemble as a dimer, are found in the asymmetric unit. Similar to Rv3249c, 
the structure of Rv1816 can be divided into N-terminal DNA-binding and C-terminal ligand-
binding domains. This regulator is also an all α-helical protein, composed of 10 α-helices 
(α1–α10 and α1’–α10’, respectively) (Fig. 7): α1 (13– 31), α2 (39 – 46), α3 (50 –56), α4 
(60 – 85), α5 (91–108), α6 (110 –117), α7 (128 –152), α8 (164 –177), α9 (183–205), and 
α10 (216 –232).  
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Figure 5. Simulated annealing electron density maps and the palmitate binding site. A, 
stereo view of the simulated annealing electron density map of the bound palmitate 
within the Rv3249c protomer (the orientation corresponds to the side view of Fig. 1B). 
The bound palmitate is shown as a stick model (green, carbon; red, oxygen). The 
simulated annealing 2Fo − Fc electron density map is contoured at 1.0 σ (blue mesh). 
The right subunit of Rv3249c is shown as orange ribbons. B, the palmitate binding site. 
Amino acid residues within 5.0 Å from the bound palmitate (green, carbon; red, oxygen) 
are included. The side chains of selected residues from the right subunit of Rv3249c in 
Fig. 1B are shown as orange sticks (orange, carbon; blue, nitrogen; red, oxygen). C, 
schematic representation of the Rv3249c and palmitate interactions. Amino acid residues 
within 5.0 Å from the bound palmitate are included. 
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The structure of Rv1816 is unique among the TetR family regulators. In the C-
terminal ligand-binding domain, helices α9 and α10 of one subunit of Rv1816, which run 
anti-parallel to each other, interact with helices α9’ and α10’ of the next subunit, forming a 
four-helix bundle at the subunit 
interface to secure the dimerization 
state. A tunnel-like cavity is formed at 
the cleft between helices α7, α8, α9, 
and α10 and the random  
loop connecting α9’ and α10’ of the 
second subunit. Unlike Rv3249c, a 
single helix, α6, forms the floor of 
this cavity, which potentially creates a 
binding tunnel for inducing ligands. 
Helix α8, which orients horizontally 
and nearly perpendicular to the 2-fold 
vertical axis of the dimer, generates a 
unique architecture of the Rv1816 
regulator. This feature has not been 
found in the existing structures of the 
TetR family regulators including TetR 
(44, 45), QacR (46, 47), CprB (48), EthR (49, 50), CmeR (51, 52), AcrR (53), SmeT (54), 
Rv3066 (55), Rv1219c (56), and Rv3249c. Based on its location, helix α8, together with the 
loop region between helices α9’ and α10’, seems to lengthen and enlarge the binding cavity 
 
 
Figure 6. Stereo view of the electron density 
maps of Rv1816 at a resolution of 2. 00 Å. A, the 
electron density maps are contoured at 1.0 σ. The 
Cα traces of the Rv1816 dimer in the asymmetric 
unit are in green and cyan. B, representative 
section of electron density in the vicinity of 
helices α5 and α10. The solvent-flattened electron 
density (40–2.00 Å) is contoured at 1.0 σ and 
superimposed with the final refined model (green, 
carbon; red, oxygen; blue, nitrogen; yellow, 
sulfur). 
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to accommodate for larger ligands. Indeed, it was found that the loop residues as well as 
residues located within helix α8 are involved in ligand binding. The volumes of the ligand 
binding cavities of the C-terminal regulatory domains of the two subunits within the Rv1816 
dimer are 500 Å3 and 450 Å3 
(corresponding to the right and 
left subunits of Rv1816 in Fig. 
7B, respectively).  
Within the N-terminal 
DNA-binding domain, helix α1 
of Rv1816 is relatively long at 
19 amino acids. However, in 
direct contrast to the structure of 
Rv3249c, this helix tilts 
downward by 10° with respect 
to the horizontal plane. The 
center-to-center distance 
between helices α3 and α3’ of 
the regulator is 39 Å, defined by 
the separation between residues 
Tyr-54 and Tyr-54’. Such 
distances in the apo form of 
TetR (44), QacR (46), and AcrR 
(53) are 35, 39, and 42 Å, 
 
 
Figure 7. Structure of the M. tuberculosis Rv1816 
regulator. A, ribbon diagram of a protomer of Rv1816. 
The molecule is colored using a rainbow gradient from 
the N terminus (blue) to the C terminus (red). B, ribbon 
diagram of the Rv1816 dimer. Each subunit of Rv1816 is 
labeled with a different color (orange and yellow). 
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respectively. This spacing indicates that the crystal structure of Rv1816 may represent its 
ligand-free conformational state. Surprisingly, a large extra electron density appears in the 
elongated binding pocket of one subunit of the Rv1816 protein, suggesting that Rv1816 is 
bound by a ligand. However, the other binding pocket in the next sub-unit of the regulator is 
still empty. As in the case of Rv3249c, GC-MS was employed to identify this fortuitous 
ligand. The data indicate that Rv1816 was co-purified and co-crystallized with the saturated 
fatty acid ester isopropyl laurate, also called propan-2-yl dodecanoate, with the molecular 
formula C15H30O2 (Fig. 8). Again, these data support the role of fatty acids as the natural  
 
 
Figure 8. Identification of the fortuitous ligand of Rv1816 by GC-MS. A, electron 
ionization spectrum of the strongest GC peak at 8.58 min. B, GC-MS spectrum of 
propan-2-yl dodecanoate from the internal GC-MS library. The ligand was 
identified as isopropyl laurate. 
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Figure 9. Simulated annealing electron density maps and the isopropyl laurate 
binding site. A, stereo view of the simulated annealing electron density map of the 
bound isopropyl laurate within the Rv1816 protomer (the orientation corresponds to 
the side view of Fig. 7B). The bound isopropyl laurate is shown as a stick model 
(green, carbon; red, oxygen). The simulated annealing 2Fo − Fc electron density map 
is contoured at 1.0 σ (blue mesh). The right subunit of Rv1816 is shown as orange 
ribbons. B, the isopropyl laurate binding site. Amino acid residues within 5.0 Å from 
the bound isopropyl laurate (green, carbon; red, oxygen) are included. The side 
chains of selected residues from the right subunit of Rv1816 in Fig. 7B are shown as 
orange sticks (orange, carbon; blue, nitrogen; red, oxygen). C, schematic 
representation of the Rv1816 and isopropyl laurate interactions. Amino acid residues 
within 5.0 Å from the bound isopropyl laurate are included. 
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ligands of these proteins. The bound fatty acid ester is partially exposed to solvent at its 
isopropyl head-group, whereas the carbon chain tail of the molecule is buried in the region of 
the binding cavity created by α6, α8, and α9 and the loop region between the adjacent 
helices α9’ and α10’. There are extensive hydrophobic interactions between the bound 
isopropyl laurate molecule and Rv1816. Within 5 Å of this bound ligand, at least 16 residues 
of Rv1816, including Pro-128, Thr-131, Ala-132, Ala-135, Thr-136, Val-139, Phe-142, Phe-
143, Phe-177, Cys-189, Phe-190, Leu-192, Trp-193, Tyr- 208’, Ala-210’, and Met-212’, are 
involved in the interaction (Fig. 9). Again, many of these residues are hydrophobic in nature. 
  
Isothermal titration calorimetry 
ITC was used to quantify regulator-ligand interactions. The strength of interaction 
between Rv3249c and the palmitate ligand was measured by ITC and possessed a negative 
enthalpic contribution of a typical hyperbolic binding curve (Fig. 10A). The enthalpic (ΔH) 
and entropic (ΔS) parameters of Rv3249c binding to palmitic acid are 629.6 ± 38.1 cal mol-1 
and 21.3 cal mol-1 deg-1, giving rise to a dissociation constant, KD, of 7.5 ± 1.2 µM.  
ITC was then employed to determine the binding affinity of the Rv1816 regulator for the 
laurate ligand (Fig. 10B). Because isopropyl laurate has a low solubility, we used lauric acid 
as a ligand for these experiments. Again, the titration depicts a typical hyperbolic binding 
curve, which is characterized by a negative enthalpic contribution. The thermodynamic 
parameters of binding of lauric acid to Rv1816 are 872.1 ± 41.4 cal mol-1 (ΔH) and 19.2 cal 
mol-1 deg-1 (ΔS), which give rise to a KD of 14.4 ± 1.8 µM.  
As the predicted binding sites of Rv3249c and Rv1816 within the promoter and 
intragenic region of the mmpL genes are partially overlapped, we thought that these two 
  
105 
regulators may share a similar set of ligands. We thus determined whether Rv1816 is able to 
bind palmitic acid (Fig. 10C). Surprisingly, ITC data depict that Rv1816 binds palmitic acid 
with a KD of 23.2 ± 2.9 µM. The thermodynamic parameters of binding of palmitic acid to 
Rv1816 are 491.6 ± 29.2 cal mol-1 (ΔH) and 19.6 cal mol-1 deg-1 (ΔS).  
 
 
 
Figure 10. Isothermal titration calorimetry for the binding of ligands. A, representative 
isothermal titration calorimetry for the binding of palmitic acid to Rv3249c. Upper panel, each 
peak corresponds to the injection of 10 µl of 500 µm palmitic acid in buffer containing 10 mm 
sodium phosphate (pH 7.2), 100 mm NaCl, and 0.001% DDM into the reaction containing 10 µm 
dimeric Rv3249c in the same buffer. Lower panel, cumulative heat of reaction is displayed as a 
function of the injection number. The solid line is the least square fit to the experimental data, 
giving a KD of 7.5 ± 1.2 µm. B, representative isothermal titration calorimetry for the binding of 
lauric acid to Rv1816. Upper panel, each peak corresponds to the injection of 10 µl of 400 µm 
lauric acid in buffer containing 10 mm sodium phosphate (pH 7.2), 100 mm NaCl, and 0.001% 
DDM into the reaction containing 10 µm dimeric Rv1816 in the same buffer. Lower panel, 
cumulative heat of reaction is displayed as a function of the injection number. The solid line is the 
least square fit to the experimental data, giving a KD of 14.4 ± 1.8 µm. C, representative 
isothermal titration calorimetry for the binding of palmitic acid to Rv1816. Upper panel, each 
peak corresponds to the injection of 10 µl of 400 µm palmitic acid in buffer containing 10 mm 
sodium phosphate (pH 7.2), 100 mm NaCl, and 0.001% DDM into the reaction containing 10 µm 
dimeric Rv1816 in the same buffer. Lower panel, cumulative heat of reaction is displayed as a 
function of the injection number. The solid line is the least square fit to the experimental data, 
giving a KD of 23.2 ± 2.9 µm. 
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Fluorescence polarization assay 
Fluorescence polarization was used to quantify the strength of regulator DNA 
interactions. To identify regulatory targets of these proteins, we utilized chromatin 
immunoprecipitation sequencing (ChIP-Seq) data from Galagan and co-workers (26 –29) and 
the Tuberculosis Database. Regions of the M. tuberculosis H37Rv genome that were found 
by these experiments to interact with Rv3249c or Rv1816 were first examined to identify a 
potential binding sequence for each individual protein. Typically, TetR family  
proteins interact with DNAs via symmetric palindromic stretches called inverted repeats, 15–
30 nucleotides long. Thus, the search was narrowed to include sequences that contain these 
patterns. For each protein we were able to identify a putative inverted repeat sequence 
located in one or more of the M. tuberculosis H37Rv genes encoding MmpL transporter pro- 
teins. These DNA sequences are in good agreement with both the consensus binding 
sequences and protein-DNA interactions determined by others (21). We found that the 
Rv3249c protein might act as a regulator for mmpS1/L1, mmpL11, and rv1067c and Rv1816 
for mmpL13b and rv1094.  
Fluorescence polarization assays were performed using purified regulator proteins 
and duplex DNA. For example, we quantified the interaction between Rv3249c and the 19-
bp DNA sequence (ACATCGAAACGGTCGATGT), which is located
 
at the mmpL11 
operon. Fig. 11A illustrates the binding isotherm of Rv3249c in the presence of 2.5 nM 
fluoresceinated DNA, indicating that Rv3249c binds this 19-bp promoter DNA with a 
dissociation constant, KD, of 5.6 ± 1.0 nM. Similarly, the interaction between Rv3249c and 
the 19-bp putative promoter DNA sequence (ACCTCGCCGTAAACGATGT) within the 
mmpS1/L1 operon was determined. The data suggest that the	KD value for this binding is 
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18.7 ± 6.5 nM (Fig. 11B). The 
binding constants of Rv3249c and 
Rv1816 with their corresponding 
DNAs are summarized in Table 2.  
 
Electrophoretic mobility shift 
assay 
 
Rv3249c is predicted to 
regulate expression of mmpS1/L1, 
mmpS5/L5, mmpL10, and  
mmpL11 (Fig. 12A). We 
performed EMSAs using purified 
Rv3249c to demonstrate direct 
transcriptional regulation by 
Rv3249c. We observed a 
concentration-dependent shift of 
the mmpL3, mmpL11, and mmpS1 
probes (Fig. 12B). A second shift 
of the mmpL3 probe with 0.5 µM 
Rv3249c suggests multiple 
binding sites for the regulator in 
this promoter region. As a control, 
EMSAs were performed in the 
presence of nonlabeled “cold”  
 
Figure 11. Representative fluorescence polarization of 
Rv3249c. A, the binding isotherm of Rv3249c with the 
27-bp DNA containing the 19-bp promoter sequence 
(ACATCGAAACGGTCGATGT) located at the mmpL11 
operon, showing a KD of 5.6 ± 1.0 nm. B, the binding 
isotherm of Rv3249c with the 29-bp DNA containing 
the 19-bp promoter sequence 
(ACCTCGCCGTAAACGATGT) within the mmpS1/L1 
operon, showing a KD of 18.7 ± 6.5 nm. Fluorescence 
polarization is defined by the equation FP = (V − 
H)/(V + H), where FP equals polarization, V equals 
the vertical component of the emitted light, and H 
equals the horizontal component of the emitted light of 
a fluorophore when excited by vertical plane polarized 
light. FP is a dimensionless entity and is not dependent 
on the intensity of the emitted light or on the 
concentration of the fluorophore. mP is related to FP, 
where 1 mP equals one-thousandth of FP. 
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Figure 12. Rv3249c binds to promoter regions of mmpS1 and mmpL3 and intragenic 
region of mmpL11. A, a schematic depicting the DNA probes used in EMSAs. B, for 
EMSA analysis, 6 nm Dig-labeled probe and the indicated micromolar concentrations of 
protein. C, to demonstrate specificity, the MmpS1 EMSA was performed in the presence 
of nonlabeled (“cold”) probe. Reactions were performed with 6 nm Dig-labeled probe, 
the indicated micromolar concentrations of protein, and 360 nm cold probe. D, ligand-
bound Rv3249c does not bind target probes. EMSA was performed using 12 nm Dig-
labeled probe and 0.1 µm Rv3249c in the absence or presence of indicated concentration 
of palmitic acid. An arrow denotes the shifted probes and the asterisk notes the 
accumulation of free Dig-labeled probe. 
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probe. Release of Dig-labeled probe was observed consistent with specific binding of 
Rv3249c to the mmpS1 probe (Fig. 12C). The probe corresponding to a significant ChIP-Seq 
peak in the coding sequence of rv3249c itself did not shift. Our EMSA conditions may not be 
ideal for Rv3249c binding to the rv3249c probe or autoregulation may depend on a ligand or 
environmental condition that we have not adequately mimicked in our EMSA conditions. 
Rv3249c crystallized with a palmitic acid molecule, and ligand binding appears to be 
incompatible with DNA binding activity. We performed an EMSA in the presence and 
absence of palmitic acid to demonstrate this experimentally. The addition of ligand reduced 
binding of Rv3249c to the rv1067c probe (Fig. 12D). ChIP-Seq data suggest that Rv1816 
potentially regulates itself, mmpL2, mmpL3, mmpS4/L4, mmpL7, mmpL8, and mmpL11 
expression. Interestingly ChIP-Seq data indicated	that Rv1816 regulates kasA, which is co-
regulated with mmpL3	and encodes a β-ketoacyl-ACP synthase involved in meromycolate 
synthesis, in addition to the mmpS3 gene, encoding an accessory MmpS protein. We 
performed EMSAs using purified Rv1816 and probes corresponding to Rv1816, the 
mmpL3/mmpL11 region, mmpL7, kasA, and mmpS3 (Fig. 13A). We observed a shift of the 
mmpL3/mmpL11 locus probes, and less so for the mmpL7 probe (Fig. 13B). We also obtained 
a robust concentration-dependent shift of the kasA, mmpS3, and rv1094 probes. These data 
indicate that Rv1816 binds several times within the mmpL3/mmpL11 genomic locus and 
suggest that Rv1816 contributes to the coordinated regulation of cell wall lipid biosynthesis 
and transport. As a control, EMSAs were performed in the presence of nonlabeled “cold” 
probe. Release of Dig-labeled probe was observed consistent with specific binding of 
Rv1816 to the rv1094 probe (Fig. 13C). Rv1816 was co-crystallized with isopropyl laurate. 
In addition, ITC experiment suggested that this regulator binds lauric acid with an affinity in  
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Figure 13. Rv1816 binds to intragenic and/or promoter regions of rv1816, mmpL3, 
rv0204, mmpL11, mmpL7, kasA, and mmpS3. A, a schematic depicting the DNA probes 
used in EMSAs. B, EMSAs were performed using 12 nm Dig-labeled probe and the 
indicated micromolar concentrations of protein. An arrow denotes the shifted probes. 
EMSAs were performed using probes spanning regions of rv0550 and rv2245. These 
were predicted binding sites by ChIP-Seq but did not shift at the indicated 
concentrations. C, to demonstrate specificity, EMSAs were performed in the presence of 
nonlabeled (“cold”) probe. Reactions were performed with 6 nm Dig-labeled probe, the 
indicated micromolar concentrations of protein, and 0.24 µm cold probe. The asterisk 
notes the accumulation of free Dig-labeled probe. D, ligand-bound Rv1816 does not bind 
target probes. EMSA was performed using 12 nm Dig-labeled probe and 0.5 µm Rv1816 
in the absence or presence of 5 µm palmitic acid. An arrow denotes the shifted probes, 
and the asterisk notes the accumulation of free Dig-labeled probe. 
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the micromolar range. We thus performed an EMSA in the presence of lauric acid. 
Surprisingly, the presence of this fatty acid did not reduce binding of Rv1816 to the rv1094 
probe. It appears that lauric acid binding does not prevent the interaction of this regulator 
with cognate DNAs. We then performed an EMSA both in the presence and absence of 
palmitic acid, because Rv1816 is also able to bind this compound. Indeed, the addition of 
ligand reduced binding of Rv1816 to the rv1094 probe (Fig. 13D).  
 
Conclusion 
In this paper, we describe the crystal structures of the Rv3249c and Rv1816 
transcriptional regulators, which participate in the regulatory network that controls the 
expression of essential and virulence-associated MmpL transporters. Specifically, existing 
ChIP-Seq data and the analyses presented herein suggest that Rv3249c regulates the genes 
mmpS1/L1, mmpL3, mmpS5/L5, mmpL7, mmpL10, mmpL11, and mmpL12, and Rv1816 
regulates mmpS2/L2, mmpL3, mmpS4/L4, mmpL7, mmpL8, mmpL11, and mmpL13b. MmpL 
transporters significantly contribute to the export of important lipid components of the 
mycobacterial cell wall and are necessary for the virulence of this pathogen. Our 
experimental data demonstrate a direct binding of these transcriptional regulators to 
intragenic and promoter DNAs, providing evidence for the transcriptional control of mmpL 
gene expression. Multiple transcriptional factor binding sites exist within the promoter and 
intragenic region of the mmpL genes, and each transcriptional regulator recognizes several 
mmpL regulatory regions. These findings highlight that mmpL gene expression relies on a 
complex interplay of multiple transcription regulators.  
Fortuitously, the crystal structures of Rv3249c and Rv1816 were resolved in 
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complexes with palmitic acid and isopropyl lauric acid, respectively. These structures 
suggest that saturated fatty acids are the natural substrates of these regulators. There are 
extensive interactions of these fatty acids with the transcriptional regulators, where the C-
terminal regulatory domain of the regulators provides a hydrophobic environment for 
substrate binding. Within the fatty acid binding site of Rv3249c, there are at least 22 residues 
that participate in binding the palmitate ligand through hydrophobic interactions. Similarly, 
16 residues are involved in binding the fatty acid ester isopropyl laurate within the ligand-
binding pocket of Rv1816. Many of these residues are hydrophobic in nature, suggesting that 
fatty acid recognition is mainly governed by hydrophobic interactions.  
The binding of palmitate to Rv3249c results in lengthening the center-to-center 
distance of this regulator, making it incompatible with cognate DNAs. However, the 
structure of Rv1816 indicates that binding of laurate does not change the center to center 
distance of the regulator. Thus, this regulator may still be able to hold onto the promoter 
DNA and repress gene expression even after interacting with this ligand. Indeed, gel shift 
experiment showed that the addition of laurate does not have any effect on the Rv1816-DNA 
complex. Rather, it appears that palmitic acid reduces DNA binding activity of Rv1816. 
Future work will define native fatty acid ligands for this regulator and dissect their effects on 
Rv1816 activity.  
The TetR family regulators use several distinct mechanisms for modulating 
transcriptional regulation. However, the net consequence of binding of inducing ligands to 
these regulators is essentially the same. Ligand binding at the C-terminal regulatory domain 
triggers a long distance conformational change at the N-terminal DNA binding domain, 
resulting in the release of the regulator from its operator DNA. The TetR family regulators 
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utilize the N-terminal recognition helix α3 to bind the major groove of B-DNA. The distance 
between two consecutive major grooves of B-DNA is ~34 Å. One major mechanism found in 
the TetR family is that ligand binding increases the center to center distance between the two 
recognition helices α3 and α3’ within the dimer, making this distance no longer  
compatible with the 34 Å separation between two successive major grooves of B-DNA. This 
results in the release of the dimeric regulator from the promoter region, allowing the 
expression of the respective regulated gene. For example, the center-to-center distance for 
QacR is 39 Å in the absence of inducing ligands (46). This distance becomes 48 Å upon 
ligand binding (47). The conformational change is augmented in the cases of CmeR (51) and 
EthR (50), where the center-to-center distances were observed to be 54 and 52 Å in the 
respective ligand-bound structures. Thus, it is most likely that ligand binding by the Rv3249c 
and Rv1816 regulators leading to derepression is primarily triggered by the increase in 
center-to-center distance, making these two regulators no longer compatible with their 
corresponding cognate DNAs. 
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CHAPTER IV 
ASSEMBLY OF THE NEISSERIA GONORRHOEAE MTRCDE TRIPARTITE 
MULTIDRUG EFFLUX SYSTEM 
 
 
 
Introduction 
Neisseria gonorrhoeae is a Gram-negative human pathogen and the cause of the 
sexually transmitted disease gonorrhea.  Recently, treatment of gonorrhea has been severely 
compromised by the development of antibiotic-resistance strains.  For example, the use of 
ciprofloxacin, formerly a first-line antibiotic, has been discontinued since 2007, when nearly 
14% of all N. gonorrhoeae infections in the US were found to exhibit some resistance to this 
drug (https://www.cdc.gov/std/gonorrhea/arg/basic.htm).  Among antimicrobial-resistance 
mechanisms, active transport is now recognized as the major means by which pathogens 
survive antibiotic regimens.1,2  To remove toxic molecules from the cell, bacteria utilize 
powerful pumping machinery, composed of one or more protein components.  These 
multidrug efflux pumps are capable of actively pumping out a broad range of noxious agents 
directly from the bacterial cell.3  Metal-ion and antibiotic resistance systems of this type have 
been found encoded on plasmids of every bacterial species tested. 
The best characterized efflux system in N. gonorrhoeae is the MtrCDE multidrug 
efflux system.  The tripartite complex, which spans both the inner and outer membranes, is 
formed by interactions between the inner membrane RND transporter MtrD, the periplasmic 
membrane fusion protein MtrC, and the outer membrane channel MtrE (Fig. 1).  This 
powerful efflux pump mediates the export of hydrophobic antimicrobial agents, such as 
antibiotics, nonionic detergents, certain antibacterial peptides, bile salts, and gonadal 
steroidal hormones.4-9  
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Recently, our group has determined the crystal structure of the MtrE outer membrane 
channel, revealing the first open conformation in this protein family.8   We have also 
determined the crystal structure of the inner membrane RND transporter MtrD.10  The 
availability of the three-dimensional structures of these efflux transporters and their 
accessory proteins should allow us to 
block their function; potentially by the 
rational design of inhibitors, as 
demonstrated by AcrB and 
DARPin.11,12  However, the direct 
approach, to interrupt the assembly of 
the tripartite complex, necessitates a 
high-resolution of a completely 
assembled RND tripartite efflux 
complex.  In the following chapter, we 
discuss our strategies to elucidate the 
crystal structure of the MtrCDE pump, 
which have resulted in a preliminary 
model of the bipartite MtrCD complex 
to 5.5 Å resolution. 
 
 
 
 
 
 
Figure 1. Ribbon diagram model of the MtrCDE 
tripartite efflux system. Each protein is labeled with a 
different color (yellow, MtrE; green, MtrC; blue, 
MtrD). The figure was prepared using PyMOL. 
 
  
121 
Co-crystal Structure of MtrCD 
 Initial screening of the bipartite MtrCD complex was carried out using hanging-drop 
vapor diffusion, with a 2:1 mixture of MtrCΔNT (MtrC lacking the N-terminal 34 amino 
acids) and the MtrD construct used to obtain our previous crystal structure.10  Using a well 
solution of 33% Polyethylene glycol 
(PEG 400), 0.1 M MgCl2, 0.1 M NaCl, 
and 0.1M Tris (pH 8.5), with the 
additions of 1% Sucrose 
monodecanoate (SM) and 0.1 mM 
Carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP), small, 
approximately 50 µm, diamond-shaped 
crystals grew from the cover slip after 
approximately 3 weeks.  The 
preliminary structure of the MtrCD 
bipartite complex was determined to a 
resolution of 5.5 Å, using molecular 
replacement with our previous structure 
of MtrD (PDB ID: 4MT1) (Fig. 2).  
This MtrCD cocrystal reveals a 
stoichiometry (3:6, MtrD:MtrC) 
consistent with previous experiments 
 
 
Figure 2. Experimental electron density map of the 
MtrCD bipartite compelx at a resolution of 5.50 Å.  
The electron density maps are contoured at 1.0 σ. 
The Cα traces of the three MtrD molecules in the 
trimer are colored green, cyan, and magenta. The 
Cα traces of the six MtrC molecules in the hexamer 
are colored green, lavender, white, light pink, 
orange, and yellow. 
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for the Mtr system13 and recent cryo-electron microscopy (cryo-EM) structures of the 
AcrAB-TolC14-16 and MexAB-OprM16 efflux pumps. 
 Unfortunately, after extensive crystallization and detergent screening, we were not 
able to improve upon this model.  Further, single particle analysis by cryo-EM did not reveal 
the presence of a significant number of intact complexes in our purified protein samples.  
Thus, a major effort was dedicated to improving the affinity of these proteins for a stable 
tripartite efflux complex. 
 
MtrD Proton-Motive Force Mutations 
  Efflux by RND transporters is 
dependent on the proton motive force 
(PMF).  Previous studies of AcrB and 
MexB revealed three highly conserved 
residues (D407, D408, and K939) that are 
essential to the pump function and the 
proposed PMF pathway.17-20  Based on 
sequence alignment, the corresponding 
charged residues D405 and D406 of TM4 
and K948 of TM10 are necessary for the PMF of MtrD (Fig. 3).  Janganan et al. found that 
mutation of these residues to lysine (MtrD D405K or D406K) or glutamic acid (K948E), 
rendered cells expressing the mutant pumps more susceptible to the antibiotics tetracycline, 
erythromycin, and novobiocin.  Further, the authors concluded that it is possible that MtrE is 
unable to dissociate from the MtrCD D405K/D406K/E948E complex.17  Thus, these 
 
 
Figure 3. Ion pairs of MtrD in the 
transmembrane domain viewed from the 
cytoplasmic side. Residues D405 and D406 of 
TM4 and K948 of TM10 that form ion pairs, 
which may play an important role in proton 
translocation, are in green sticks.  Figure and 
caption borrowed from Bolla et al.10 
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mutations are ideal for assembly of the tripartite complex. 
Although the single point mutations MtrD D405K, D406K, or E948E, as well as the 
double mutation D405K D406K, severely attenuated the expression of the pump, we were 
able to purify ~1 mg of each protein using similar procedures as for wild-type MtrD.  
 Initial crystal screening of the bipartite complex was done by hanging-drop vapor 
diffusion, using a 2:1 mixture of MtrC:MtrD D405K D406K and 1% sucrose monodecanoate 
(SM) as the protein solution.  Crystals were obtained for well solutions of: i) 6.6% PEG 
4000, 0.1 M NaCl, 0.02 M K-MES (pH 6.7); and ii) 28% PEG 400, 0.1 M Lithium citrate, 
0.1 M Glycine (pH 9.3).  Unfortunately, these conditions could not be improved to obtain 
high-quality diffraction data. 
 
MtrC Crosslinking 
 Janganan et. al also reported success in stabilizing high-order complexes of both 
MtrC and the MtrCE bipartite complex using a chemical crosslinking strategy.13  The 
chemical crosslinker bismaleimidohexane (BMH) forms a covalent ~13 Å bond between 
sulfhydryl groups of neighboring Cysteine residues.  As the MtrCΔNT construct lacks any 
Cysteine residues, the single point mutation E149C ensures that only two neighboring 
MtrCΔNT molecules will be bonded into a chemically stabilized dimer.  Using our low-
resolution bipartite cocrystal structure as a model, these residues were found to be 14.9 Å 
apart in the MtrC hexamer (Fig. 4).  As this strategy could be used to stabilize the MtrC 
hexamer, and MtrCE bipartite complex, it is also possible that the stable tripartite complex 
could be formed via crosslinking of MtrC. 
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 Thus, we purified MtrCΔNT E149C (Fig. 5a) and subjected it to crosslinking by 
BMH.  After incubation with BMH at room temperature for 1 hr, a strong upper band 
appeared in SDS-PAGE analysis of the protein sample, corresponding to the molecular 
weight of the MtrCΔNT dimer (Fig. 5b).  Additional higher molecular weight bands also 
appeared in the sample, presumably corresponding to higher order complexes of MtrCΔNT 
E149C.  These dimeric and hexameric bands were not present in the sample before BMH 
crosslinking. 
 Size exclusion chromatography (SEC) analysis of the cross-linked sample resulted in 
a single peak, which eluted at a much lower volume (much higher molecular weight) 
compared to MtrCΔNT alone.  When this sample was analyzed by SDS-PAGE, three 
prominent bands were visible, which correspond very closely to the theoretical monomeric, 
 
 
Figure 4. Ribbon diagram of the hairpin domain of the MtrC hexamer as viewed from a) 
the periplasmic side and b) top-down, from the inner-membrane.  Each molecule is colored 
in green and the residue E149, used for cross-linking, is highlighted in magenta.  The 
distance between adjacent E149 residues is depicted in red dashed lines and calculated 
using PyMol. 
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dimeric, and hexameric weights of MtrC (Fig. 6).  Indeed, cross-linking of MtrC by BMH 
does appear to stabilize the expected native hexamer.  
 When this sample was mixed with MtrD in a 2:1 MtrC:MtrD ratio and subjected to 
crystal screening by hanging drop vapor diffusion, easily reproducible crystals were obtained 
from a well solution of 12% PEG 4000, 0.1 M (NH4)2SO4 or NH4-citrate dibasic or NH4-
citrate tribasic, 0.1 M Na-citrate (pH 5.6), and 22% glycerol.  Unfortunately, we were not 
able to improve upon this condition and high-resolution data is unavailable.  We have also 
attempted to combine this approach with the previous MtrD PMF mutants.  A 2:1 mixture of 
MtrCΔNT E149C with the single-point mutants MtrD D405A, D406A, or the double mutant 
D405A D406A, respectively, did not result in any crystals which diffracted to high 
resolution.  It is interesting to note that by mutation to alanine, instead of lysine, expression 
of these MtrD mutants greatly improved. 
 
 
Figure 5. SDS-PAGE analysis of purified MtrCΔNT E149C a) before and b) after cross-
linking with BMH. a) Lane 1, protein molecular weight standards. Lane 2, MtrCΔNT E149C. 
b) Lane 3, protein molecular weight standards. Lane 4, 2:1, MtrCΔNT E149C:BMH. 
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Chimeric Protein Construction 
 Recently, one of the first low-resolution models of a tripartite efflux pump was 
obtained in the AcrABZ-TolC system.14  This was achieved, in part, by the use of chimeric 
protein constructs that fused one AcrA molecule to a loop region preceding the first large 
periplasmic domain of AcrB.  This construct was found to preserve the periplasmic location 
of AcrA and the native interaction between AcrA and AcrB, while stabilizing this complex 
by forcing AcrA and AcrB in close proximity. 
 Similarly, we designed chimeric constructs of MtrC and MtrD.  Utilizing our co-
crystal structure, we located a flexible loop region immediately preceding TM helix α2 of 
MtrD.  At residue P324 of MtrD, we inserted one molecule of MtrCΔNT, flanked by two 
 
 
Figure 6. After crosslinking, the MtrCΔNT E149C protein was passed through a Superdex 
200 gel filtration column.  A single peak was collected and analyzed by SDS-PAGE, 
revealing monomeric, dimeric and hexameric species. 
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flexible 6xGS linkers at the N- and C-termini, to allow MtrC and MtrD to adopt their native 
conformation (Fig. 7).  Preceding TM helix α8, and after the second large periplasmic 
domain of MtrD, is a similar flexible region.  We designed a second construct containing one 
molecule of MtrCΔNT, with flexible N- and C-termini, in this region that precedes MtrD 
residue G858.  While we were able to obtain a small signal, corresponding to expression of 
these MtrCD chimeric proteins in E. coli C43(DE3), (Fig. 8) we were not able to optimize 
the process to produce the mg quantities of protein needed for crystallization trials. 
 
MtrC Engineering 
 The essential link in tripartite RND efflux complexes is the periplasmic membrane 
fusion protein.  In the highest resolution structures of these complexes that are currently 
available, there is no evidence of interaction between the inner-membrane transporter and the 
outer-membrane channel.14,16  Instead, the periplasmic adaptor protein alone mediates the 
 
 
Figure 7. Topology of the MtrD protein.  View from the side of the inner-membrane.  To 
create the MtrCD chimera, we inserted one MtrC molecule flanked by flexible linkers 
preceding TM helix α2 at residue P324 or preceding TM helix α8 at residue G858 (dotted 
line). 
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interaction between these components, forming a bridge between inner and outer membranes 
to expel diverse antimicrobials from the cytoplasm all the way to the cell exterior.  
 Based on the currently available structural information, these proteins can be divided 
into 5 domains.  The three β-sheet domains, comprising the lipoyl, β-barrel, and membrane 
proximal domains, primarily interact with 
the two large periplasmic domains of the 
RND transporter, while the α-helical 
hairpin domain is the only domain to 
contact the outer membrane channel (Fig. 
9) Finally, the N-terminal residues of 
these proteins typically contain both a 
signal peptide (SP) sequence, targeting 
the protein to the periplasm, as well as an 
anchoring sequence for permanent 
attachment to the periplasmic side of the 
inner-membrane.21-30 
 The mechanisms of inner-membrane anchoring among the membrane fusion protein 
family are diverse.  For example, AcrA26, BesA22, MexA27 and MtrC all contain N-terminal 
cysteine residues which undergo lipidation to covalently attach to fatty acids of the inner 
membrane.28-30  In the cases of MacA25 and EmrA,21 the N-terminal amino acids comprise a 
TM α-helix, which anchors these proteins to the inner-membrane.  Naïvely, anchoring the 
adaptor protein to the inner membrane should remove a degree of freedom, restricting its 
motion to the plane of the RND transporter and increasing the likelihood of the adaptor-
 
 
Figure 8. Western analysis of the expression of 
the MtrCD chimeric proteins.  Lane 1, protein 
molecular weight standards. Lane 2, empty. 
Lanes 3 and 4, MtrCD chimeric proteins. 
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transporter interaction.  In fact, membrane attachment has been proposed to augment the 
adaptor-transporter complex in both AcrA and MexA.31-33  We recently decided to explore 
this hypothesis, using two constructs: the full-length MtrC (MtrC FL) and MtrC with the 
native N-terminal replaced by that of AcrA (AcrASP-MtrC) (Fig. 10b and c). 
 We were able to express each of these proteins in E. coli BL21ΔB(DE3), which 
harbors a genomic deletion of the E. coli efflux pump gene acrB.  Unsurprisingly, these 
proteins were not detected in the soluble fraction of the cell lysate, but in the membrane 
fraction (data not shown).  This result is distinct from that of MtrCΔNT, which was always 
recovered in the soluble fraction, supporting the role of the N-terminal residues as an anchor 
to the inner membrane. 
 
 
Figure 9. Structural comparison of periplasmic adaptor proteins EmrA (Aquifex aeolicus), 
BesA (Borrelia burgdorferi), MexA (P. aeruginosa), AcrA (E. coli), MacA (E. coli 
macrolide efflux pump), and MtrC (N. gonorrhoeae) and the metal efflux pump adaptors 
CusB (E. coli) and ZneB (C. metallidurans). N-terminal domains of BesA, MexA, AcrA, 
and MtrC have an N-terminal lipoyl attachment site anchoring the adaptor in the IM, 
while EmrA and MacA are anchored by one TM helix.  Dotted orange lines indicate 
unobserved MP domain terminal regions. Figure and caption adapted from Greene et al.22 
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Further, in large-scale purification experiments, we were able to recover well-folded, 
pure MtrC-FL protein from detergent solubilization of the E. coli cell membrane.  We 
analyzed this purified protein sample using SEC to confirm that it was well-folded and 
homogeneous.  Surprisingly, while MtrCΔNT eluted as a single peak at low molecular 
weight, MtrC FL predominantly formed a very high molecular weight peak, with a secondary 
peak roughly corresponding to the elution volume of MtrCΔNT (Fig. 11).  These results 
indicate that, although a fraction of MtrC FL remains a monomer in solution, it tends toward 
a certain higher molecular weight species.  As a comparison, we also analyzed purified MtrD 
protein in an identical fashion.  Surprisingly, this protein eluted at almost an identical volume 
as MtrC FL, indicating that the molecular weight of the MtrD trimer is similar to the 
 
 
Figure 10. Schematic depiction of the MtrC constructs used to assemble the tripartite 
MtrCDE pump.  a) The full-length MtrC protein includes 24 N-terminal residues which 
target it to the periplasm of N. gonorrhoeae.  Residue C25 is linked directly to fatty acids 
in the inner-membrane.  b) The first 24 residues of the full-length MtrC construct were 
replaced by the corresponding residues of AcrA, which target it to the periplasm of E. coli.   
c) The first 34 residues of the full-length MtrC construct, including the lipidation site C25, 
were replaced by the 18-residue E. coli periplasmic signaling peptide gIII. 
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molecular weight of the higher MtrC FL species (Fig. 11).  For comparison, the theoretical 
molecular weight of the MtrD trimer is approximately 338.6 kDa, while hexameric MtrC FL 
is approximately 261.6 kDa.  Our hypothesis remained that the hexameric MtrC FL would 
more tightly associate to the MtrD trimer.  However, when the purified MtrC FL and MtrD 
samples were mixed in a ratio of 2:1, respectively, the elution volume of the predominant 
peak remained unchanged (Fig. 11).  If these two proteins were indeed associating with each 
other, we were not able to detect the complex using this technique.  
We also analyzed the 
antimicrobial efflux activity of 
these proteins in vivo, using a 
minimum inhibitory 
concentration (MIC).  In the 
MIC assay, serial dilutions of 
antimicrobials are incorporated 
into agar media to determine 
the lowest concentration of 
antimicrobial that will still 
permit bacterial growth.  If the 
MtrCDE tripartite efflux 
system confers resistance to a 
particular toxin, then cells expressing these proteins should be able to tolerate a higher 
concentration compared to cells that do not contain the MtrCDE proteins.   
 
 
Figure 11. Gel filtration experiment for the molecular size 
of MtrC FL and MtrD.  Representative SEC analyses of 
MtrC FL (orange), MtrD (cyan), and a 2:1 (C:D) molar 
ratio mixture of MtrC FL and MtrD (green).  The results 
shown are for the homologous CmeABC efflux system of 
C. jejuni, but similar results were obtained for MtrC and 
MtrD. 
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We induced expression of the MtrCΔNT, MtrC FL, and AcrASP-MtrC proteins, 
along with MtrD and MtrE in each case, in E. coli BL21ΔB(DE3), to remove the background 
resistance of these cells conferred by the AcrB RND efflux protein.  As the MtrCΔNT protein 
does not contain a SP sequence and, therefore, would not be targeted to the periplasm in this 
experiment, the protein was modified with an N-terminal gIII signal peptide, which is native 
to E. coli and should allow efficient secretion of MtrCΔNT to the periplasm (Fig. 10c).  As 
expected, western blot analysis revealed 
that this gIII-MtrCΔNT protein was 
found in the soluble fraction, while 
MtrC FL was only found in the 
membrane fraction (Fig. 12).  E. coli 
cells harboring these proteins, as well as 
a control sample that contained only the 
empty expression vector, were plated 
onto increasing concentrations of TX-
100, a non-ionic detergent and known 
substrate of the Mtr system.34,35  The 
results were striking.  While E. coli cells 
harboring the empty vector were only 
able to grow to concentrations of 40 
µg/mL TX-100, cells expressing gIII-MtrCΔNT tolerated concentrations exceeding 2560 
µg/mL (Fig. 13).  More surprising is that cells expressing either MtrC FL or AcrASP-MtrC 
 
 
Figure 12. Western blot analysis of MtrD, MtrE, 
and MtrC constructs co-expressed for MIC 
assays. Lane 1, MtrCDE positive control. Lane 
2, protein molecular weight standards. Lane 3, 
MtrC FL-DE coexpression, soluble fraction.  
Lane 4, MtrC FL-DE coexpression, membrane 
fraction. Lane 5, gIII-MtrCΔNT-DE 
coexpression, soluble fraction. Lane 6, gIII-
MtrCΔNT-DE coexpression, membrane fraction. 
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were even less resistant than cells harboring the empty vector, growing only at the lowest 
concentration of TX-100 (20 µg/mL).  
Contrary to the results of Yoneyama et al.,30 which indicate that lipid modification of 
the membrane fusion protein is not essential to the operation of the pump, our results indicate 
that it may actually impair it.  This cannot be the case, as the membrane anchoring domain of 
the adaptor protein is a well-conserved feature across all tripartite efflux systems.  Instead, it 
is possible that the native signal sequence of N. gonorrhoeae MtrC is not recognized by the 
E. coli cells we used in this experiment.  Thus, we repeated the MIC experiment with the 
native SP of MtrC replaced by that of AcrA.  Again, we obtained the same results: cells 
expressing the gIII-MtrCΔNT protein outperformed AcrASP-MtrC with an MIC greater by 
two orders of magnitude.  It is possible that the engineering of MtrC did interfere with its 
function.  In this case, the important result is that MtrC is indispensable for the pump 
function. 
 
 
Figure 13. MIC assay for the function of the MtrCDE efflux pump.  Outer drop, empty 
vector.  Middle drop, gIII-MtrCΔNT-MtrD-MtrE.  Inner drop, AcrASP-MtrC-MtrD-MtrE.   
E. coli BL21ΔB(DE3) cells were used for all experiments.  Identical results were observed 
for both AcrASP-MtrC-MtrD-MtrE and MtrC FL-MtrD-MtrE. 
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Conclusion 
We have successfully co-crystallized the bipartite MtrCD complex, which yielded a 
preliminary low resolution model.  This model confirms the stoichiometry of 3:6 
adaptor:transporter, which has been observed directly in the Acr and Mex systems.  Using a 
combination of mutagenesis, chemical cross-linking, and protein engineering, we have 
developed first steps to increase the affinity of the MtrC, MtrD, and MtrE proteins for the 
tripartite complex.  Using MIC assays, we have demonstrated the efficiency of the MtrCDE 
efflux system, which is capable of increasing the tolerance of E. coli cells for the 
antimicrobial TX-100 by two orders of magnitude.  This result also demonstrates the 
importance of the membrane fusion protein to the function of the pump, as expression of a 
modified MtrC protein in E. coli even failed to restore the intrinsic bacterial resistance for 
TX-100.  Thus, MtrC is a particularly attractive target for drugs to combat the growing 
prevalence of antibiotic resistant strains of N. gonorrhoeae.  This task still necesitates a high-
resolution structure of the assembled tripartite efflux complex.  We are hopeful that the 
techniques presented in this chapter will contribute to this important work. 
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CHAPTER V 
 COCRYSTAL STRUCTURE OF THE INTERMEMBRANE SPACE REGION OF THE 
PLASTID DIVISION PROTEINS PARC6 AND PDV1 
 
 
Introduction 
Like their cyanobacterial ancestors, chloroplast division in plants and algae proceeds 
by binary fission.  The fission process involves the coordinated assembly of four rings both 
inside and outside the cell at the midplastid: the inner PD ring, the inner FtsZ ring (Z-ring), 
the outer PD ring and the outer DRP5B ring.1,2  The simultaneous constriction of the stromal 
Z-ring and the periplasmic DRP5B ring, along with the inner and outer PD rings, pinches the 
chloroplast cell in two.  Separation into daughter cells requires a large network of 
coordinating proteins. 
Within this network, a pair of paralogous inner envelope membrane proteins, PARC6 
and ARC6, and a pair of paralogous outer envelope membrane proteins, PDV1 and PDV2, 
are likely responsible for bridging both the inner and outer membranes to connect the Z-ring 
and DRP5B ring (Fig. 1).3,4  Recent data indicates that these proteins have similar topologies, 
with a single transmembrane region and short C-terminal region residing in the 
intermembrane space (IMS).3,5-7  In particular, PARC6 possesses a long stromal region that 
interacts with the FtsZ2 protein component of the inner Z-ring.5  The IMS region of PARC6 
has been shown to interact with the IMS region of PDV1.4,5  Similar interactions have been 
observed between ARC6, FtsZ2 and PDV2.3,5,8,9  Thus, the PARC6-PDV1 and ARC6-PDV2 
complexes are capable of spanning both the inner (IEM) and outer (OEM) chloroplast 
membranes to coordinate the FtsZ and DRP5B rings during chloroplast cell division.  
Although PARC6 and ARC6 share significant sequence identity (24%), data suggests that 
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PARC6, which inhibits FtsZ assembly, acts antagonistically to ARC6, which promotes FtsZ 
assembly.1,2,4,5,7,8,10    
While ARC6 is conserved 
throughout green-lineage 
chloroplasts, PARC6 is unique to 
vascular plants.4,5  Like ARC6, 
PARC6 is a nuclear-encoded, IEM 
protein and a descendant of the 
cyanobacterial cell division protein 
Ftn2/ZipN.7,11-13  Alignment of 
protein sequences suggests that 
Arabidopsis thaliana PARC6 and 
Synechocystis sp. Ftn2 share about 
21% identity.  The first 67 amino 
acids of A. thaliana PARC6 
encode a cleavable chloroplast 
transit peptide.7  The remainder of 
the protein can be divided into a 
larger N-terminal stromal-facing region (residues 77-573), transmembrane region (574-596) 
and smaller C-terminal IMS region (597-819).5  A majority of the PARC6 IMS domain 
(residues 692-811) belongs to the highly-conserved Domain of unknown function 
(DUF4101) superfamily. 
 
 
Figure 1. Model of the chloroplast cell division 
machinery.  The stromal proteins FtsZ1 and FtsZ2 
and the cytosolic protein DRP5B form contractile 
rings.  These two rings are coordinated by a pair of 
paralogous IEM proteins, ARC6 and PARC6, and a 
corresponding pair of paralogous OEM proteins, 
PDV1 and PDV2. 
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We report here the crystal structure of this highly conserved domain in the IMS 
portion of A. thaliana PARC6 (residues 684-819) at 2.52 Å resolution.  This is the first 
structural characterization of the PARC6 protein.  In addition, we have obtained the crystal 
structure of this PARC6 domain in complex with the IMS domain of A. thaliana PDV1, 
revealing the molecular details of the intermembrane space interaction during chloroplast cell 
division.  Based on gel filtration experiments, PARC6 appears to form a dimer in solution, 
and that dimerization is dependent on interaction with PDV1.  Using isothermal titration 
calorimetry, we find that the PARC6-PDV1 interaction is highly specific.  It is likely that the 
DUF4101 domain and the C-terminal residues of the PDV proteins, especially the terminal 
glycine G272, are responsible for linking the stromal and cytosolic protein components of 
chloroplast cell division, bridging both the inner Z-ring and outer DRP5b-ring to coordinate 
chloroplast cell division. 
 
Structure of PARC6-IMS684-819 
Initial efforts to crystallize the full-length IMS region of PARC6 (residues 596-819) 
using hanging-drop vapor diffusion were unsuccessful. However, long bar-shaped crystals 
were obtained when the protein was pretreated with trypsin. The crystal structure of residues 
684-819 of PARC6 (referred to hereafter as PARC6-IMS684-819) was determined to a 
resolution of 2.52 Å with excellent geometric qualities, using molecular replacement. The 
structure of the paralogous ARC6-IMS667-799 (PDB ID: 5D9R)11 was utilized as a search 
model. Presumably, trypsin cleaved a substantial portion of the PARC6 N-terminal, as we 
were not able to model the first 88 N-terminal amino acids. The final crystal structure was 
refined to Rwork and Rfree of 18.1% and 25.9%, respectively (Table 1, Figure 2). 
  
141 
 
 
 
Table 1.  Data collection, phasing and structural refinement statistics of PARC6-IMS684-819 and 
PARC6-IMS684-819-PDV1-IMS248-272 
 
Data set PARC6-IMS684-819   PARC6-IMS684-819-PDV1-IMS248-272 
Data collection  
Wavelength (Å) 0.979 0.979 
Space group C2221  P1 
Cell constants (Å)  
a 44.53 61.23 
b 124.55 80.19 
c 130.05 84.07 
α, β, γ (°) 90,90,90 88.36,80.99,83.49 
Resolution (Å) 2.52 (2.60-2.52) 3.37 (3.50-3.37) 
Completeness (%) 99.5 (98.4) 97.1 (87.0) 
Total reflections 1,365,108 2,395,188 
Unique reflections 12,616 23,564 
CC1/2(high resolution shell) 0.658 0.536 
Redundancy 8.3 (7.0) 3.1 (2.5) 
Rpim (%) 4.9 (35.5)  19.4 (72.8) 
〈I/σ(I)〉  12.1 (1.8) 4.2 (1.1) 
Refinement  
Rwork (%) 18.1 25.0 
Rfree (%) 25.9 31.8 
B-factors  
Overall(Å2) 61.96 56.23 
Chain A/B 66.08/65.59 53.79/48.87 
Chain C/D/E/F/G/H    48.83/55.74/59.45/61.27/64.02/58.69 
Rms deviations  
Bond (Å) 0.010 0.006 
Angles (o) 1.02 0.90 
Ramachandran analysis  
Most favored (%) 97.6 96.5 
Allowed (%) 2.0   3.3 
Disallowed (%) 0.3 0.2 
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Figure 2. Stereo view of the experimental electron density maps of PARC6-IMS596-819 at a 
resolution of 2.52 Å.  a) The electron density maps are contoured at 1.3 σ.  The Cα traces of the 
two PARC6-IMS596-819 molecules are colored green and cyan.  b) Representative section of 
electron density in the vicinity of α1 and α3, within the α/β barrel.  The solvent-flattened 
electron density (40-2.52 Å) is contoured at 1.3 σ and superimposed with the final refined 
model (green, carbon; red, oxygen; blue, nitrogen; yellow, sulfur). 
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Two molecules of PARC6-IMS684-
819 were found in the asymmetric unit and 
appear to be arranged as an anti-parallel 
dimer (Figure 3). Otherwise, the structure 
of PARC6-IMS684-819 is very similar to 
that of ARC6-IMS636-801.11 Each protomer 
is composed of three α-helices and four β-
strands: α1 (690-708), α2 (714-720), α3 
(724-739), β1 (742-760), β2 (763-780), β3 
(788-803) and β4 (806-815 (Figure 5).  
Like ARC6-IMS667-799, these three α-helices and 
four β-strands form an α/β barrel within each 
protomer. The bottom half of the barrel, adjacent 
to the IEM, is completely closed.  
The interior wall of the α/β barrel is lined 
with several charged and aromatic residues, 
including W700, K704, W729, E775, and Y798, 
which are conserved among PARC6, ARC6 and 
 
Figure 3. Ribbon diagram of PARC6-IMS684-
819.  Two molecules in the asymmetric unit are 
arranged as an anti-parallel dimer.  Each 
molecule is colored using a rainbow gradient 
from the N-terminal (blue) to the C-terminal 
(red).  The extra helix, corresponding to 
residues 641-658 of PARC6, is colored grey.  
The two views correspond to a 180° rotation 
about the axis shown (dotted line). 
 
 
 
Figure 4.  Conserved amino acids within 
the PARC6-IMS684-819 α/β barrel (rainbow, 
carbon; red, oxygen; blue, nitrogen).  The 
secondary structural elements are colored 
using a rainbow gradient from the N-
terminal (blue) to the C-terminal (red). 
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Ftn2 proteins (Fig. 4). In addition, residue Y794, which is conserved between PARC6 and 
ARC6, but not Ftn2, is found within this α/β barrel. Interestingly, F745 is also conserved 
here, but only among PARC6 homologues.  It is expected that these conserved residues are 
important for the function of this plastid division protein.  
Surprisingly, an extra density, which forms an α-helical secondary structure, was 
discovered in the open face of the cavity created by the α/β barrel. We determined 
unambiguously that this density corresponds to residues 641-658 of PARC6, which was 
presumed to be removed from the IMS of PARC6 by trypsin digestion.  The extra helix is 
secured atop the cavity by a disulfide bond between residues C657 and C741, which lies in 
the loop region between α3 and β1 (Fig. 5).  
 
 
Figure 5.  Ribbon diagram of a single protomer of PARC6-IMS684-819.  Each molecule 
comprises three α-helices and four β-strands: α1 (residues 690-708), α2 (714-720), α3 
(724-739), β1 (742-760), β2 (763-780), β3 (788-803) and β4 (806-815).  The secondary 
structural elements are colored using a rainbow gradient from the N-terminal (blue) to the 
C-terminal (red).  Helix α4 (642-657), colored grey, is secured atop the PARC6-IMS684-819 
α/β barrel by a disulfide bond between C657 and C741 (rainbow, carbon; red, oxygen; 
blue, nitrogen; yellow, sulfur). 
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Co-crystal Structure of PARC6-IMS684-819-PDV1-IMS248-272 
We suspected that the cavity formed by the PARC6-IMS α/β barrel could create an 
ideal interaction site for the IMS domain of the PDV1 outer envelope membrane protein.  To 
understand how PARC6 and PDV1 interact, we decided to co-crystallize the IMS domains of 
PARC6 and PDV1.  We first expressed and purified the PARC6-IMS684-819 protein that 
contains the C-terminal residues 684-819 of PARC6, elucidated by our previous crystal 
structure.  We also produced the purified PDV1-IMS225-272, which comprises the predicted 
IMS domain of PDV1 (Fig. 1).  Initially, we mixed these two purified chloroplast proteins at 
a molar ratio of 1:1 for co-crystallization trials; unfortunately, these attempts were 
unsuccessful.  We then made a construct that co-expresses PARC6-IMS684-819 and PDV1-
IMS248-272.  This construct contains a 6x(Gly-Ser) flexible linker that directly connects 
residue 819 of PARC6 to residue 248 of PDV1 to produce the PARC6-IMS684-819-PDV1-
IMS248-272 protein complex (Fig. 6). The PARC6-IMS684-819-PDV1-IMS248-272 fusion protein 
was expressed, purified and subjected to crystallization using vapor diffusion.  
 
 
Figure 6.  Schematic depiction of the construct used for co-crystallization of PARC6-IMS 
and PDV1-IMS.  The stable core of PARC6-IMS identified by crystallization (PARC6-
IMS684-819) was linked directly to the C-terminal 25 amino acids of PDV1 (PDV1-IMS248-
272) by a flexible 6xGly-Ser linker to create PARC6-IMS684-819-PDV1-IMS248-272.  The 
PARC6-PDV1 chimera was tagged with 6xHis at the N-terminal and included a thrombin 
restriction site (LVPRGS) for removal of the tag. 
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The structure of PARC6-IMS684-819-PDV1-IMS248-272 was determined to a final 
resolution of 3.37 Å.  We utilized our structure of PARC6-IMS684-819 as a search model for 
molecular replacement to obtain the crystal structure of PARC6-IMS684-819-PDV1-IMS248-272.  
 
 
Figure 7.  Stereo view of the experimental electron density maps of PARC6-IMS684-819-
PDV1-IMS248-272 at a resolution of 2.52 Å.  a) The electron density maps are contoured at 
1.3 σ.  The Cα traces of the eight PARC6-IMS596-819 molecules are colored green, cyan, 
magenta, yellow, pink, white, blue, and orange.  b) Representative section of electron 
density in the vicinity of PDV1.  The solvent-flattened electron density (40-3.37 Å) is 
contoured at 1.3 σ and superimposed with the final refined model (cyan, carbon; red, 
oxygen; blue, nitrogen; yellow, sulfur).  The cartoon model of PARC6 is colored magenta. 
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Eight molecules of PARC6-IMS684-819-PDV1-IMS248-272 are found in the asymmetric unit, 
with dimeric arrangements quite similar to that of PARC6-IMS684-819 (Fig. 7a, Fig. 8).  
Superimposition of these eight molecules gives root mean square deviations (RMSDs) 
between 0.6 and 0.8 Å over 139-146 Cα atoms.  
Indeed, we found the C-
terminal residues of PDV1-IMS stuck 
into the cavity created by the PARC6-
IMS α/β barrel.  At least twelve PDV1 
amino acids, including residues 261-
272, are visible in the crystal structure 
(Fig. 7b).  These C-terminal residues 
of PDV1 mainly form a random coil 
(Fig. 9).  Interestingly, the location of 
this PDV1 C-terminal random coil is 
found to overlap with that of the extra 
helix α4 (residues 641-658) of our 
previous PARC6 structure. Based on 
the PARC6-IMS684-819-PDV1-IMS248-
272 complex structure, the PDV1 C-
terminal residue G272 is buried deep within the PARC6-IMS cavity.  Previously, this residue 
was shown to be indispensable to the PARC6-PDV1 interaction.5  This C-terminal glycine is 
also conserved between PDV1 and PDV2. It has been found that a single point mutation of 
these glycines to aspartic acid resulted in weak or no interaction with either PARC6 or 
 
 
Figure 8.  Ribbon diagram of PARC6-IMS684-819-
PDV1-IMS248-272.  Two molecules in the 
asymmetric unit are arranged as an anti-parallel 
dimer.  Each molecule is colored using a rainbow 
gradient from the N-terminal (blue) to the C-
terminal (red).  The residues corresponding to 
PDV1-IMS are colored grey.  The two views 
correspond to a 180° rotation about the axis 
shown (dotted line). 
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ARC6, respectively.3   
Within hydrogen bonding distance of PDV1 G272 in our crystal structure is the 
conserved aromatic residue W700 of PARC6 (Fig. 9).  The NE1 atom of this W700 is 2.6 Å 
away from the O atom of G272 of PDV1, on average, interacting to form a hydrogen bond. 
 
PARC6-PDV1 Interaction 
To determine the strength of interaction between PARC6 and PDV1, we used 
isothermal titration calorimetry (ITC). The IMS region of PDV1, including residues 225-272 
(PDV1-IMS225-272), was purified alone and titrated into solution containing PARC6-IMS684-
 
 
Figure 9.  Ribbon diagram of a single protomer of PARC6-IMS684-819-PDV1-IMS248-272.  
Consistent with the structure of PARC6-IMS684-819, each molecule comprises three α-
helices and four β-strands.  The secondary structural elements are colored using a 
rainbow gradient from the N-terminal (blue) to the C-terminal (red).  The C-terminal 
glycine (G272) of PDV1-IMS is buried deep within the PARC6-IMS α/β barrel.  Within 
hydrogen-bonding distance of G272 carboxyl group are the highly conserved residues 
W700 and Y798 of PARC6-IMS (rainbow, carbon; red, oxygen; blue, nitrogen). 
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819. This titration is characterized by a negative enthalpic contribution and yields a typical 
hyperbolic binding curve indicative of a specific interaction between these two chloroplast 
proteins (Fig. 10). The enthalpic (∆H) and entropic (∆S) parameters of binding of PDV1-
IMS225-272 to PARC6-IMS684-819 are -
9521 ± 60 cal·mol-1 and -0.87 
cal·mol·deg-1, giving rise to a 
dissociation constant, KD, of 0.16 ± 0.01 
µM. 
According to our co-crystal 
structure, the PARC6 residue W700 was 
found in close proximity to the essential 
PDV1 C-terminal glycine.5  We 
strongly suspect that this tryptophan 
residue might be involved in securing 
the binding of PDV1 to PARC6.  
Therefore, we decided to create single-
point mutants of PARC6-IMS684-819 in 
order to similarly study their interaction 
with the IMS domain of PDV1 by ITC. 
Unfortunately, all attempts to mutate 
this residue resulted in an unstable 
PARC6 protein and the binding data is 
unavailable. 
 
 
Figure 10.  Isothermal titration calorimetry for 
the binding of PARC6-IMS684-819 and PDV1-
IMS225-272.  Upper panel, each peak corresponds 
to the injection of 10 µL of 333 µM of PDV1-
IMS225-272 in buffer containing 20 mM Na-
HEPES (pH 7.5), 250 mM NaCl, and 100 mM 
imidazole into the reaction containing 33 µM of 
PARC6-IMS684-819 in the same buffer.  Lower 
panel, cumulative heat of reaction is displayed 
as a function of the injection number.  The solid 
line is the least square fit to the experimental 
data, giving a KD of 0.16 ± 0.01 µM. 
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PARC6 Dimerization 
During chloroplast cell division, interactions between FtsZ proteins are necessary to 
form the Z ring. Preceding Z ring formation, these proteins have been shown not only to self-
interact, forming homodimers, but proteins from each family of FtsZ (FtsZ1 and FtsZ2) can 
also interact to form heterodimers.14 The interaction between FtsZ2 and the stromal domain 
of PARC6 is necessary for the proper division of chloroplast cells.5 
To determine if PARC6 is similarly capable of dimerizing in solution, we employed 
analytical gel filtration experiments using the purified PARC-IMS684-819, which comprises the 
conserved domain DUF4101 (Fig. 11a, 11b). The results suggest an average molecular 
weight of 15.8 ± 0.2 kDa (Fig. 12). This value is in agreement with the theoretical value of 
16.8 kDa for one PARC-IMS684-819 molecule, indicating that PARC-IMS684-819 exists as a 
monomer in solution.  
 
 
Figure 11.  Gel filtration experiment for the molecular size of PARC6-IMS684-819 in the absence 
and presence of PDV1-IMS225-272.  a) Representative SEC analyses of PARC6-IMS684-819 
(magenta) and a 1:1 molar ratio mixture of PARC6-IMS684-819 and PDV1-IMS225-272 (cyan).  b) 
and c) SDS-PAGE analysis of the indicated SEC peak fractions, respectively.  The molecular 
mass of each marker protein (lane 1) is indicated on the left of each gel. 
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To test if the interaction between PARC6 and PDV1 influences the oligomerization of 
PARC6, we also carried out gel filtration experiments with a mixture of the purified PARC6-
IMS684-819 and purified PDV1-IMS225-272 in a 1:1 molar ratio (Fig. 11a, 11c).  Suprisingly, the 
molecular weight of the PARC6 and PDV1 mixture was measured to be 37.0 ± 1.6 kDa (Fig. 
12).  The mass of the theoretically calculated dimer, including two molecules of PARC6-
IMS684-819 and two molecules of PDV1-IMS225-272, is 44.8 kDa.   
To test if the chimeric protein PARC6-IMS684-819-PDV1-IMS248-272, used for 
crystallization, is also capable of forming a dimer in solution, we carried out gel filtration 
experiments for this protein.  The resulting elution profile was nearly identical to that of the 
1:1 mixture of PARC6 and PDV1 (data not shown), with a measured mass of 37.2 ± 3.0 kDa. 
 
 
Figure 12.  Gel filtration experiments to determine molecular weight.  The experiments 
demonstrate that while PARC6-IMS684-819 (magenta square) is a monomer in solution, both 
PARC6-IMS684-819-PDV1-IMS248-272 (green circle) and a 1:1 molar ratio mixture of 
PARC6-IMS684-819 and PDV1-IMS225-272 (cyan triangle) are dimers.  The y-axis values were 
defined as: Kav = (Ve – Vo)/(VT – Vo), where VT, Ve, and Vo are the total column volume, 
elution volume, and void volume of the column, respectively.  Standards used were: A, 
cytochrome C (12,400 Da); B, carbonic anhydrase (29,000 Da); C, albumin bovine serum 
(66,000 Da); D, alcohol dehydrogenase (150,000 Da); and E, β-amylase (200,000 Da).  
The void volume was measured using blue dextran (MW 2,000,000). 
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This value is in excellent agreement with the theoretically calculated mass of 39.3 kDa for 
two molecules of PARC6-IMS684-819-PDV1-IMS248-272, suggesting the PARC6-IMS684-819-
PDV1-IMS248-272 complex is dimeric in solution (Fig. 12).  
The observed dimerization of PARC6-IMS684-819-PDV1-IMS248-272 is consistent with 
the dimeric arrangement observed in our crystal structure (Fig. 8).  However, we observed an 
identical arrangement in our structure of the trypsin-digested PARC6-IMS684-819 (Fig. 3).  
While there is no PDV1 protein present in this crystal, the extra helix α4, corresponding to 
residues 641-658 of PARC6, occupies a similar position in the α/β barrel binding pocket.  
Thus, we suspected that PARC6 dimerization may also be induced by interaction with α4. 
To test this hypothesis, we used a semi-native SDS-PAGE protocol, in which SDS 
and reducing agents (in this case, DTT) are absent from the loading buffer.  Thus, it is 
possible for native complexes to remain intact.  When PARC6-IMS596-819 was run in the 
presence of SDS and DTT, only bands corresponding to the theoretical weight of the 
PARC6-IMS monomer (26.5 kDa) could be observed (Fig. 13, Lane 3).  However, when run 
with the semi-native protocol, upper bands appeared corresponding to the weight of the 
PARC6 dimer (Fig. 13, Lane 4).  When digested with trypsin, a single band was observed, 
corresponding to the weight of residues 596-819 of PARC6 alone (Fig. 13, Lane 6).  
Interestingly, when this same protein was run with the semi-native protocol, we observed an 
upward shift in the lower band by several kDa (Fig. 13, Lane 7).  As the helix α4 was shown 
in our crystal structure to be secured by a disulfide bond, we expect that the removal of DTT 
in the semi-native protocol allowed this helix to remain attached to the PARC6 protein.  This 
shift was coupled to the appearance of an upper (dimeric) band in the gel.  Consistent with 
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our crystal structures, it appears that the interaction between α4 and the PARC6-IMS α/β 
barrel may induce dimerization of this protein. 
Taken together, our experiments suggest that the specific interaction between PARC6 
and PDV1 may be essential for PARC6-IMS684-819 dimerization.  Interestingly, we were also 
able to observe dimerization which did not depend on PDV1, but on other residues within the 
IMS domain of PARC6-IMS.  While the interaction between PARC6 and PDV1 has been 
shown to be necessary for chloroplast cell division,4 our results suggest that the resulting 
PARC6 dimerization may also play a role in this process. 
 
 
Figure 13. Trypsin was added to purified PARC6IMS596-819 at a molar ratio of 1:100, 
protease:PARC6IMS, with and without the addition of SDS and DTT, and the results were 
analyzed by SDS-PAGE.  Lane 1, the molecular weight standard.  Lane 2, empty.  Lane 3, 
Purified PARC6IMS596-819; no protease, with SDS and DTT.  Lane 4, Purified 
PARC6IMS596-819 no protease, without SDS and DTT.  Lane 5, empty.  Lane 6, Purified 
PARC6IMS596-819 digested by trypsin, with SDS and DTT.  Lane 7, Purified PARC6IMS596-
819 digested by trypsin, without SDS and DTT. 
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Conclusion 
Our crystal structures of PARC6-IMS encompass the highly conserved DUF4101 
domain (residues 692-811), which spans most of the IMS domain of PARC6 and its paralog 
ARC6 (kumar 2016). Sequence alignment shows that the cyanobacterial cell division protein 
Ftn2 bears identical or similar residues at most of these positions, suggesting the importance 
of DUF4101 in the cell division processes of both cyanobacteria and its evolutionary 
descendant chloroplasts.7,11 Interestingly, PARC6 and ARC6 share only 12% protein 
sequence identity over this region. The IMS regions of PARC6 and ARC6 interact with 
PDV1 and PDV2, respectively, and chloroplast cell division has been shown to rely on this 
interaction.3-5   
Previously, it was not clear whether DUF4101 was necessary for the intermembrane 
space interaction during chloroplast cell division. Our experiments indicate that the 
DUF4101 domain of PARC6 and the C-terminus of PDV1, specifically the C-terminal 
glycine G272, are capable of mediating the interaction between these two proteins. Based on 
our crystal structures, the conserved aromatic residue PARC6 W700 is suspected to contact 
PDV1 G272 via a hydrogen bond, securing the binding between these two chloroplast 
division proteins. The fact that DUF4101 is also conserved in cyanobacterial Ftn2 proteins 
suggests that Ftn2 may function in a manner similar to the plant-specific PARC6 and ARC6 
cell division machines. 
Oligomerization in several chloroplast division-associated proteins has been shown to 
be necessary for their function. Specifically, FtsZ proteins can form homodimers as well as 
heterodimers among two protein families FtsZ1 and FtsZ2.  It is possible that these 
interactions precede Z-ring formation during chloroplast division.14  Recently, FtsZ2 proteins 
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have been found to interact directly with the stromal domain of PARC6.5  According to our 
experimental data, the DUF4101 domain of PARC6 is a monomer in solution.  However, 
when mixed or co-expressed with the C-terminal residues of PDV1, the dominant species is a 
dimer.  Whether the PARC6 dimer we observe is important for the function of this protein in 
chloroplast cell division awaits further analysis.  It is expected that our crystal structures, the 
first depicting interactions in the intramembrane space during chloroplast division, will 
facilitate further functional studies of these proteins and their roles in chloroplast and 
cyanobacterial cell division. 
 
Methods 
Expression and purification of PARC6-IMS596-819 
The plasmid pET15bΩPARC6-IMS596-819 bearing the PARC6-IMS region (amino 
acids 596-819) with a 6xHis tag at the N-terminus was overproduced in E. coli BL21(DE3) 
cells.  Cells were grown in 6 L of Luria Broth (LB) medium with 100 µg/mL ampicillin at 
37°C.  When OD600 reached 0.4, the culture was treated with 0.2 mM isopropyl-β-d-
thiogalactopyranoside (IPTG) to induce PARC6-IMS expression, and cells were harvested 
within 3 h.  The cell pellet was suspended in 100 mL ice-cold buffer containing 20 mM Na-
HEPES (pH 7.5) and 250 mM NaCl.  The cells were then lysed with a French pressure cell.  
Cell debris was removed by centrifugation for 45 min at 4°C and 100,000 g.  The crude 
lysate was filtered through a 0.2 µm membrane and was loaded onto a 5 mL Hi-Trap Ni2+-
chelating column (GE Healthcare Biosciences, Pittsburgh, PA) pre-equilibrated with 20 mM 
Na-HEPES (pH 7.5) and 250 mM NaCl. To remove unbound proteins and impurities, the 
column was first washed with six column volumes of buffer containing 50 mM imidazole, 
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250 mM NaCl and 20 mM Na-HEPES (pH 7.5).  The PARC6-IMS protein was then eluted 
with four column volumes of buffer containing 300 mM imidazole, 250 mM NaCl, and 20 
mM Na-HEPES (pH 7.5).  The purity of the protein was judged using 15% SDS-PAGE 
stained with Coomassie Brilliant Blue.  The purified protein was extensively dialyzed against 
buffer containing 20 mM Na-HEPES (pH 7.5), 250 mM NaCl and 100 mM imidazole and 
concentrated to 20 mg/mL.  The procedures for purifying PARC6-IMS684-819 were identical to 
those of PARC6-IMS596-819.  
 
Expression and purification of PARC6-IMS684-819-PDV1-IMS248-272 
The procedures for purifying PARC6-IMS684-819-PDV1-IMS248-272 were identical to 
those of PARC6-IMS596-819.  Prior to crystallization of PARC6-IMS684-819-PDV1-IMS248-272, 
the N-terminal 6xHis tag was removed by thrombin digestion.  1 U of thrombin (Roche) was 
added to 10 mg of purified 6xHis PARC6-IMS684-819-PDV1-IMS248-272 protein and incubated 
for 12 h at room temperature.  The resulting tag-less PARC6-IMS684-819-PDV1-IMS248-272 was 
further purified using size-exclusion chromatography in buffer containing 20 mM Na-HEPES 
(pH 7.5), 250 mM NaCl and 100 mM imidazole and concentrated to 20 mg/mL. 
 
Expression and purification of PDV1-IMS226-272 
The plasmid pGEX4T1Ω PDV1-IMS226-272 bearing the PDV1-IMS region (amino 
acids 226-272) with a GST tag at the N-terminus was overproduced in E. coli BL21(DE3) 
cells.  Cells were grown in 6 L of Luria Broth (LB) medium with 100 µg/mL ampicillin at 
37°C.  When OD600 reached 0.4, the culture was treated with 0.2 mM isopropyl-β-d-
thiogalactopyranoside (IPTG) to induce PDV1-IMS expression, and cells were harvested 
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within 3 h.  The cell pellet was suspended in 100 mL ice-cold buffer containing 20 mM Na-
HEPES (pH 7.5) and 250 mM NaCl.  The cells were then lysed with a French pressure cell.  
Cell debris was removed by centrifugation for 45 min at 4°C and 100,000 g.  The crude 
lysate was filtered through a 0.2 µm membrane and was loaded onto a 5 mL Glutathione 
Sepharose High Performance column (GE Healthcare Biosciences, Pittsburgh, PA).  To 
remove unbound proteins and impurities, the column was first washed with six column 
volumes of buffer containing 100 mM imidazole, 250 mM NaCl and 20 mM Na-HEPES (pH 
7.5).  The PDV1-IMS protein was then cleaved from the GST-bound beads by thrombin 
digestion.  1 U of thrombin (Roche) was added to the column per 10 mg of protein and 
incubated for 12 h at room temperature.  The PDV1-IMS protein was then eluted with two 
column volumes of buffer containing 100 mM imidazole, 250 mM NaCl and 20 mM Na-
HEPES (pH 7.5).  The purity of the protein was judged using 18% SDS-PAGE stained with 
Coomassie Brilliant Blue. 
 
Crystallization of PARC6-IMS596-819 
All crystals were grown using hanging-drop vapor diffusion. Crystals could only be 
obtained after removing the 6xHis tag and the first 88 N-terminal amino acids from PARC6-
IMS596-819 using trypsin.  A 72 µg/mL final concentration of trypsin was added to 20 mg/mL 
purified PARC6-IMS596-819.  The protein mixture was incubated at 4°C for 30 min before 
crystallization, producing PARC6-IMS684-819.  For crystallization, 0.3 µL of the protein 
mixture was mixed with 0.3 µL of reservoir solution containing 18% polyethylene glycol 
(PEG) 4000, 0.1 M Magnesium acetate, 0.1 M Na-MES (pH 6.5), 0.05 M Potassium nitrate 
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and 5% glycerol.  The resultant mixture was equilibrated against 500 µL of the reservoir 
solution.  Bar-shaped crystals grew to full size within the drop within one week.   
 
Crystallization of PARC6-IMS684-819-PDV1-IMS248-272 
For crystallization of PARC6-IMS684-819-PDV1-IMS248-272, 0.3 µL of protein solution 
was mixed with 0.3 µL of reservoir solution containing 12% polyethylene glycol (PEG) 
8000, 160 mM ammonium sulfate and 0.8% glycerol.  The resultant mixture was equilibrated 
against 500 µL of the reservoir solution.  Crystals grew to full size within the drop within one 
week. 
 
Data collection, structural determination, and refinement of PARC6-IMS684-819 
All diffraction data were collected at 100K at beamline 24ID-C located at the 
Advanced Photon Source, using an ADSC Quantum 315 CCD-based detector. Diffraction 
data were processed using DENZO and scaled using SCALEPACK.15  The crystals of 
PARC6-IMS684-819 belong to space group C2221 (Table 1).  Based on the molecular weight 
(15.8 kDa), two monomers per asymmetric unit are expected with a solvent content of 
56.8%.  The phases of PARC6-IMS684-819 were obtained using molecular replacement. The 
structure of the paralogous ARC6-IMS (residues 667-799) (PDB code 5D9R) was utilized as 
a template.11  The resulting phases were then subjected to density modification and NCS 
averaging using the program RESOLVE.16  The remaining part of the model was manually 
constructed using the program Coot.17  The model was then refined using TLS refinement 
techniques adopting a single TLS body as implemented in PHENIX,18 leaving 5% of 
reflections in Free-R set. Iterations of refinement using PHENIX18 and model building in 
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Coot17 led to the current structure, which consists of 134 residues with excellent geometrical 
characteristics (Table 1). 
 
Data collection, structural determination, and refinement of PARC6-IMS684-819-PDV1-
IMS248-272 
Diffraction data for crystals of PARC6-IMS684-819-PDV1-IMS248-272 were obtained 
and processed similar to that of PARC6-IMS684-819.  The crystals of PARC6-IMS684-819-
PDV1-IMS248-272 belong to space group P1 (Table 1).  Based on the molecular weight (19.5 
kDa), eight monomers per asymmetric unit are expected with a solvent content of 55.15%.  
The phases of PARC6-IMS684-819-PDV1-IMS248-272 were obtained using molecular 
replacement. The structure of PARC6-IMS684-819 was utilized as a template.  The resulting 
phases were then subjected to density modification and NCS averaging using the program 
RESOLVE.16  The remaining part of the model was manually constructed using the program 
Coot.17  The model was then refined using TLS refinement techniques adopting a single TLS 
body as implemented in PHENIX,18 leaving 5% of reflections in Free-R set. Iterations of 
refinement using PHENIX18 and model building in Coot17 led to the current structure, which 
consists of 143 residues with excellent geometrical characteristics (Table 1). 
 
Isothermal titration calorimetry 
All measurements were performed at 25°C using a VP-Microcalorimeter (MicroCal, 
Northampton, MA).  Before titration, the protein concentrations were determined using the 
Bradford assay.  To measure the interaction between PARC6-IMS and PDV1-IMS, the titrant 
solution contained the IMS domain of PDV1 (PDV1-IMS226-272) at a concentration of 333 
  
160 
µM.  The sample cell solution contained the IMS domain of PARC6-IMS (PARC6-IMS684-
819) at a concentration of 33 µM.  The buffer for both the titrant and sample cell solutions 
contained 20 mM Na-HEPES (pH 7.5), 250 mM NaCl and 100 mM imidazole.  Thirty 10 µL 
injections of the titrant solution were used for data collection.  Injections occurred at intervals 
of 200 s and the duration of each injection was 10 s.  Heat transfer (µcal·s-1) was measured as 
a function of elapsed time (s).  The mean enthalpies measured from injection of the titrant in 
the buffer were subtracted from raw titration data before data analysis with ORIGIN software 
(MicroCal, Northampton, MA).  Titration curves were fitted by a nonlinear least squares 
method to a function for the binding of a ligand to a macromolecule.  Nonlinear regression 
fitting to the binding isotherm provided the equilibrium binding constant (KA = 1/KD) and 
enthalpy of binding (∆H).  Based on the values of KA and ∆H, the change in free energy (∆G) 
and entropy (∆S) were calculated with the equation, ∆G = - RT ln(KA) = ∆H - T∆S, where T 
is 298 K and R is 1.9872 cal·K-1·mol-1.  Calorimetry trials were also carried out in the 
absence of PDV1-IMS in the same experimental conditions.  These heats of dilution were 
subtracted to produce the final data. 
We also used isothermal titration calorimetry to determine the binding affinity of 
PARC6-IMS684-819 W700A to PDV1-IMS226-272.  Experimental conditions were identical to 
those of the wild type proteins. 
 
Gel filtration 
 
A protein liquid chromatography Superdex 200 16/60 column (GE Healthcare 
Biosciences, Pittsburgh, PA) with a mobile phase containing 20 mM Na-HEPES (pH 7.5), 
250 mM NaCl and 100 mM imidazole was used in the gel filtration experiments. Blue 
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dextran (Sigma-Aldrich, St. Louis, MO) was used to determine the column void volume and 
proteins for use as gel filtration molecular weight standards were cytochrome C (12,400 Da), 
carbonic anhydrase (29,000 Da), albumin bovine serum (66,000 Da), alcohol dehydrogenase 
(150,000 Da) and β-Amylase (200,000 Da). All standards were purchased from Sigma-
Aldrich (St. Louis, MO). The molecular weights of the experimental samples were 
determined following the protocols supplied by the manufacturers. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 A high-resolution protein crystal structure can allow us to picture how medicine 
interacts with its target; visualize conformational changes that determine what a protein does 
and how it does it; and rationally design better drugs or enzymes with enhanced activity.  
Nearly every pharmaceutical company harnesses this technique for drug discovery.  Due to 
recent advances in robotic technology, the ‘brute force’ method of protein crystallization is 
increasingly viable.  However, the biggest obstacle in membrane protein crystallography is 
not obtaining the crystals, but optimizing them for high-resolution X-ray diffraction.  
Therefore, it is necessary to have intimate knowledge of a particular protein’s interaction 
with the detergent, precipitant, salt, and buffer present in a vapor diffusion crystallization 
experiment.  The techniques outlined in Chapter I have allowed us to determine the high-
resolution crystal structures of the outer membrane multidrug efflux channels of Neisseria 
gonorrhoeae MtrC and Campylobacter jejuni CmeC, the outer membrane metal ion efflux 
channel Escherichia coli CusC, the inner membrane RND multidrug efflux pumps N. 
gonorrhoeae MtrD and E. coli CusA, the first adaptor-transporter complex E. coli CusBA, 
and more. 
 Notably, we have obtained crystal structures of each of the proteins in the CusCBA 
tripartite efflux channel, allowing us to discern their mechanism of copper and silver efflux.  
This model is presented in Chapter II.  Based on the crystal structure of CusA, it is possible 
that the methionine ladder created by M410 and M501, M403 and M486, and M391-M1009 
could shuttle Cu+ and Ag+ ions from the cytoplasm to the primary three-methionine binding 
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site created by M573, M623, and M672.  The periplasmic cleft of CusA containing these 
residues presumably remains closed in the resting state.  However, as observed in our crystal 
structure of ligand-bound CusA, the periplasmic cleft is open in the presence of the substrate, 
which closely coordinates the three-methionine binding site and reveals it to the cytoplasm. 
Thus, CusA should also be able to transport metal ions from the periplasm, directly through 
this cleft.  Upon entering the central pore of the channel, the electrostatic gradient formed by 
the inner surfaces of the hexameric CusB and trimeric CusC channels may draw the ions 
across the outer membrane for final extrusion.  The availability of the three-dimensional 
structures of these efflux transporters and their accessory proteins allows us to determine 
their mechanism of action and, therefore, should allow us to block their function.  Potentially, 
by the rational design of inhibitors, as demonstrated by AcrB and DARPin.  Therefore, the 
long-term goal of this project is to determine a high-resolution three dimensional structure of 
a completely assembled tripartite efflux system. 
In Mycobacterium tuberculosis, pathogenicity and antimicrobial resistance has been 
shown to depend on the MmpL family of proteins, which is a subset of the RND transporter 
family.  The MmpL transporters have been proposed to transport fatty acid components of 
the mycobacterial cell wall.  In Chapter III, we present the high-resolution crystal structures 
of two transcriptional regulators of M. tuberculosis H37Rv: Rv1816 and Rv3249c.  
Surprisingly, the electron density maps revealed that the C-terminal ligand binding domains 
of each protein contained fortuitous ligands.  Using GC-MS we identified possible ligands in 
the protein sample which also fit the unknown densities: palmitic acid in Rv3249c and lauric 
acid in Rv1816.  Using data made available by the TB Systems Biology Consortium, we 
identified potential DNA binding sites in the TB genome which comprise the mmpL genes.  
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We quantified the binding of Rv1816 and Rv3249c to these sequences and demonstrated that 
palmitic acid can trigger a conformational change in Rv3249c that disengages it from the 
DNA.   
While we have demonstrated the probability that these proteins regulate the 
expression of several MmpL transporters, we have not shown their direct effect.  Thus, future 
work should focus on measuring the effect of Rv1816 or Rv3249c on transcription levels of 
MmpL proteins; possibly by measuring steady state mRNA levels in M. tuberculosis or M. 
smegmatis.  That only one lauric acid molecule was found in Rv1816 and the binding cavity 
of one subunit was left empty is intriguing.  Although we were not able to determine the apo 
structure of Rv1816, lauric acid did not seem to trigger a conformational change in our 
ligand-bound structure.  Similarly, lauric acid did not release Rv1816 from its operator DNA 
in gel-shift assays.  Thus, lauric acid occupies the Rv1816 binding cavity like an inducing 
ligand, but has no effect on its action—it is possible that we stumbled upon a natural 
inhibitor.  Considerable effort should be invested in determining the possible toxicity of 
lauric acid, and other short-chain fatty acids, on M. tuberculosis or M. smegmatis, as well as 
the link between these molecules and other genes that Rv1816 and Rv3249c are proposed to 
regulate. 
In N. gonorrhoeae, the potent MtrCDE tripartite efflux pump mediates resistance to 
diverse hydrophobic antimicrobial agents, such as antibiotics, nonionic detergents, 
antibacterial peptides, bile salts, and gonadal steroidal hormones.  We have previously 
determined the crystal structures of MtrD and MtrE.  In Chapter IV, we present a low-
resolution crystal structure of MtrCD.  As antibiotic resistance in N. gonorrhoeae is 
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developing into an urgent global problem, we hope to leverage our structural information into 
the first high-resolution model of any tripartite multidrug efflux pump.   
Based on our MtrD structure, our MtrCD structure, and homology with our previous 
structure of CusBA, we designed chimeric protein constructs that fused MtrC to MtrD in the 
same protein chain.  Ideally, by forcing these proteins in close proximity, the likelihood of 
the complex forming increases dramatically.  Although we were able to obtain minimal 
levels of expression of chimeric MtrCD in E. coli, more effort should be made to express the 
mg levels of protein necessary for crystallization trials; possibly in Pichia pastoris or higher 
organisms.   
In our efforts to assemble the tripartite MtrCDE complex, we discovered that the N-
terminal signal peptide and lipidation site of MtrC is not necessary for the drug efflux 
activity of the pump.  Surprisingly, the MIC of E. coli expressing the soluble truncated 
MtrCΔNT, along with MtrD and MtrE, exhibit resistance to TX-100 more than two orders of 
magnitude above that of E. coli missing these three proteins.  Further, the expression of full-
length MtrC (MtrC FL) or MtrC containing a signal peptide from the homologous membrane 
fusion protein AcrA (AcrASP-MtrC), actually inhibited the resistance of E. coli to TX-100, 
failing to restore it to even the control level. 
As we purified MtrC FL in a large scale and subjected the sample to gel-filtration 
experiments, we do expect that this protein is well-folded and active.  We also found that 
inclusion of the first 33 residues of MtrC anchored the protein to the membrane of E. coli.  
However, the question remains if MtrC FL or AcrASP-MtrC were targeted to the periplasm, 
as intended, or if they were attached to the correct membrane.  Further experiments are 
needed to localize these proteins, perhaps by separation and isolation of E. coli cell fractions 
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expressing these proteins or in vivo fluorescence experiments.  In any case, we can conclude 
that removal of MtrC from the tripartite pump has a dramatic effect on its function.  Thus, the 
periplasmic adaptor protein MtrC represents an attractive drug target to disrupt antibiotic 
resistance conferred by the MtrCDE system.  Our lab is currently focused on developing 
peptides which bind specifically to MtrC to prevent its interaction with either MtrD or MtrE. 
Finally, in Chapter V, we demonstrate the application of X-ray crystallography to the 
distinct problem of chloroplast cell division in Arabidopsis thaliana.  To this end, we have 
determined the first crystal structures of the PARC6 protein in the intermembrane space 
(IMS) region of the chloroplast.  We also co-crystallized this protein with PDV1, providing 
the first structural characterization of this interaction that is essential to chloroplast cell 
division.  In our crystal structure, the carboxyl group of PDV1 G272 is located within 
hydrogen bonding distance of PARC6 W700, revealing the first evidence that PARC6 W700 
is essential to the PARC6-PDV1 interaction.  Unfortunately, we were not able to carry out 
mutagenesis experiments to test this, as all attempted mutants of W700 resulted in unstable 
PARC6 protein. 
The arrangement of protein in the asymmetric unit of our initial PARC6 crystal 
suggests that the protein forms a homodimer.  This interaction was also predicted by the 
program PDBePISA (data not shown) and we observed an identical arrangement in our 
PARC6-PDV1 co-crystal structure.  Surprisingly, a bound peptide was found within the α/β 
cavity of PARC6 in both structures.  In the PARC6-PDV1 crystal, the peptide was, 
predictably, the C-terminal residues of PDV1.  However, the bound ligand in the initial 
PARC6 structure was identified as a short α-helical segment of PARC6 itself, which was 
cleaved during pre-crystallization trypsin digestion.  It appears that the binding of a peptide 
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in the α/β cavity of PARC6 induces dimerization, and this result was confirmed by gel-
filtration experiments.  However, we do not know if the dimerization of PARC6 that we 
observe has any biological significance. This important question must be addressed in future 
studies of the roles of PARC6 and PDV1 in chloroplast cell division.   
 
